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Diversity of Receptor Tyrosine Kinase Signaling Mechanisms
Abstract
Receptor tyrosine kinases (RTKs) are a family of 58 transmembrane proteins in humans that play crucial
roles in many biological processes and diseases. Different RTKs utilize subtly (but importantly) distinct
molecular mechanisms for transmembrane signaling, and understanding these differences is crucial for
devising new ways to intervene pharmacologically when aberrant RTK signaling causes cancer and other
diseases. In this thesis, I focus on three RTK families: the ALK/LTK family, the Wnt-binding RTKs, and the
EGF receptor – where I concentrate on efforts to understand its C-terminal regulatory region.
My studies of ALK, for anaplastic lymphoma kinase, were motivated by the fact that this RTK sub-group
has a unique domain architecture in its extracellular region. Little is known about the mechanisms of
ligand binding to – and activation of – ALK, and the nature of its ligand(s) is(are) still not completely clear.
Using biochemical, biophysical and structural biology approaches, I characterized the low-resolution
structure of the ALK extracellular region. I further identified the binding mode of ALK binding to heparin, a
recently discovered modulatory ligand for ALK. Based on a low-resolution structural analysis of ALK/
heparin complex, I propose a model for ligand-induced ALK dimerization and activation.
Ryk is one of the five RTKs that are now known to be Wnt receptors. In this thesis, I studied the Drosophila
homolog of Ryk, Derailed (Drl), and its binding to ligand DWnt5. We were able to express and purify
milligrams of active DWnt5 – thus overcoming a major obstacle in this field. We further characterized Drl/
DWnt5 interactions. Using hydrogen/deuterium exchange approaches, I identified the DWnt5-binding
interface on Drl. My efforts to understand the molecular mechanisms of Drl/DWnt5 binding using
experimental and computational approaches suggest that DWnt5 may interact with Drl through a binding
mode that differs from Wnt binding to other receptors.
Across the RTK family, many receptors contain a long carboxy-terminal tail (C-tail) that harbors
autophosphorylation sites for docking of downstream signaling molecules. This region is generally
considered to be intrinsically disordered. I studied the dynamics of the EGFR C-tail, and showed that it is
highly unstructured – but contains some somewhat ‘structured’ regions. I also showed that
phosphorylation of the EGFR C-tail promotes receptor dimerization. Using hydrogen exchange, I identified
possible C-tail docking sites on the kinase domain that may be responsible for this effect. I also studied
binding of downstream SH2 domain-containing molecules to the EGFR C-tail, with results that indicate
that not all features of SH2 domain binding to the C-tail can be recapitulated by simple phosphopeptides;
binding of SH2 domains to the C-tail exhibits binding affinities and stoichiometries that are not captured
by simple peptide-level studies. Moreover, my binding competition assays suggest that there may be
cooperativity in binding of multiple SH2 domains to a single phosphorylated C-tail.
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ABSTRACT
DIVERSITY OF RECEPTOR TYROSINE KINASE SIGNALING MECHANISMS
Zhengyi Wu
Mark A. Lemmon

Receptor tyrosine kinases (RTKs) are a family of 58 transmembrane proteins in humans that play
crucial roles in many biological processes and diseases. Different RTKs utilize subtly (but
importantly) distinct molecular mechanisms for transmembrane signaling, and understanding
these differences is crucial for devising new ways to intervene pharmacologically when aberrant
RTK signaling causes cancer and other diseases. In this thesis, I focus on three RTK families:
the ALK/LTK family, the Wnt-binding RTKs, and the EGF receptor – where I concentrate on
efforts to understand its C-terminal regulatory region.
My studies of ALK, for anaplastic lymphoma kinase, were motivated by the fact that this
RTK sub-group has a unique domain architecture in its extracellular region. Little is known about
the mechanisms of ligand binding to – and activation of – ALK, and the nature of its ligand(s)
is(are) still not completely clear. Using biochemical, biophysical and structural biology
approaches, I characterized the low-resolution structure of the ALK extracellular region. I further
identified the binding mode of ALK binding to heparin, a recently discovered modulatory ligand for
ALK. Based on a low-resolution structural analysis of ALK/heparin complex, I propose a model
for ligand-induced ALK dimerization and activation.
Ryk is one of the five RTKs that are now known to be Wnt receptors. In this thesis, I
studied the Drosophila homolog of Ryk, Derailed (Drl), and its binding to ligand DWnt5. We were
able to express and purify milligrams of active DWnt5 – thus overcoming a major obstacle in this
field. We further characterized Drl/DWnt5 interactions. Using hydrogen/deuterium exchange
approaches, I identified the DWnt5-binding interface on Drl. My efforts to understand the
molecular mechanisms of Drl/DWnt5 binding using experimental and computational approaches
suggest that DWnt5 may interact with Drl through a binding mode that differs from Wnt binding to
other receptors.
iii

Across the RTK family, many receptors contain a long carboxy-terminal tail (C-tail) that
harbors autophosphorylation sites for docking of downstream signaling molecules. This region is
generally considered to be intrinsically disordered. I studied the dynamics of the EGFR C-tail,
and showed that it is highly unstructured – but contains some somewhat ‘structured’ regions. I
also showed that phosphorylation of the EGFR C-tail promotes receptor dimerization. Using
hydrogen exchange, I identified possible C-tail docking sites on the kinase domain that may be
responsible for this effect. I also studied binding of downstream SH2 domain-containing
molecules to the EGFR C-tail, with results that indicate that not all features of SH2 domain
binding to the C-tail can be recapitulated by simple phosphopeptides; binding of SH2 domains to
the C-tail exhibits binding affinities and stoichiometries that are not captured by simple peptidelevel studies. Moreover, my binding competition assays suggest that there may be cooperativity
in binding of multiple SH2 domains to a single phosphorylated C-tail.
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Chapter 1 Introduction
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1.1
1.1.1

General principles of RTK-mediated cell signaling
The discovery of RTKs

Receptor tyrosine kinases (RTKs) are a family of trans-membrane proteins that play essential
roles in many biological procedures. Although first discovered in the early 1970s (insulin
receptor), the mechanisms (and nature) of RTKs did not begin to become clear until the late
1970s (Schlessinger 2014). Two different lines of research during that time accelerated the
understanding of RTKs. One centered on the newly discovered v-src-encoded protein product,
the first cellular oncoprotein (Brugge and Erikson 1977; Collett and Erikson 1978), which was
found in the late 1970s to be a kinase different from all other kinases known at that time –
phosphorylating tyrosines instead of serines and threonines(Eckhart, Hutchinson, and Hunter
1979; Hunter and Sefton 1980; Hunter and Eckhart 2004).
The insights into the mechanisms as to how tyrosine kinase causes cells to transform
came from the second seemingly unrelated research area. Researchers interested in cell-to-cell
communications found that EGF has mitogenic effects when applied to epithelial cells, suggesting
that a (then hypothetical) receptor on the cell surface might recognize EGF and trigger
transforming events inside cells (Das 1980). Later, this receptor (the EGF receptor) was isolated
from epidermoid carcinoma of the uterus. Sequencing of EGFR revealed an ectodomain
responsible for EGF binding, a transmembrane region, and a cytoplastic domain that resembles
Src in its amino acid sequence (Downward et al. 1984; Ullrich et al. 1984). Given this sequencing
result, it became clear how EGF might exert its mitogenic effects. Binding of EGF to the
ectodomain of EGFR somehow activates the intracellular kinase domain of the receptor, which
then phosphorylates cytoplasmic substrates and, like the Src oncoprotein, causes cells to
proliferate.
Today it is clear that RTKs constitute an entire family of cell-surface receptors – with 58
RTKs in the human proteome, which fall into 20 different families (Lemmon and Schlessinger
2010). RTKs regulate crucial cellular processes such as proliferation, differentiation, cell
metabolism, migration and cell-cycle control. They are the entry point to the complicated
signaling networks inside cells. Aberrant regulation, amplification, and/or mutations of RTKs
2

result in numerous diseases, including cancers, diabetes, inflammations, cardiac diseases,
development disorders. Thus, RTKs are also important drug targets.

Figure 1.1 The family of receptor tyrosine kinases in humans. The 58 receptor tyrosine kinases
can be grouped into 20 subfamilies. All RTKs have an extracellular region containing various
domains, a single transmembrane helix, and a tyrosine kinase domain (shown in red) and Cterminal tail (shown in black line) in the intracellular region. Figure is adapted from (Lemmon and
Schlessinger 2010).
1.1.2

RTK activation involves receptor dimerization

Early studies suggested that growth factors bind to receptors and induce receptor dimerization,
leading to their activation. For instance, upon binding of EGF, the EGF receptor undergoes
significant conformational changes (from a ‘tethered’ to an ‘extended’ conformation’) and exposes
regions in the extracellular region that mediate receptor-receptor interactions to form dimers.
Similar paradigms were also reported for other RTKs, such as KIT, VEGF, and TrkA (the NGF
3

receptor). Receptor dimerization brings two kinase domains in the dimer into close proximity,
leading to their activation. The exact mechanism of how the kinase domains are activated in the
‘dimer complex’ varies from one RTK to another. For instance, the kinase domains in EGFR
dimer form an asymmetric dimer in which one kinase domain (‘receiver’) is activated by the other
(‘activator’) through an allosteric mechanism (X. Zhang et al. 2006). In some other RTKs an autoinhibitory component blocks the activity of the kinase domain. Upon receptor dimerization, this
component becomes trans-phosphorylated, releasing the auto-inhibitory effect so that the kinase
domain can adopt its active form.
Although this simplified view of ligand-induced receptor dimerization and kinase domain
activation is conceptually straightforward, it is important to note that this pattern is not true for
every RTK. For instance, the insulin receptor forms disulfide-linked dimers on the cell surface in
the absence of its ligand. Binding of insulin to insulin receptors induces conformational changes
within the receptor dimers that are responsible for signaling (Ward et al. 2007). In addition, there
is evidence suggesting that the Tie2 and Eph family RTKs form higher-order oligomers on the cell
surface, although the exact stoichiometry and structures remain unknown, as does the influence
on signaling (Barton et al. 2006; Himanen and Nikolov 2003).
There are also members of RTKs for which it is not clear whether or how the ligandinduced receptor dimerization paradigm applies. For instance, it is not known whether Ryk family
receptors follow this paradigm. Ryk family receptor binds to Wnts through the Wnt-inhibitory
factor (WIF) domain in the extracellular region, but the intracellular region contains an inactive
pseudokinase domain (REF). Several other RTKs (mostly implicated in Wnt signaling) also have
intracellular pseudokinases. For other RTKs such as anaplastic lymphoma kinase (ALK) the
nature of the activating ligand is not known – although kinase domain dimerization appears to
lead to activation.
1.1.3

RTKs propagate signals through autophosphroylated tyrosines

The kinase domain in the intracellular region of RTKs (excepting pseudokinases) is activated
upon receptor dimerization. Subsequently it phosphorylates tyrosine residues in the adjacent
receptor within the RTK dimer. In some RTKs, phosphorylation of specific tyrosines in the
4

activation loop further enhances their kinase activity. In others, only tyrosines in the C-terminal
region (or ‘tail’) of the receptor are phosphorylated – by trans-autophosphorylation within the
receptor dimer. In most cases (with IR as the primary exception), the resulting phosphotyrosines
serve as ‘docking sites’ for downstream molecules to assemble signaling complexes. Multiple
signaling molecules are thus recruited to the cell membrane where they act. Recognition of (and
recruitment by) phosphotyrosines is largely mediated by Src homology 2 (SH2) domains and
phosphotyrosine binding domains (PTB) (Pawson, Gish, and Nash 2001; Schlessinger and
Lemmon 2003).
As SH2 domain-containing proteins were identified as signaling molecules recruited by
RTKs, the entire RTK-mediated signaling network as we now understand it was gradually
uncovered. The current consensus view is that those SH2 domain-containing proteins promote
further signaling events, in a linear fashion (thus ‘signaling pathway’) – although it is clear that
several pathways operate in parallel. A key example of such a linear cascade is the MAPK
pathway, in which signal follows the path RTK-Grb2-Sos-Ras-Raf-MAPKK/MEK-MAP Kinase.
2+

Other canonical signal pathways that RTKs can invoke include the PI3K/Akt and PLCγ/Ca /PKC
pathways. Which pathway(s) an RTK initiates will be determined by its complement of
phosphotyrosines and the selectivity of SH2 domains in downstream signaling molecules.
Peptide-based studies have indicated that this selectivity of SH2 domain binding is encoded in
part by the primary sequence flanking the tyrosine residue, in particular the nature of the sidechain at the positions immediately following and three residues following the phosphotyrosine
(Zhou 1993; Songyang and Cantley 2004). It has thus been hypothesized that different RTKs
have different ‘codes’ for characteristic subsets of downstream molecules, which define which
specific signaling pathways they switch on. It is worth noting that some RTKs are more restricted
and specific than others. For instance, the EGF receptor is thought to contain ‘codes’ that can
recruit many different SH2 domains, whereas ErbB3 primarily harbors YxxM motif in its C-tail,
suggesting it mainly recruits p85 SH2 domain in phosphoinositide 3-kinase (PI3K) (Prigent and
Gullick 1994; Hellyer, Cheng, and Koland 1998).
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1.1.4

RTKs are implicated in many diseases and are drug targets

Not only do RTKs regulate many biological procedures, but they are also involved, and even
responsible for, many human diseases. For example, the ErbB/EGFR family RTKs are well
known for their oncogenic relevance. Point mutations, deletions and insertions in EGF receptor
have been linked to non-small cell lung cancer (NSCLC) and to the sensitivity to kinase inhibitors
(Thatcher et al. 2005). Structural studies have rationalized some of the effects of these mutations
and alterations. For example, the L834R (L858R) EGFR mutation destabilizes a conserved set of
autoinhibitory hydrophobic interactions in the inactive kinase and thus effectively activates EGFR
(Lynch et al. 2004; Paez et al. 2004; Pao et al. 2004; Sharma et al. 2007; Yun et al. 2007). In
another form, about 200 residues are deleted form the extracellular region, resulting in an EGFR
variant (variant III, or vIII), which appears to show constitutive kinase activity despite the lack of
dimerization arm (Burgess et al. 2003). Other activating alterations are found in the
juxtamembrane regions of EGFR, which presumably affect the asymmetric dimerization of the
receptor (Red Brewer et al. 2009).
ErbB2 or HER2, another member of the ErbB family, is thought to be an orphan receptor
(it adopts an extended conformation in its extracellular region in the absence of ligand bound).
ErbB2, when overexpressed in NIH3T3 cells, has a strong transforming capacity (Di Fiore et al.
1987). It is also aberrantly expressed in ~30% of breast cancers as a result of gene amplification,
and its overexpression level is correlated with poor prognosis in breast cancer patients (Slamon
et al. 1989) – as well as response to the ErbB2-targeted antibody Herceptin.
ALK is another RTK that is strongly associated with various cancers. ALK was originally
discovered in anaplastic large-cell non-Hodgkin’s lymphoma (ALCL) in the form of fusion protein.
Nucleophosmin (NPM) becomes fused to the ALK kinase domain by chromosomal translocation,
resulting in production of a soluble dimeric (and thus constitutively activated) form of ALK’s
tyrosine kinase (Morris et al. 1994). Other ALK fusion proteins are also found, such as with
echinoderm microtubule-associated protein-like 4 (EML4) in EML4-ALK (Soda et al. 2007) in
other tumors. In addition to fusion proteins, activating point mutations in full-length ALK have
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been found to cause neuroblastoma, by activating the kinase domain in a manner similar to that
seen for EGFR in lung cancer (Hallberg and Palmer 2013; Mossé et al. 2008; Bresler et al. 2014).
In addition to ErbB family and ALK, many other RTKs are involved in cancers and other
diseases. The realization that this is the case has led to RTKs becoming important drug targets –
with the goal of limiting cancer by reducing aberrant signaling activity of oncogenic RTKs. Two
main forms of therapeutics have been specifically developed for RTKs - antibodies targeting the
extracellular regions and kinase inhibitors targeting the kinase domains. Antibodies can either
compete with ligand binding or directly bind to a different region in ECR to inactivate receptors
and promote immune responses. Kinase inhibitors are small molecules that are usually ATP
analogues that compete with ATP for binding to the active site of the kinase. For example,
Imatinib (Gleevec®) targets both PDGFR and Kit (as well as the non-receptor tyrosine kinases
Abl and Arg), and is widely used to treat chronic myelogenous leukemia that is caused the
Philadelphia chromosome – which leads to expression of Bcr-Abl fusion as a result of a
chromosomal translocation (Heinrich et al. 2000). Gefitinib, an EGFR-specific kinase inhibitor,
was initially shown to be not effective in the general population of lung adenocarcinoma patients,
but was found to be efficacious in a small subset of patients classified as Asian female neversmokers (in the early stage of the cancer, Gefitinib has a superior efficacy compared to
chemotherapy). Sequencing results showed that tumors from these responding patients harbor
mutations in the kinase domain of EGFR, which we now know to be activating (Fukuoka et al.
2003; Kris et al. 2003; Thatcher et al. 2005). Crizotinib, a kinase inhibitor originally developed at
Sugen as an inhibitor of the Met tyrosine kinase, has turned out to be useful as an ALK inhibitor in
ALK-translocated NSCLC, for which it has Food and Drug Administration approval – as well as
other cancers including neuroblastoma, where it is helpful for certain patients (Bresler et al. 2011;
Bresler et al. 2014).
Kinase inhibitors have shown promising effects by inhibiting several TKDs. It is worth
noting, however, that acquired resistance to these drugs almost always develops, leading to
relapse of the cancer. Biochemical and structural analyses of the kinase domain in those
resistant tumors have shown that new mutations can emerge that decrease inhibitor binding, or
7

increase (competing) ATP binding, resulting in an overall reduced inhibitor efficacy. Fully
understanding the mechanisms of drug resistance is a key step towards personalized treatment
of cancers involving TKD mutations in RTKs and other kinases.

1.2

EGF receptor and ErbB family receptors

The ErbB family of RTKs has four members in mammals: EGFR, ErbB2 (or HER2), ErbB3
(HER3) and ErbB4 (HER4). The four receptors share high sequence identity and a common
protein architecture including an extracellular region, a single transmembrane helix, and an
intracellular region that contains a tyrosine kinase domain and an intrinsically disordered Cterminal region of 230 amino acids or so. EGFR can be activated directly by several growth
factor ligands, including EGF itself, transforming growth factor α (TGF-α), amphiregulin (ARG),
epiregulin (EPR), epigen (EGN), betacellulin (BTC), and heparin-binding EGF-like growth factor
(HB-EGF). ErbB3 and ErbB4 are both regulated by neuregulins (NRGs). ErbB2, on the other
hand, has no known soluble ligand. It is generally considered to be an ‘orphan’ receptor and is
thought to function through heterodimerization with other ErbB family receptors when they bind to
their ligands. Among these four receptors, ErbB3 is unique in that its kinase domain lacks key
residues thought to be important for catalyzing phosphotransfer – notably the catalytic base
aspartate through to abstract the proton from the substrate side-chain hydroxyl group. Thus,
ErbB3 is usually termed a ‘pseudokinase’. Recent studies have shown that ErbB3 does retain
some kinase activity despite lacking the catalytic base, although it is significantly weaker than the
EGFR tyrosine kinase (Shi et al. 2010). Whether such low level of activity is biologically relevant
(or, whether the kinase domain in ErbB3 has a function completely different from catalyzing the
transfer of phosphate group) remains unclear – although mutations that block ErbB3’s kinase
activity do not appear to abolish all of its ability to signal (Shi, unpublished data).
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Figure 1.2 The ErbB family receptor tyrosine kinases, their ligands and downstream effectors
(figure adapted from (Yarden and Sliwkowski 2001)).
Crystal structures of EGFR extracellular regions with- and without bound ligand revealed
high-resolution snapshots of the ligand-induced receptor dimerization process for this receptor
(Burgess et al. 2003; Cho and Leahy 2002; Ogiso et al. 2002; Schlessinger 2002; Garrett et al.
2002). Each bound ligand contacts two points (domain I and III) in a single receptor molecule.
Domains I and III themselves are rigid. However, ligand binding changes their positions with
respect to one another in a global conformational change that exposes the dimerization arm in
the intervening domain II. Receptor dimerization is almost exclusively mediated by this projected
dimerization arm, thus EGFR dimerization is termed ‘receptor-mediated’.
Ligand-induced dimerization of the EGF receptor brings two kinase domains close
together in the resulting dimer complex. However, until 2006, it was not clear how the kinase
domain was activated by this event – even though it was already known by that time that
phosphorylation of the activation loop in EGFR was not required for its activation (Burke and
Stern 1998; Gotoh et al. 1992; Moriki, Maruyama, and Maruyama 2001; Stamos 2002). The key
insights that explain EGFR activation came from the Kuriyan lab (X. Zhang et al. 2006). A series
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of crystallographic analyses of the EGFR kinase domain, combined with mutational studies, led to
the conclusion that the two kinase domains in an EGF-induced dimer form an asymmetric dimer
in which the carboxy-terminal lobe (C-lobe) of one TKD contacts the amino-terminal lobe (N-lobe)
of the other TKD, through interactions resembling those seen in complexes between cyclins and
cyclin-dependent kinases (CDKs) (De Bondt et al. 1993). When the two kinase domains form this
asymmetric dimer, one kinase domain activates the other through an allosteric mechanism (X.
Zhang et al. 2006). This allosteric mode of activation explains why EGFR does not require
phosphorylation of the activation loop in order to activate its kinase.
In addition to the C-lobe/N-lobe interactions the intracellular juxtamembrane region (iJM)
also plays an important role in EGFR activation. Among RTKs, JM regions differ significantly in
their length, sequence, and function. In some cases, the iJM region contains tyrosines to which
SH2 domains can bind. In some of these and other cases, the iJM regions can also serve an
autoinhibitory role by folding against the N-lobe and/or C-lobe of the kinase domain to inhibit its
activation. For example, in the case of Flt3 (FMS-like tyrosine kinase 3, a VEGF receptor),
crystal structures suggest that the iJM region projects into the cleft between the N- and C-lobes,
also contacting the A-loop, the αC-helix and the glycine-rich loop (Griffith et al. 2004). Together,
these interactions prevent the A-loop from transitioning to the active conformation and thus ‘lock’
the kinase in its inactive form. In EGFR, the iJM region plays a key activating role (Red Brewer et
al. 2009) – rather than exerting an inhibitory effect. Crystallographic studies of the EGFR TKD
showed that a segment in the iJM region of the ‘receiver’ kinase directly contacts the C-lobe of
the ‘activator’, to form a so-called ‘latch’ that stabilizes the asymmetric (activating) interactions
between the two kinase domains (Red Brewer et al. 2009). This region (residues 664-672)
essentially functions as a ‘juxtamembrane latch’ and enhances the kinase activity by promoting
the formation of asymmetric dimers.
In addition to the kinase domain, EGFR has a carboxy-terminal tail (C-tail) in its
intracellular region. The C-tail contains ~230 amino acids (residues 956-1186) and accounts for
~20% of the full-length receptor. This region contains all of the known regulatory
autophosphorylation sites of EGFR with the exception of Y845 (in the activation loop – which is
10

phosphorylated, but does not regulate kinase activity). These phosphotyrosines function as
docking sites to recruit downstream signaling molecules. Multiple SH2 domain-containing
proteins can bind to these pTyr sites (Lemmon, Schlessinger, and Ferguson 2014). The C-tail
region is generally considered to be disordered. Therefore, it is generally assumed that all of the
exposed phosphotyrosine residues can individually initiate assembly of signaling complexes, with
the specificity governed by the primary sequence flanking the phosphorylation site as mentioned
above (Gajiwala 2013). In addition to its role of propagating signaling, the C-tail is also
considered to negatively regulate kinase activity. One piece of evidence supporting this
hypothesis is that truncation mutations in the C-tail region alter the kinase activity, suggesting that
some parts of the C-tail may modulate kinase activity directly (Walton et al. 1990; Alvarez et al.
1995) However, the complete picture of the regulatory role of the C-tail remains to be
understood.

1.3
1.3.1

ALK family receptors
ALK and LTK receptors fall into a separate subgroup of RTKs

Anaplastic lymphoma kinase (ALK) was originally identified in ALCL (anaplastic large cell
lymphoma) cell lines. The protein was originally described as a then-novel kinase domain of ALK
fused to the N-terminal portion of the NPM (nucleophosmin) protein. This fusion arises because
of a translocation event between chromosomes (2;5)(p23;q35) (Morris et al. 1994). The NPMALK protein is thought to oligomerize, such that the kinase domain of ALK becomes activated –
resulting in the transforming ability of this fusion protein (Morris et al. 1994). Subsequent studies
revealed that the composition of full-length ALK is similar to that of other RTKs, with an
extracellular ligand-binding domain, single transmembrane α helix, an intracellular kinase
domain, and an extended C-tail (Iwahara et al. 1997; Morris et al. 1997). Based on sequence
homology, ALK is grouped with LTK (leucocyte tyrosine kinase), another RTK, and together they
form their own subgroup within the RTK family. In mammals, ALK is believed to play a role in
normal development of the nervous system (Vernersson et al. 2006), but its function in D.
melanogaster is much better understood (Palmer et al. 2009). The transcription and expression
11

of ALK is highly regulated – peaking after birth, and diminishing after three weeks of age in mice
(Vernersson et al. 2006).
ALK exhibits a unique domain architecture in its extracellular region (ECR). It contains
two MAM (meprin, A5 protein and receptor protein tyrosine phosphatase mu) domains and an
LDLa (low-density lipoprotein class A) motif between them. Although LTK does not contain the
two MAM domains and the LDLa motif, both the ALK and LTK ECRs also contain a glycine-rich
region proximal to the cell membrane.
1.3.2

ALK-mediated signaling

Since the original discovery of ALK in ALCL, ALK has been linked to many human diseases. ALK
fusion proteins, ALK overexpression and gain-of-function ALK mutations have all been linked to
cancers including ALCL, IMTs (inflammatory myofibroblastic tumors), NSCLC (non-small cell lung
cancer), DLBCLs (diffuse large B-cell lymphoma), and neuroblastoma (Hallberg and Palmer
2013). Despite its implication in these diseases, and its status as a potentially important drug
target, the regulation of the ALK RTK remains poorly understood. The most thoroughly studied
ALK receptor is Drosophila ALK (dALK). In Drosophila, ALK plays a critical role in the formation
of the visceral musculature of the gut during embryonic development (Palmer et al. 2009). Two
groups simultaneously reported that a secreted protein called jelly belly (Jeb), which also contains
an LDLa domain, might function as a ligand for Drosophila ALK (Englund et al. 2003; Lee et al.
2003). Activation of dALK signaling in flies is thought to be initiated by Jeb binding to the ALK
extracellular region. This binding is suggested to be mediated by the LDLa domain in Jeb, since
Jeb lacking the LDLa domain failed to bind to the receptor (Englund et al. 2003). Genetic and
other studies suggest that Jeb/dALK signaling also plays key roles in an anterograde signaling
pathway governing neuronal circuit assembly in the Drosophila visual system (Bazigou et al.
2007). Despite this evidence for Jeb as an ALK ligand in Drosophila, no structural/biochemical
studies have been reported characterizing its binding to the receptor. It is not clear what the
binding affinity and stoichiometry are, and whether Jeb binding to dALK induces receptor
dimerization has not been established. Although there is significant sequence identity between
Drosophila and human ALK, no mammalian homologue of Jeb can be identified.
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In humans, several molecules have been postulated as ALK ligands, including
pleiotrophin (PTN), midkine (MK) and more recently heparin (Iwahara et al. 1997; Stoica et al.
2001; Stoica et al. 2002; Murray et al. 2015). However, the roles and physiological relevance of
these ligands seem much less clear than in the case of Jeb and Drosophila ALK. PTN and MK
are small, heparin-binding, growth factors that are involved in neural development, cell migration
and angiogenesis (Chauhan, Li, and Deuel 1993; Czubayko et al. 1996; Stoica et al. 2002).
Controversial data as to whether PTK and MK activate ALK were reported in the literature
(Mourali et al. 2006; Mathivet, Mazot, and Vigny 2007; Dirks et al. 2002; Moog-Lutz et al. 2005;
Motegi et al. 2004). In addition, PTK and MK are also known to bind and signal through
RPTPβ/ζ (receptor protein tyrosine phosphatase β/ζ), leading to the possibility that PTK and MK
regulate ALK indirectly by modulating their dephosphorylation (Perez-Pinera et al. 2007). Very
recently, the Schlessinger lab reported that heparin itself can bind, oligomerize, and activate
mammalian ALK (Murray et al. 2015). This leaves two questions unanswered: whether PTN and
MK bind to ALK through heparin, and whether binding and activation by heparin itself is
physiologically relevant.
LTK receptor lacks the MAM domains and LDLa motif – elements that typically mediate
protein-protein interactions, and therefore was thought to be an orphan receptor. Recently, a
large-scale screening of extracellular proteome led to the identification of two proteins FAM150A
and FAM150B, which bind and stimulate LTK (H. Zhang et al. 2014). The molecular basis for
these proteins binding and activating LTK is yet to be established, and it is not clear whether they
are also ligands for human ALK – but this study effectively deorphanized LTK.
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Figure 1.3 Overview of molecular mechanisms of ALK signaling. Left: In Drosophila, ALK is
activated by binding of the ligand jelly belly (Jeb). Activation of dALK promotes Ras/MAPK
pathway and ERK phosphorylation and regulates various target genes. Right: In mammals, ALK
is activated by its proposed ligands, MK and PTN. ALK mediates various signaling cascades
including RAS/MAPK, PI3K/Akt, JAK/STAT, and PLCγ pathways. In the absence of ligands, ALK
is proposed to be cleaved by caspase 3, promoting apoptosis, and has been suggested to
function as a dependence receptor (Mourali et al. 2006). Figure from (Palmer et al. 2009).

1.4
1.4.1

RTKs as Wnt receptors
Wnt and RTKs

The 19 Wnt family proteins in humans play important yet diverse roles in embryonic development
and adult homeostasis of all metazoans – including segment polarity and neural tube
development during embryogenesis, stem cell maintenance, cell fate determination, and cell
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proliferation. Mutations and aberrant regulation of Wnts are involved in many diseases (Clevers
and Nusse 2012; MacDonald, Tamai, and He 2009; Nusse and Varmus 2012).
It is now clear that that Wnt signaling involves an array of different receptors, some of
which are summarized in Figure 1.4. The best known (canonical) pathway involves Frizzled (Fz)
receptors (Bhanot et al. 1996) and low-density lipoprotein receptor-related proteins (LRP5/6 in
human and arrow in Drosophila) as co-receptors (Tamai et al. 2000; Pinson et al. 2000; Wehrli et
al. 2000). Wnt binds to Fz and LRP5/6 at the cell surface, causing the recruitment of Dishevelled
(Dvl) to the Frizzled receptor(Chen et al. 2003). This further promotes Axin recruitment to the
LRP cytoplasmic tail and dissociation of the so-called ‘destruction complex’ that normally
phosphorylates β-catenin and targets it for proteasomal degradation. β-catenin is thus stabilized
by Wnt signaling, and is translocated to the nucleus to regulate TCF-controlled gene transcription.
Independent of LRP and β-catenin, Wnts also mediate the planar cell polarity (PCP) pathway
(through Rho, Rac and Jnk)(Veeman, Axelrod, and Moon 2003), and Ca
2000).
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2+

signaling(Kühl et al.

Figure 1.4 A. β-catenin/TCF dependent (‘canonical’) Wnt signaling in which a Wnt (yellow)
engages a Frizzled and LRP (green) as a co-receptor, leading to LRP phosphorylation and
membrane recruitment of Axin and Dvl – promoting dissociation of the ‘destruction complex’ and
β-catenin stabilization. B. Ror family RTKs inhibit β-catenin/TCF signaling and activate Jnk C.
Frizzled receptors also mediate Wnt regulation of planar cell polarity (PCP), through Dvl, Rho,
Rac, and Jnk – as well as Ca

2+

signaling (‘non-canonical Wnt pathways’). D. Ryk family RTKs

also mediate Wnt signaling – involving Src in some cases. Figure is adapted from (Clevers and
Nusse 2012).
As work on human receptor tyrosine kinases (RTKs) has advanced, it has become clear
that 4 or 5 of the 58 human RTKs function as Wnt receptors. Ror1 and Ror2 (for Receptor
tyrosine kinase-like orphan receptor) have a cysteine-rich domain (CRD) in their extracellular
regions (ECRs), resembling the extracellular CRD known to be responsible for Wnt binding to
Frizzleds and suggesting a similar mode of interaction (Minami et al. 2010). MuSK (for musclespecific kinase) also has a related CRD and is clearly linked to Wnt signaling (Jing et al. 2009;
Banerjee et al. 2011). In addition, PTK7/CCK4 (Peradziryi et al. 2011; Bin-Nun et al. 2014) has
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been linked to Wnt signaling, as has Ryk (for Receptor tyrosine kinase-related), which has a
putative WIF (for Wnt Inhibitory Factor) domain in its ECR, suggesting its capability of binding to
Wnt ligands (Cheyette 2004; Fradkin, Dura, and Noordermeer 2010).
1.4.2

Ryk and its invertebrate orthologs

The first clue to the functions of Ryk family RTKs came in Drosophila, where the Ryk ortholog
Derailed (Drl) was shown to control CNS axon path finding (Thomas et al. 1999; Yoshikawa et al.
2003). Drl is a receptor for Drosophila Wnt5 (DWnt5). Both Drl and its homolog Derailed-2 (Drl-2)
function as Wnt receptors in nervous system development, but play different roles depending on
the cell types in which they are expressed. It is also known that Ryk plays a role in mammalian
PCP signaling (Macheda et al. 2012), and Ryk is reported to cooperate with Fz7 to mediate
Wnt11 regulation of convergent extension in Xenopus (Kim, Her, and Han 2008). Human Ryk is
involved in CNS development (Liu et al. 2005) and regulates axon regeneration after CNS injury
(Hollis and Zou 2012). Dysregulation of Ryk has also been reported in ovarian cancer (Katso,
Russell, and Ganesan 1999; Katso et al. 1999; Wang et al. 1996).
The Ryk family is unique among RTKs, being the only family with an extracellular WIF
domain (Cheyette 2004). Moreover, Ryk’s intracellular kinase domain lacks key residues for
catalysis of phosphotransfer, and is presumed to be kinase-dead – like the other putative Wnt
receptors Ror2 and CCK4/PTK7). Understanding the molecular mechanism of Wnt/Ryk signaling
is therefore likely to reveal a new paradigm in RTK signaling that involves pseudokinases.
Drl, being Ryk’s ortholog in Drosophila, shares 34% sequence identity in the extracellular
WIF domain and 48% sequence identity in the kinase domain. Despite the known crystal
structure of WIF domain (Liepinsh et al. 2006), little is known about the molecular mechanisms of
Drl/DWnt5 interactions. Moreover, unlike most Wnt molecules, our data suggest that DWnt5 is
not modified by lipid groups. Therefore, understanding how DWnt5 and Drl bind has the potential
not only to unveil the molecular mechanism of Ryk signaling, but also to reveal a new mechanism
for signaling by Wnt family ligands.
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1.5

Diversity of the molecular mechanisms of RTKs

As illustrated in previous sections, the general principles of RTK activation and signaling appear
straightforward – most known RTKs utilize a variation on the ligand-induced receptor dimerization
paradigm to activate their kinase domain and thus transduce signals across cell membranes
(Lemmon and Schlessinger 2010). However, such a generalization is somewhat oversimplified,
since there is significant diversity in the molecular mechanisms for different RTKs.
1.5.1

Diversity in the extracellular region of RTKs

The receptor dimerization paradigm itself varies in different receptors. For example, in the EGF
receptor, ligand binding induces conformational changes but the bound ligand is not directly
involved in receptor dimerization (Lemmon and Schlessinger 2010). At the other extreme, nerve
growth factor (NGF) sits at the interface between two TrkA molecules in an exclusively ‘ligandmediated’ receptor dimer (Wehrman et al. 2007). Between these extremes is KIT, the receptor
for stem cell factor (SCF), which requires both receptor-mediated and ligand-mediated
interactions for dimerization (Yuzawa et al. 2007). In addition to the very different natures of the
receptor dimerization interface (whether ligand-mediated or receptor-mediated), the
ligand/receptor binding stoichiometry can also vary. For instance, some EGF receptors can form
a dimer with a 1:2 molar ratio of ligand/receptor (Alvarado, Klein, and Lemmon 2010). Moreover,
there is evidence suggesting the existence of oligomrization of EGF receptor without ligand
bound (Clayton et al. 2005; T W Gadella and Jovin 1995). Such preformed dimers are
themselves not active but may be important for certain ligands. Therefore, for EGF receptor,
these seemingly controversial results do suggest the diversity of its ‘receptor dimerization’,
although a complete mechanistic view is still missing (Bessman et al. 2014). It is not clear
whether such diversity generally exists in all RTKs, but it is safe to say that some RTKs utilize
diverse receptor dimerization mechanisms to carry out their biological functions – and it is
certainly true that there is diversity in the nature of domain types found in RTK ECRs and in the
nature of their activating ligands.
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1.5.2

Diversity in the kinase and pseudokinase domains

The mechanisms of kinase domain activation are also diverse across the ‘RTKome’. For
instance, EGFR uniquely utilizes asymmetric dimerization to activate its kinase domain through
an allosteric mechanism. Other TKDs are activated by quite different mechanisms. For example,
the FGFR, insulin receptor and IGF1 receptor TKDs are autoinhibited as a result of interactions
between parts of their activation loop and the active site – which serves to block access of protein
(and ATP) substrates (Lew et al. 2009; Hubbard et al. 1994). In each of these cases,
phosphorylation of a key tyrosine in the activation loop disrupts this autoinhibitory interaction and
leads to the activation of the kinase domain. In the case of PDGFR and Kit, the juxtamembrane
region interacts with the kinase domain to stabilize an inactive form or autoinhibit the kinase.
Phosphorylation of tyrosines in the juxtamembrane region disrupts this interaction and allows the
kinase domain to form active conformation (Chan et al. 2003; Hubbard 2004). In Tie2, the Cterminal tail interacts with the active site of the kinase domain to stabilize the inactive
form(Shewchuk et al. 2000). In all of these cases, once the auto-inhibitory interactions are
removed, the resulting active kinase domains all adopt similar conformations (Huse and Kuriyan
2002).
It is worth noting that no kinase domain has to use one of those mechanisms exclusively.
Rather, multiple autoinhibitory mechanisms can co-exist in one TKD. For instance, in the case of
EGFR, in addition to the allosteric activation mechanism, the juxtamembrane region also
regulates kinase activity – although unlike JM regions in other RTKs, the EGFR JM region
promotes kinase activity in the receptor dimer (Red Brewer et al. 2009). In addition, the Cterminal tail in EGFR has been shown to modulate kinase activity. Taking these considerations
together, it seems that each part of the intracellular region of any given RTK plays some
regulatory role. Only through a more thorough analysis of full-length RTKs in cellular contexts –
with all other possible players taken into consideration – will our understanding of this diversity in
kinase domain regulation be complete.
As mentioned above, among all 58 known RTKs in the human proteome, eight lack one
or more conserved residues in the kinase domain that are known to be important for catalyzing
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phosphotransfer reactions, and are thus termed ‘pseudokinases’ (Mendrola et al. 2013; Boudeau
et al. 2006; Zeqiraj and van Aalten 2010). All of these pseudokinases (except for ErbB3) appear
to be kinase inactive – and most do not even bind ATP (Murphy et al. 2014) – raising key
questions as to how these RTKs might signal. For ErbB3, although low-level kinase activity was
detected in vitro, it has yet to be determined what (if any) role this low-level activity plays in
biological contexts – and unpublished results from the Lemmon laboratory so far suggest that it
may be vestigial. Moreover, many of these pseudokinase RTKs (PTK7/CCK4, Ror1,Ror2, and
Ryk) appear to be Wnt receptors, suggesting a new Wnt signaling paradigm involving
pseudokinases. The exact characterization of Wnt binding to these receptors, however, is still
unclear. Despite these unknowns in pseudokinases and Wnt receptors, it is highly likely that
pseudokinases are equipped with a different receptor signaling mechanism. For ErbB3, given its
low level kinase activity and its ability to form heterodimers with other ErbB family receptor, it is
possible that ErbB3 could still phosphorylate some tyrosines within a receptor complex. In
addition, the allosteric nature of the pseudokinase domain allows for the possibility that other yetto-be-discovered molecules bind to and enhance ErbB3 kinase activity. For pseudokinases that
are completely kinase-dead, the kinase domain can still function as an ‘activator’, through the
allosteric mechanism, to activate other kinases.
To sum up, in RTKs, the kinase domains utilize a variety of mechanisms, not necessarily
mutually exclusively, to regulate their kinase activity and/or their partner molecules.
Understanding these mechanisms will shed more light on RTK-mediated cell signaling and
provide insights into the development of novel therapeutics targeting these kinases and
pseudokinases. Studies at both the molecular and systems levels are required to tackle these
important yet challenging questions.

1.5.3

RTKs have diverse ligands

The current consensus view of RTK activation mentioned in this Chapter is centered on ligandinduced receptor dimerization. Unlike well-studied RTKs such as EGFR, searches for ligands is
still ongoing for some ‘orphan’ RTKs. For instance, since the 1990s, potential ligands for ErbB2
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have been under extensive investigation, yet ErbB2 remains an orphan receptor today. Jelly
belly may be one of the missing ligands for Drosophila ALK – although it remains unclear whether
it can regulate the receptor directly – and no human ortholog of jelly belly has been identified. To
complicate the situation with ALK ligands even further, heparin, a completely different class of
molecule, has recently been reported to bind and activate human ALK (Murray et al. 2015). The
other member of ALK family receptor, LTK, was recently deorphanized as well by the discovery of
two novel secreted proteins, which are completely different from Jeb or heparin (H. Zhang et al.
2014). Clearly, there is much to learn for this RTK family. Across the RTK family more broadly,
several receptors contain domains that are typically found in Wnt-interacting molecules,
suggesting that these RTKs might be Wnt receptors as well. Nevertheless, exactly which Wnt
binds and regulates each receptor is still unclear. Also, if the different RTKs share the same
ligand, might these receptors form ligand-induced heterodimers? These examples suggest that,
just as RTKs are diverse in the nature of their extracellular regions, their ligands have diverse
functions and share few common features. Investigating the diversity of RTK ligands, and how
they regulate their cognate RTKs are thus crucial for understanding how the entire family of RTKs
functions and how they cooperate with other components in cellular contexts.
1.5.4

Diversity at the systems level

The majority of research on RTKs in the last few decades was done using a reductionism
approach. Indeed, such methodology is ideal to tackle complex questions when, say, a full-length
membrane protein was technically difficult to prepare, or, the phosphorylation level of a protein
containing five phosphorylation sites was too complicated to quantitate, or a signaling pathway
containing both positive and negative feedback loops was too variable to comprehend (even
today, few biologists are familiar with chaos theory). In the case of RTKs, biochemical and
structural studies have focused mainly on an individual part of the receptor (such as the ligandbinding extracellular region, the transmembrane α-helix, the kinase domain, or the C-terminal tail),
or individual pairs of molecules (such as ligand/receptor, JM/kinase domain, kinase
domain/inhibitor, C-tail/SH2 domain, etc.). The majority of our understanding of RTKs remains at
this rather focused level, whereas the biological systems regulated by the RTKs are highly
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complex. It is now clear that simply adding up the behavior of the individual components will not
lead to a proper picture of the system – the complexity of biological systems such as these really
originates from the interplay between individual components, so a systems view is crucial.
Take EGF receptor for example, the next step towards a better understanding of its
mechanism would be to lift one level up to study the full-length receptor. The receptor
dimerization model based on the crystal structure of ligand-bound ECR fails to reflect the
negative cooperativity of ligand binding – a phenomenon known since the 1970s when ligand
binding to the cell-surface EGFR and insulin receptor was first found to yield concave-up
Scatchard plots. Importantly, negative cooperativity provides a mechanism for receptors to
differentially respond to/interpret concentration gradients of growth factors. However, this feature
is only seen for the full-length receptor in membranes, suggesting that it may arise from the
interactions between different components of the receptor and between them and other
molecules proximal to cell surface. Clearly, any analysis with only part of the full-length receptor
will miss this feature. Therefore, a better understanding of the full-length RTK should be (and is
becoming) one of the frontiers of RTK research.
To really understand RTK signaling in cells, one needs to go an additional step further,
and understand the systems-centered RTK signaling. The complexity of signaling networks is
brought about by feedback loops between the ‘nodes’ in the network (Kholodenko 2006;
Kholodenko, Hancock, and Kolch 2010). Multiple pathways are connected by various feedback
and feedforward loops, resulting in what is termed ‘cross talk’ by those focused on individual
pathways. For example, a recent study illustrated this cross-talk between EGFR and insulin
receptor-mediated signaling events (Borisov et al. 2009). It has long been observed that,
although EGFR and IR signaling ‘pathways’ share many common downstream signal-processing
proteins, the responses to these two ligands are completely different. Whereas EGF stimulates
EGF receptor, leading to activation of ERK through the MAPK cascade in HEK293 cells, insulin
hardly affects ERK. However, insulin and EGF can both potentiate MAPK/ERK activation at low
levels of EGF in HEK293 cells. This study, using combined experimental and computational
approaches, showed that at low physiological concentrations of EGF, cross talk between the two
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pathways enhanced ERK activation in response to the increase of PtdInsP3 concentration
resulting from insulin stimulation. Such an effect of insulin became insignificant at saturating
concentration of EGF.
Feedback loops result not only in interplays between different signaling pathways, but
also create intricate dynamic spatiotemporal behaviors of the signaling network, such as
oscillation, bistability and excitability. These behaviors significantly enhance the robustness of
the system in response to perturbations, and define the properties of the system and its
responses. Understanding these effects is also therapeutically important because the flip side of
robustness is the difficulty to perturb the cells once they turn cancerous – although cancer itself
may be a manifestation of loss of robustness. Despite the importance of such a network view,
studies of RTKs at the systems level remain challenging. Tackling complex systems requires a
high-level of mathematical thinking and scientific reasoning, and demands ‘cross-talk’ between
experimentalists and modelers – modelers need experimental data to instruct and fit models,
while experimentalists need modelers in order to make sense of complicated systems-level
datasets. Therefore, an iterative approach is essential – in which predictions are made and
tested – in order to make progress in understanding the newly-emerged diversity and complexity
of RTK-mediated signaling.
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Chapter 2 Towards understanding the molecular basis for
activation mechanisms of anaplastic lymphoma kinase
(This chapter is collaborative work done with Dr. Camilla Oxley in the Lemmon laboratory)
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2.1

Introduction

Anaplastic lymphoma kinase (ALK) and leukocyte tyrosine kinase receptor (LTK) form an
important RTK sub-family as described in Chapter 1. ALK plays central roles in the nervous
system and embryo development. ALK fusion proteins and mutants have been implicated in
many diseases, such as various human cancers including large cell lymphoma, NSCLC (nonsmall cell lung cancer), breast cancer, and neuroblastoma (Palmer et al. 2009).
It has become clear that ALK is an important drug target in cancer. Extensive studies
focusing on the aberrant tyrosine kinase activity of ALK mutants as well as development of
potential kinase inhibitors have been conducted (Bresler et al. 2011; Hallberg and Palmer 2013).
For example, a recent study integrated biochemical analysis, clinical studies and computational
approaches to investigate oncogenic activity and kinase inhibitor sensitivity of various ALK
mutants found in pediatric neuroblastoma (Bresler et al. 2014). Compared to its kinase activity,
however, very little is known regarding ALK’s extracellular region and its ligand(s). The
architecture of the ALK extracellular region (ECR) is unique (Figure 1.3), and there is currently no
clear view of how its unique domain-set functions in receptor activation and response to ligands.
It is not clear which domain(s) in the ECR are involved in ligand binding. In fact, it is still unclear
what is/are ALK’s ligand. In Drosophila melanogaster, a secreted protein named jelly belly (Jeb)
was identified as a potential ligand over a decade ago (Lee et al. 2003; Englund et al. 2003), but
the biochemical and structural bases for Jeb binding to (and activation of) ALK remains to be
established. In mammals, ALK is considered an ‘orphan’ receptor. There is no mammalian
ortholog of Jeb, and no alternative ligand has been convincingly identified. Several putative
protein ligands have been proposed (namely midkine, pleiotrophin), but there are contradictory
reports regarding their effectiveness and relevance in the literature (Iwahara et al. 1997; Stoica et
al. 2002). A recent study identified a heparin-binding motif in N-terminus of mammalian ALK and
found that heparin binding can promoted receptor phosphorylation in certain cell lines, suggesting
that heparin could be a ligand for mammalian ALK (Murray et al. 2015) – although the biological
significance of this observation has not been established.

40

LTK – ALK’s partner in this small family of RTKs – has been implicated in neuronal
development, autoimmunity and cancers (Weiss et al. 2012; Li et al. 2004). Until very recently an
orphan receptor like ALK, ligands for LTK have been identified in a signaling screen of the
extracellular proteome. Two related secreted proteins, FAM150A and FAM150B were identified
as ligands that bind and activate LTK, with FAM150A binding to LTK with a picomolar range
dissociation constant (Zhang et al. 2014). This work sets the stage for understanding the
molecular basis for ligand-dependent activation of LTK. It should be noted, however, that LTK
lacks the MAM and LDLa domains in the extracellular region that characterize ALK.
In this Chapter, the studies described aimed to shed more light on the structural features
of ALK extracellular region, with the goal also of understanding ligand binding and activation –
using biochemical and biophysical approaches.

2.2

ALK possesses a unique domain architecture in its extracellular region

In addition to an LDLa domain and two MAM domains flanking it, ALK has a glycine-rich region
proximal to membrane. By using the Phyre2 server (Kelley and Sternberg 2009), a protein
structure homology recognition server, we further detected a tumor necrosis factor-like domain
(TNF-like) and an epidermal growth factor–type (EGF-type) module in the membrane–proximal
region in ALK ECR. These two domains appear to exist in LTK receptors as well. Figure 2.1
shows the query results returned from Phyre2 server.
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Figure 2.1 Structure homology detection in the membrane-proximal region of ALK ECR. Top: a
list of 3D models that are structurally homologous to EGF-type module in ALK. Bottom: a TNFlike domain was found in the ALK ECR, with 81.2% confidence and 19% identity.
In our sequence analysis, the ALK ECR contains a sequence (residues 680 – 794 in
human ALK) that is highly homologous to a TNF-like domain, with 81.2% confidence in Phyre2
and 19% sequence identity. TNF-like domains are found in both tumor necrosis factors and C1q
family proteins. Structurally, two conserved cysteine residues form a disulfide linkage and
stabilize an anti-parallel β sheet in TNF-like domains. These domains typically self-associate to
form a homotrimer (Oren et al. 2002). The EGF-type module in ALK was found in the C-terminal
region of the ALK ECR (residues 906 -986 in human ALK). Six conserved cysteine residues
predicted to form three disulfide bonds based on their positions were found in this region (Nagata
et al. 1994; Downing et al. 1996). Phyre analysis showed ~ 95% confidence of existence of an
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EGF-type module in this region, with a sequence identity around 40% compared to a structurally
available EGF-like domain.
In sum, ALK family receptors indeed possess a unique domain composition in its
extracellular region (illustrated in Figure 2.2). How these domains, typically playing a role in
protein-protein interactions in other proteins, function in ALK remains unknown.

Figure 2.2 Domain composition of the extracellular region (ECR) of ALK and LTK receptors. ALK
contains two MAM domains flanking an LDLa domain, plus one TNF-like domain, one glycine-rich
region and one EGF-type module in the membrane-proximal region.
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2.3

Drosophila ALK and human LTK ECR are monomeric in solution

Most well-understood receptor tyrosine kinases follow the ‘ligand-induced receptor dimerization’
paradigm in their activation mechanisms (Schlessinger 2000; Lemmon and Schlessinger 2010).
It is worth noting, however, that there are certain ‘outliers’ of this pattern. One example is the
insulin receptor (IR), which exists as a pre-formed dimer linked by disulfide bonds. Ligand
binding to the IR induces conformational changes in the pre-formed dimer that result in activation
of the intracellular kinase domain of IR (Lawrence, McKern, and Ward 2007; Ward et al. 2007).
ALK and LTK are grouped into the insulin receptor super-family due to sequence
similarity between ALK and IR in the kinase domains (Iwahara et al. 1997), most notably the
YxxxYY sequence in the activation loop. However, the extracellular compositions of ALK and IRs
differ significantly. Therefore, there is not reason to expect that ALK follows the same ‘preformed dimer’ mechanism as IR – although this remains a possibility. Indeed, it is worth noting
that the MAM, LDLa and EGF-like domains modules are all typically involved in protein-protein
interactions. This suggests three hypotheses for how these domains might function. In one,
these domains could mediate receptor-receptor interactions to form a pre-formed ALK dimer, and
ligand binding is required to induce conformational changes in the dimer in order to render the
kinase domain active. In a second hypothesis, the MAM, LDLa, and/or EGF-like domains could
interact intramolecularly to occlude a dimerization site, as in the tethered EGFR extracellular
region, and ligand binding could serve to expose a dimerization site. In the third and simplest
hypothesis, activating ligands induce dimerization simply by binding to equivalent sites in two
receptor molecules – effectively cross-linking them in a ligand-mediated dimer. In order to
distinguish between these hypotheses, we undertook a biophysical analysis of ALK family
extracellular regions – to determine oligomerization state and domain organization.
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Figure 2.3 Size exclusion chromatography (SEC) analysis of Drosophila ALK (A: green) and
human LTK (B: purple) ECR proteins. SEC standard profile is shown in gray dotted line.
In size exclusion chromatography (SEC) proteins elute based on their hydrodynamic radii.
Therefore (for spherical proteins), the elution time of a protein sample is approximately correlated
to its molecular weight. We measured the SEC profiles of ECR proteins from Drosophila ALK (sDmALK) and human LTK (s-HsLTK), together with an SEC standard. Figure 2.3 shows the
chromatograms of s-DmALK and s-HsLTK superimposed with a standard sample. Based on the
standard run, the elution of the two protein samples is consistent with their theoretical molecular
mass (s-DmALK: 120 kDa, s-HsLTK ECR: 45 kDa, ignoring glycosylation effects). This simple
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result argues that neither ECR protein is a covalently-linked dimer in solution, although it does not
exclude the possibility of weak (Kd ≥ 1-5 µM) non-covalent dimerization, where dissociation during
chromatography would yield a SEC profile suggesting monomeric protein. In addition, given that
LTK lacks the MAM and LDLa domains and appears to be monomeric as well, it can be inferred
that the MAM and LDLa domains do not exist simply to block homotypic interactions mediated by
the TNF-like, glycine-rich and EGF-type modules in the membrane proximal regions of ALK.

Figure 2.4 Analytical ultracentrifugation sedimentation equilibrium studies of s-DmALK protein.
The natural logarithm of absorbance at 280 nm was plotted against the difference of radius
squared and the r0 (meniscus) squared, resulting in a logarithmic plot (‘log plot’) whose slope is
proportional to the weight-averaged molecular mass of the species.
Given that SEC cannot identify dimers with fast off-rates of weak affinity – or dimers that
share similar hydrodynamic radius with the monomer (for instance, ligand-induced dimerization of
EGFR has never been observed by using SEC-based analysis, since the ECR geometry is such
that the Stokes radius for monomer and dimer are similar), we next used analytical
ultracentrifugation sedimentation equilibrium (AUC-SE) to analyze the size of the Drosophila ALK
ECR protein. This approach has been widely used to measure receptor dimerization, including
ErbB family receptor dimerization (Ferguson et al. 2000). In AUC-SE analysis, a logarithmic plot
of the absorbance against a function to the difference of the radius squared (Figure 2.4) can
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unambiguously determine the molecular weight (weight-averaged molecular mass) of the
samples. A linear plot of such type indicates a monodisperse species in solution, and the slope
of the plot is proportional to the molecular weight. Unlike the SEC-based approach, AUC-SE
provides a measure of shape-independent molecular mass. Figure 2.4 shows such a plot for
purified Drosophila ALK ECR protein at concentration of 4 µM. The plot is linear, suggesting a
single species, and approximates the straight line anticipated for a 120 kDa monomer (Figure
2.4).

2.4

Drosophila ALK and human LTK adopt extended conformations

In efforts to visualize the structure of an ALK-family ECR, we attempted (unsuccessfully) to
crystalize both human and Drosophila ALK ECR, as well as human LTK ECR proteins. In
parallel, we used Small-Angle X-ray Scattering (SAXS) to gain a low-resolution view of the ALK
and LTK ECRs in solution. SAXS has been used in studies of the EGF receptor and other ErbB
family receptors in order to determine domain arrangements, and to monitor conformational
changes upon ligand binding as well as dimerization (Dawson, Bu, and Lemmon 2007). Figure
2.5 shows SAXS data for s-DmALK and s-HsLTK ECR proteins to perform the SAXS analysis.
Studies of both proteins yielded a linear Guinier region, suggesting that neither protein is
aggregating – and that the proteins are monodisperse in solution. From these Guinier plots, we
also extrapolated values for the scattered intensity at zero angle (I(0)), which is proportional to the
(shape-independent) weight-averaged molecular weight of a monodisperse species. The
resulting values (listed in Table 2.1) were consistent with our SEC and AUC-SE analyses, and
indicate that both proteins are monomeric.
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Figure 2.5 SAXS analysss of s-DmALK (A) and s-HsLTK (B). In each panel, a P(r) curve is
shown at the left, with a Guinier plot in the center, and a calculated low-resolution envelope (see
text) at far right.
SAXS also provides information on the ‘shape’ of the receptor ECRs, which can provide crucial
hints on the structures and mechanisms of the receptors. For instance, SAXS analysis of the
EGFR ECR unveiled the unliganded tethered conformation in which intramolecular interactions
autoinhibit the receptor – which contrasts with the ‘extended’ conformation of the ErbB2 ECR,
which SAXS studies showed lacks the tethered conformational features seen in EGF receptor
(Alvarado, Klein, and Lemmon 2009). SAXS data provide two key shape parameters. One is the
radius of gyration (Rg), which can be directly extrapolated from Guinier plot (reciprocal space Rg)
or from P(r) curves (real space Rg). Our Guinier analyses suggest Rg values for s-DmALK and
s-HsLTK of 45.1 Å and 29.5 Å, respectively (Table 2.1). In addition, the P(r), or pairwise distance
distribution, curve yields structural information since it summarizes all the distances between any
two points in the molecule. P(r) curves of a spherical protein usually show a unimodal distribution,
whereas proteins containing multiple domains usually exhibit P(r) curves with multiple peaks.
The P(r) curve for s-DmALK protein shows a multi-modal pattern, consistent with a conformation
in which multiple domains are ‘chained’ together in a ‘string-of-beads’-like conformation. This
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analysis also yields a value for Dmax, which delineates the maximum distance between two points
on the molecule – effectively the maximum dimension/length of the molecule. Dmax for s-DmALK
is 130 Å (Table 2.1), which is also consistent with an elongated ‘beads-on-string’ conformation.
These data therefore indicate that the multiple domains in the DmALK are relatively independent,
and further suggest that intramolecular autoinhibitory interactions analogous to the EGFR tether
are not relevant for ALK.
The P(r) curve for s-HsLTK appears more unimodal P(r), as expected for an ECR with
fewer domains, but Dmax is 90 Å – suggesting again an extended structure that contains no
equivalent of the EGFR intramolecular tether.
A further view of these structural considerations is provided by conducting 3D shape
reconstructions using software DAMMIF (Franke and Svergun 2009). As expected, the lowresolution (approximately 20 Å) envelope shown in Figure 2.5A of s-DmALK reveals a relatively
elongated conformation, where multiple ‘beads’ can be clearly seen. On the other hand, LTK
exhibits a smoother shape. This is likely due to the relatively small domains in membraneproximal region, and the intrinsically disordered region in LTK.

2.5

Heparin promotes ALK receptor dimerization to form side-by-side dimer

Human ALK has remained an ‘orphan’ receptor because of the lack of an identified ligand. As
mentioned in Chapter 1, several putative ligands have been suggested, including pleiotrophin
(PTN) and midkine (MK). Both PTN and MK are heparin-binding molecules. Quite surprisingly, a
recent study revealed that it may not be PTN or MK, but heparin itself, that mammalian ALK
directly binds to (Murray et al. 2015). In addition, binding of heparin was shown to induce ALK
receptor phosphorylation in cell-based assays. Hence, heparin is likely to be a ligand or co-ligand
for mammalian ALK. The heparin-binding motif in ALK turned out to be in the N-terminal region
of ECR (N-terminal to the first MAM domain), where conserved lysine and arginine residues are
responsible for mediating the electrostatic interactions with negatively charged heparin. The
binding stoichiometry varies from 1:1 to 1:5 (ALK:heparin) depending on the length of heparin
molecule (and thus charge patterns). Given that heparin binding appears to causes ALK
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oligomerization, we decided to use SAXS to determine its structural basis – that is of how heparin
binding induces receptor dimerization/oligomerization? Does this process involve significant
conformational changes, such as in the case of EGF receptor? Is receptor dimerization mediated
by ligand (as in Trk receptor) or by receptor (as in EGF receptor), or both (as in FGF receptor or
Kit)?

Figure 2.6 SAXS analyses of dog (Canis familiaris) ALK ECR protein (s-CfALK). P(r) curves,
Guinier plots and shape reconstructions of dog ALK-ECR protein (A), dog ALK-ECR protein in
complex with heparin (dp15) (B) and dog ALK-ECR protein in complex with sucrose octasulfate
(SOS) (C).
In order to address these questions, we collected SAXS data for the ECR of dog ALK (sCfALK) and its complexes with dp15 (a heparin molecule containing a 15-mer of disaccharide
unit) and sucrose octasulfate (SOS) (blue, cyan and orange in Figure 2.6, respectively). The
Guinier plots all showed a relatively linear Guinier region, suggesting these samples were all
monodisperse. From the Guinier plot, we also extrapolated the forward scattering intensity (I(0)),
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and further determined the average molecular mass of the samples (summarized in Table 2.1).
The molecular weight is consistent with the previous result that dp15 dimerizes dog ALK. Both
receptor alone and receptor in complex with SOS showed a molecular weight of monomer,
suggesting that SOS cannot dimerize dog ALK. This result suggests that the chain length of the
heparin molecule is crucial for dimerizing the receptor (15 disaccharide units in dp 15, and 1
disaccharide unit in SOS).

Table 2.1 Molecular masses and shape parameters of ALK proteins

Similar to s-DmALK, or SAXS studies showed that s-CfALK also exhibits an elongated
conformation, with a Dmax value of 140 Å. The reconstructed envelope of s-CfALK also closely
resembles that of s-DmALK, arguing that our results for the invertebrate ALK protein are also
relevant for this mammalian ortholog. The complex of s-CfALK with SOS displayed a slightly
larger envelope, with a Dmax value of 150 Å, also with an elongated conformation. In addition, the
P(r) curves of s-CfALK alone closely resembled those of s-CfALK bound to SOS – arguing that
SOS binding does not significantly affect the overall conformation of the receptor. We suggest
that the small ~10 Å increase in Dmax of s-CfALK upon SOS binding may reflect changes in the
local conformation of the N-terminal heparin-binding region – possibly causing it to become more
extended (and thus increase Dmax). Indeed, secondary structure predictions indicate that the Nterminal region of mammalian ALK receptors is largely disordered. In order to bind to heparin,
the heparin-binding motif must align its basic residues to match the sulfate groups in SOS. As a
result, heparin binding could effectively ‘rigidify’ the heparin-binding region and thus increase the
dimension of the receptor slightly. In order to test this hypothesis, we conducted the same SAXS
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analysis using sCf-ALK from which the N-terminal region had been deleted (dN-sCfALK). Figure
2.7 showed the P(r) curves of dN-sCfALK alone and in complex with SOS, and their
reconstructed envelopes. Both samples now have the same Dmax and Rg values. Their lowresolution shapes also resemble each other quite closely.

Figure 2.7 SOS has minimal effect on dN-sCf-ALK protein conformation. Top: P(r) curve of dNsCf-ALK-ECR alone (red) and in complex with SOS (gray). Bottom: Shape reconstruction of dNsCf-ALK-ECR alone (red) and in complex with SOS (gray).
In contrast to the s-CfALK/SOS complex, the complex between sCfALK and dp15 (which
contains 15 disaccharide units) shows a significantly altered P(r) curve and a greatly increased
I(0) consistent with dimerization. The major peak in the P(r) curve (Figure 2.6B) is much broader,
and shows a multi-modal pattern not evident for s-CfALK alone. Despite this – and clear
evidence from the I(0) value that s-CfALK is dimeric – the Dmax value increased only to 160 Å (i.e.
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by only 20 Å). These findings suggest that s-CfALK dimerizes in a ‘side-by-side’ (rather than an
‘end-to-end’) geometry to form the dimer upon dp15 heparin binding. In addition, the fact that the
Dmax value of s-CfALK only increases 20 Å suggests that the receptor forms a ‘parallel’ dimer,
with dp15 likely to be linking the N-terminal regions of the two molecules. Thus, these findings
provide the structural views – albeit at low resolution – for how a ligand can dimerize ALK, leading
to its activation in cells.

2.6

Efforts to make jelly belly, a proposed ligand for Drosophila ALK

Heparin has been identified as a ligand for mammalian ALK – although it is likely that there are
others. It is difficult to see how an RTK could be acutely regulated by modulating heparin levels.
Moreover, Drosophila ALK lacks the N-terminal heparin-binding motif that appears to be
conserved in mammalian ALKs. It has been reported that in Drosophila, a secreted protein called
jelly belly (Jeb) is a ligand for fly ALK. This is genetically supported by developmental studies
where jelly belly and ALK both appear to contribute to mesodermal embryo development. The
two molecules also co-localize during that development stage, and loss-of-function mutataions in
ALK resemble those in Jeb – and vice versa (Englund et al. 2003; Lee et al. 2003). An alkaline
phosphatase fusion protein of Jeb was also reported to bind to mammalian cells expressing
Drosophila ALK, and to activate Erk in these cells (Lee et al., 2003). Beyond this analysis,
however, the biochemical properties of Jeb and its interaction with Drosophila ALK have not been
characterized. This is largely due to the difficulty of making recombinant Jeb. I aimed to overexpress recombinant Jeb from insect cells so that I could characterize its binding to s-DmALK,
and initiate structural studies. Protein expression turned out to be extremely difficult. Only a
trace amount of protein could be produced in Sf9 cells. Moreover, the majority of the generated
protein was not secreted. Having tested several insect cell expression systems and various
expression conditions, I eventually found a condition under which I express Coomassie Blue
stainable amounts of Jeb by secretion from baculovirus-infected Trichoplusia ni (T. ni) cells. The
secreted protein was N-terminally hexahistidine tagged and I was able to purify it using a Ni-NTA
affinity column. Figure 2.8 shows gels of test expressions and Ni-NTA column purifications of
Jeb. To the best of our knowledge, this is the first time full-length Jeb was purified from insect
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cells with such yields. However, my subsequent SPR-based binding assays failed to detect any
binding of Jeb to the Drosophila ALK ECR protein.

Figure 2.8 Test expression and Ni-NTA affinity purification of full-length Jeb. Top: Coomassiestained gel and Western blot of Jeb in 100 ml T. ni cell culture shaking at three speed, 70 rpm, 90
rpm and 100 rpm. Bottom: Purified Jeb is eluted from Ni-NTA affinity column using 150 mM
imidazole.
Since the LDLa domain of Jeb had been implicated by earlier studies as being key for the
interaction of Jeb with Drosophila ALK (Lee et al., 2003), I also undertook efforts to express the
isolated Jeb LDLa domain – the only identifiable domain within Jeb. I used an E. coli expression
system to generate recombinant protein corresponding to LDLa domain in Jeb. I tested several
E. coli strains, expression vectors, and fusion tags and eventually discovered an approach that
yielded protein by using a specific E. coli strain engineered for expressing disulfide-containing
protein, and maltose-binding protein (MBP) as the fusion tag (Figure 2.9). A factor X protease
cleavage site was engineered between the MBP and the LDLa domain. Sequence analysis also
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suggests that the LDLa domain in Jeb is likely to require calcium as a cofactor to properly fold
and form disulfide linkage – so I refolded the protein under the same conditions that were used
for refolding calcium-binding LDLa proteins (North and Blacklow 2000). The resulting protein was
cleaved by using factor X protease to get rid of the MBP tag. However, SPR studies again didn’t
reveal any binding of this LDLa protein to fly ALK ECR.

Figure 2.9 LDLa domain in Jeb. Top: sequence alignment of Jeb LDLa motif (486-540) with
structurally-available LDLa domains. (1ajj: LDL receptor, LDLa module 5, 1d2l: LDLa module in
low densitiy lipoprotein receptor-related protein (lrp), 1jrf and 1k7b: LDLa in viral receptor domain
of Tva, 2jm4: LDLa module in relaxin receptor). Bottom: Coomassie Blue-stained SDS PAGE gels
of purified Jeb LDLa domain fusion proteins (Jeb residues 454-542 and 489-542) and cleaved
products (lanes indicated by asterisk).
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2.7

A possible model for ALK receptor activation

Significant efforts have been made to search for ALK’s ligand(s). In Drosophila, Jeb appears
capable of regulating ALK – with crucial roles in fly embryonic development. The LDLa domain in
Jeb was proposed to mediate its interaction with fly ALK, since Jeb/alkaline phosphatase fusion
proteins lacking LDLa did not bind to the surface of mammalian cells expressing Drosophila ALK
(Lee et al., 2003). In addition, the MAM domains and glycine-rich regions of ALK have been
suggested to be significant in ligand/receptor binding, with mutations in these regions resulting in
loss-of-function phenotypes (Lorén et al. 2003). These pieces of data all suggest that Jeb
functions (at least in part) through ALK-mediated cell signaling. However, it remains unclear
whether Jeb can directly activate the receptor – rather than affecting it indirectly.
In mammals, pleiotrophin (PTK) and midkine (MK) have been proposed as ALK ligands
(Stoica et al. 2001; Stoica et al. 2002), although contradictory results regarding these molecules
exist in literature (Mourali et al. 2006; Mathivet, Mazot, and Vigny 2007; Dirks et al. 2002; MoogLutz et al. 2005; Motegi et al. 2004). Both PTK and MK are heparin-binding proteins – which
inspired a recent study to determine that heparin can bind to and activate mammalian ALK. Both
SPR-based binding assays and cell-based activity assays supported this argument. However,
only the N-terminal region containing the heparin-binding motif is responsible for this interaction.
Deletion of this motif from ALK completely abolished heparin binding and receptor dimerization.
This raises an important question: what is the function of the rest of ALK receptor, which includes
two MAM domains, an LDLa domain, an EGF-type module, a glycine-rich region and a TNF-like
domain? It seems unlikely that these domains have no function – particularly since Drosophila
ALK lacks the the heparin-binding motif and Drosophila genetics reveals important roles for
several of the other domains. Our cell-based analysis also confirmed that heparin cannot activate
Drosophila ALK (Figure 2.10), so how does fly ALK get activated?
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Figure 2.10 Heparin fails to activate Drosophila ALK.
Given the findings in Drosophila and mammalian ALK, we hypothesize that ALK is a receptor that
requires multiple co-ligands and/or co-receptors. Such a paradigm is not uncommon in biology.
Among RTKs, one example is FGFR, which needs both fibroblast growth factor and heparin or
heparin sulfate proteoglycans to form receptor dimers (Schlessinger 2000). Another RTK, RET
(rearranged during transfection) also needs its ligand glial-derived neurotrophic factor (GDNF) as
well as a GPI-anchored co-receptor named GDNF-family receptor-α (GFRα) to promote receptor
dimerization (Lemmon and Schlessinger 2010). We speculate that heparin functions as a coligand to bring together multiple ALK receptors through charge-charge interactions. In addition,
the MAM domains, TNF-like domain, G-rich region and EGF-type module could all interact with
their counterparts in an adjacent receptor either directly or indirectly. We consider three possible
scenarios. (i) The interaction of the two domains is direct – with low affinity, because this
interaction itself is not sufficient to induce receptor dimerization. (ii) The interaction of two
domains across a dimer interface is mediated by a ligand. (iii) The interaction of two domains is
induced by a ligand. That is, a domain in ALK is blocked and binding of a ligand induces
conformational change, which exposes the domain to allow for domain-domain interactions.
These three scenarios could co-exist, and evolution may select a subset of them for ALKs in
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different species. For example, in Drosophila Jeb may contribute to interactions around ‘MAMLDLa-MAM’ region, whereas in mammals, the N-terminal region may have evolved to play an
important role. A similar pattern may also be true in LTK family receptors. In zebrafish, LTK
contains two MAM domains, but mammalian LTK has lost the MAM domains – the membrane
proximal regions are sufficient to activate the receptor and to respond to FAM150A (Zhang et al.
2014). In fact, this suggests that the ligand-binding site in LTK (and possibly in ALK) involves
some combination of the TNF-like domain, the G-rich region, and/or the EGF-type module.
Finally, our proposed model also allows for the formation of hetero-complexes involving coreceptors. It is worth noting that some membrane-anchored phosphatases also contain MAM
domains (e.g. phosphatase µ), or even bind to heparin (e.g. phosphatase σ). Figure 2.11
illustrates our proposed model of ALK activation mechanism.

Figure 2.11 A proposed model for ALK activation mechanism. Each of the components in ALK
ECR could function differently to interact with a co-ligand/co-receptor, or with the same domain in
a different receptor.
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2.8

Conclusions

In this chapter, we aimed to study the molecular basis for ALK activation. We re-assessed the
domain composition of ALK and LTK extracellular region, and found that TNF-like domain and
EGF-type module were likely to exist in ALK ECR. Using biochemical and biophysical
approaches, we determined that the ALK and LTK ECR proteins are monomeric in solution,
suggesting ALK and LTK resemble RTKs like EGF, FGFR, etc, rather than IR superfamily
receptors. Small-angle x-ray scattering studies further provided low-resolution structures of the
ALK and LTK ECRs, revealing that they have elongated conformations. Using heparin, a recently
identified ligand for mammalian ALK, we investigated the low-resolution structure of a heparinpromoted receptor dimer. Our SAXS analysis suggests that heparin binding causes two ALK
ECRs to form a parallel ‘side-by-side’ dimer. Finally, we proposed a model suggesting that ALK
is a multivalent receptor. Ligand-induced activation and regulation of ALK receptor are likely to
involve multiple molecules (co-ligands, or co-receptors).

2.9
2.9.1

Experimental procedures
Domain identification of ALK-ECR protein

Domain identification in ALK ECRs was conducted by submitting to the Phyre2 server a truncated
ALK sequence corresponding to the membrane-proximal region. An iterative approach was used
in order to discover the new domains. The results coming back from Phyre2 server were further
analyzed on Tcoffee Expresso server to evaluate the structural similarity using sequence
information.
2.9.2

Expression and purification of Drosophila ALK-ECR protein

Drosophila ALK ECR protein was expressed from baculovirus-infected insect cells (Sf9 or T. ni).
DNA encoding full-length ALK was subcloned into pFastBac-1 (Invitrogen) for expression of Cterminal histidine-tagged protein. Recombinant baculovirus was generated using Bac-to-bac
system (Invitrogen), following recommended procedures. Sf9 cells were infected with virus and
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incubated for three days at 27°C, and then harvested by centrifugation. The supernatant was
dialyzed against a buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl. The resulting
solution was flowed through a Ni-NTA bead packed column. ALK was eluted with 100 mM
imidazole buffer containing 20 mM phosphate buffer (pH 8.0), 150 mM NaCl. The elution was
slightly concentrated by a concentrator (Millipore, spinning at 2000 g) and then diluted to bring the
imidazole concentration down to 20 mM and NaCl concentration below 50 mM. Cation exchange
chromatography was subsequently used to purify the protein on a TAME column. A typical
gradient started from 50 mM NaCl. ALK was eluted at 130 mM NaCl. The eluted factions were
pooled together and concentrated in a concentrator (Millipore, spinning at 2000 g). The resulting
sample was then injected onto a Superose 6 gel filtration column (GE Healthcare) for size
exclusion chromatography. On the Superose 6 column, ALK eluted at 15.6 ml volume (buffer: 20
mM HEPES pH 7.5, 150 mM NaCl).
2.9.3

Expression and purification of jelly belly protein

Full-length Jeb protein was expressed from baculovirus-infected insect cells (T.ni cells). DNA
encoding full-length Jeb was subcloned into pFastBac-1 (Invitrogen) for expression of Cterminally histidine-tagged protein. Recombinant baculovirus was generated using Bac-to-bac
system (Invitrogen), following recommended procedures. 250 ml culture of T. ni cells were
6

infected with virus at a cell density of 2x10 cells/ml, in a 1-liter spinner flask. The infected cell
culture was incubated for three days at 27°C with a 90 rpm spinning speed, and then cells were
pelleted. The supernatant was dialyzed against a buffer containing 20 mM HEPES (pH 7.5), 150
mM NaCl. The resulting solution was flowed through a Ni-NTA bead packed column. Jeb was
eluted with 150 mM imidazole buffer containing 20 mM phosphate buffer (pH 8.0), 150 mM NaCl.
In occasions where highly purified protein was needed, size exclusion chromatography was used
to further purify the protein. A Superose 6 column (GE Healthcare) was used, with a buffer
containing 20 mM HEPES, pH 7.5 and 150 mM NaCl. On the Superose 6 column, Jeb eluted at
12.5 ml volume (suggesting Jeb is largely disordered).
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2.9.4

Analytical ultracentrifugation analysis of ALK-ECR protein

Sedimentation equilibrium experiments were performed using purified ALK ECR proteins.
Freshly prepared proteins (see above sections for expression and purification) from sizeexclusion chromatography were immediately pooled and concentrated. Proteins were
concentrated to 1.3 µM (O.D. 0.2), 2.7 µM (O.D. 0.4) and 4 µM (O.D. 0.6) and loaded into 6
sector center piece AUC assemblies. Experiments were performed in a Beckman XL-A
ultracentrifuge equipment at 4°C using 9000,12000 and 15000 rpm speeds. Data were collected
at 280 nm absorbance with a 0.001 cm scan step. Scans were continued until the reach of
equilibrium monitored by SedFit software (Schuck 2000). Log plots were generated by using a inhouse developed script that truncates, transforms and plots data.
2.9.5

Small-angle x-ray scattering studies of ALK proteins

For SAXS analyses of fly ALK and human LTK ECR proteins, data were collected at MacChess
G1 beamline. 50 µl of protein sample was loaded in a flow cell so the sample is oscillating in the
cell. A generous oscillation size was used to minimize radiation damage. Data were collected at
one second exposure intervals. Lysozyme and glucose isomerase were used as standard for I(0)
measurement. Data were first reduced using software RAW developed at MacChess (Skou,
Gillilan, and Ando 2014). The subsequent analyses were performed using in-house developed
SAXS program suite EZsaxs, EZshape and EZanalysis, which themselves utilize Gnome, Dammif
and Damaver (Petoukhov et al. 2012; Franke and Svergun 2009).
For dog ALK SAXS experiments, all data for receptor alone and in complex with heparin
(gift from Schlessinger lab) were collected at Penn using a Rigaku PSAXS S-Max3000 smallangle X-ray scattering system equipped with a Osmic mirror optics, an evacuated sample
chamber kept at 4 °C, and a gas-filled multi-wire detector. A Rigaku MicroMax-007 HF
microfocus rotating anode generator was used as x-ray source. The raw data were first averaged
and reduced using SAXSGUI software (ver. 2.5.7). The resulting data were analyzed by using
ATSAS Primus software (Konarev et al. 2003). P(r) curves calculation and shape reconstruction
were conducted using the software suite EZsaxs, EZshape and EZanalysis, which themselves
utilize Gnome, Dammif and Damaver (Petoukhov et al. 2012).
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Chapter 3 Investigating the molecular basis of Ryk/Wnt
interactions
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3.1

Introduction

Ryk (Related to tYrosine Kinase) is a sub-family of receptor tyrosine kinases (Yee et al. 1993;
Hovens et al. 1992). It is unique among RTKs in that it is the only receptor that contains a Wntinhibitory factor (WIF) domain in its ectodomain. The WIF domain suggests a link to the Wntfamily ligands. In addition, the kinase domain in Ryk lacks key residues known for carrying
phosphotransfer catalysis. Therefore, like other RTKs that are also Wnt receptors (Ror1, Ror2
and PTK7/CCK4), Ryk appears to be a pseudokinase (Mendrola et al. 2013).
The WIF domain in Ryk contains about 130 residues and shares 23% sequence identity
with the human WIF-1 protein. Studies have shown that Ryk and certain Wnts coimmunoprecipitate (Lu et al. 2004), and knockdown of Ryk abolishes Wnt-promoted TCF
pathways, suggesting Ryk and Wnt interacts.
In Drosophila, Ryk has three homologues, Derailed (Drl), Derailed-2 (Drl-2) and
Doughnut (Dnt). Drl plays a key role in mediating axon pathfinding in Drosophila embryonic
central nervous system (CNS) (Bonkowsky et al. 1999; Callahan et al. 1995). Expression of Drl
guides the neurons to project axons through the anterior commissure (instead of the posterior
commissure). Flies lacking Drl fail this process and their axons show defective paths (thus the
name derailed). The Drl-guided axon pathfinding is mediated by DWnt5, which is expressed
predominantly in the posterior commissure(Fradkin, Noordermeer, and Nusse 1995). In addition,
a Drl-FC fusion protein is able to bind to a DWnt5-expressing region in Drosophila embryos, and
to co-immunoprecipitate Dwnt5, suggesting that Drl and DWnt5 interact (Yoshikawa, Bonkowsky,
and Kokel 2001). In addition to directing axon pathfinding, Drl and DWnt5 also play important
roles in other Drosophila developmental processes, such as patterning of olfactory receptor
neurons (ORNs) in the fly antennal lobe (Sakurai et al. 2009; Yao et al. 2007), development of
mushroom bodies (Moreau-Fauvarque et al. 1998; Grillenzoni et al. 2007), and migration of the
salivary gland (Harris and Beckendorf 2007).
Drl-2 shares 44% sequence identity with Drl in the WIF domain. Drl-2 is also expressed
in Drosophila ORNs and functionally complements Drl in the development of the Drosophila
olfactory system (Sakurai et al. 2009). The third ortholog, Dnt, shares 64% sequence identity
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with Drl. Studies have shown that Dnt can partially rescue embryonic muscle attachement
defects caused by lack of Drl during fly embryogenesis, suggesting that Dnt and Drl may function
similarly during embryonic development (Oates et al. 1998).
There are several alterations in the kinase domain of Ryk/Drl that suggest that it lacks
activity: (i) the first GxGxxG motif is altered, (ii) the DFG motif is replaced with the sequence D-NA in Ryk and D-S-A in Drl, and (iii) the alanine in VAIK motif (in the ATP-binding pocket) is
replaced by phenylalanine in Ryk and by leucine in Drl. Efforts to characterize the kinase activity
of Ryk/Drl so far all seem to suggest that the kinase domain in Ryk/Drl is completely kinase-dead
(by contrast with the pseudokinase ErbB3, which still has a low-level kinase activity (Shi et al.
2010)). For example, a lysine to alanine Drl mutant (K371A), which would be presumed to disrupt
the active conformation of the kinase (and abolish kinase activity), did not alter the phenotype
associated with wild-type Drl (Yoshikawa, Bonkowsky, and Kokel 2001; Taillebourg et al. 2005).
This variant appears to function competently in Drosophila axon guidance and muscle attachment
assays, suggesting Drl/DWnt5 signaling doesn’t require the kinase activity of Drl. Similarly, a
TrkA-ECR/Ryk-ICR chimeric protein did not show any phosphorylation upon stimulation by NGF,
the ligand for TrkA – again suggesting that Ryk is kinase-dead (Katso, Russell, and Ganesan
1999).
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Figure 3.1 WIF domains in Ryk and Derailed. A: Domain architecture of Ryk and Derailed. WIF:
Wnt inhibitory factor domain; S/T rich: serine/threonine rich motif; PTK: protein tyrosine kinase
domain. B,C: Sequence alignment of WIF domains in Derailed, Ryk and human Wnt inhibitory
factor-1 (B), and of Derailed, Doughnut and Derailed-2 in Drosophila (C).
Given the evidence for DWnt5/Drl signaling events and the lack of kinase activity in Drl, it
seems likely that Ryk/Drl signals through a mechanism that differs from that of other RTKs.
Moreover, other studies have suggested the inactive kinase domain in Ryk/Drl is competent for
signaling in several contexts. For instance, the kinase domain of Ryk fused with a nuclear
localization signal (NLS) can functionally replace full-length Ryk to determine cell fate in neural
progenitor cells (Zhong et al. 2011). The TrkA-ECR/Ryk-ICR chimeric protein is able to activate
the MAPK pathway and induce Erk phosphorylation in response to NGF (Katso, Russell, and
Ganesan 1999). Importantly, the chimeric protein with a K334A mutation abolished Erk
phosphorylation, suggesting it is likely to be the conformation, rather than the activity, of the
kinase domain that plays the role in Ryk/Drl signaling, since the K334A mutation, which disrupts a
key salt-bridge, might significantly alter the conformation of the kinase domain. In Drosophila, it
has been shown that the Src family kinases are required for DWnt5 signaling in the embryonic
central nervous system (Wouda et al. 2008), leading to a hypothesis that the pseudokinase
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domain in Ryk/Drl may function as a scaffold protein to allosterically regulate an associated
kinase (Src in this case) (Wouda et al. 2008). Despite these clues, the detailed molecular
mechanism as to how Wnt binds to and activates Ryk/Drl and how Ryk/Drl signals remains to be
determined.

3.2

Expression and Purification of Drosophila Wnt5 protein

One big obstacle in studying Wnt family proteins and their receptors biochemically and
structurally is the difficulty of over-expressing and purifying Wnt proteins. This is thought to be
due in part to the post-translational modifications of Wnt (lipidation in particular), which usually
generates insoluble protein samples in in vitro experiments. While we have experienced the
same technical difficulty in expressing mammalian Wnt proteins, our efforts in screening various
expression systems and Wnts from various species led to success in generating milligram
quantities of soluble Drosophila Wnt5 protein that can be purified to homogeneity.
We expressed the full-length DWnt5 protein from Drosophila Schneider 2 (S2) insect
cells. We initially tested two expression systems in S2 cells, a metallothionein promoter-based
inducible system with pMT-based plasmids, or pUAST plasmids (with co-transfection of pAcGAL4 to drive the expression and pCoHygro for selection). The latter system yielded slightly
higher amounts of protein from S2 cells.
To further facilitate biochemical and crystallographic studies of DWnt5, we next
engineered a second generation of DWnt5 constructs (depicted in Figure 3.2), in order to improve
protein yield and purity. We observed that the N-terminal domain (~450 residues) of full-length
DWnt5 protein is cleaved in generation of the mature protein. The cleavage might be
heterogeneous, and the resulting mature protein contains a disordered region N-terminal to the
beginning of the Wnt homologous domain (based on our HX-MS experiments with DWnt5). In
addition, there is a unique insert in the Wnt-homologus domain in DWnt5, which appears to have
no sequence homology to any known motifs. Based on these observations, I introduced a TEV
cleavage site at the beginning of the Wnt-homologus domain (Figure 3.2), to allow removal of the
disordered remainder of the N-terminal domain in the full-length protein after cleavage. In
addition, I engineered a hexa-histidine tag in the insert region to facilitate affinity purification. I
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also engineered a construct in which the predicted disordered region in the insert was removed,
with the intention of generating a ‘minimal’ Wnt protein construct for crystallography.

Figure 3.2 DWnt5 constructs used for expressing DWnt5 proteins from Drosophila Schneider 2
cells. The full-length DWnt5 is composed of a signal peptide, a large N-terminal domain that is
removed by cleavage in generating the mature protein, and a Wnt-homologous domain with an
insert domain of ~150 residues that is unique among all Wnt-family proteins.

I purified DWnt5 protein that had been secreted by transfected S2 cells using a low-resolution
cation exchange step (SO3 column), followed by a high-resolution cation exchange step (SO3
column), a hydroxapatie (CHT) column and finally a gel-filtration column, as described in detail in
Section 3.9.2 below. These purification steps led to reasonably pure protein that gave two major
bands on Coomassie-stained SDS-PAGE gels. Western blotting confirmed that both bands
contained a key epitope close to the C-terminal end of the N-terminal region. In order to
determine which species correspond to these two bands, I used mass spectrometry to ‘sequence’
these two bands. Each band was extracted from the SDS-PAGE gel, destained, reduced, and
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digested with trypsin. The sample was then loaded to an Orbitrap ESI-MS spectrometer, and
spectra were collected using standard protocols. The resulting peptides were compared
unbiasedly with a Drosophila proteome database. As illustrated in Figure 3.3, the spectral counts
analysis of the MS data suggest that the two major bands on the gel are indeed DWnt5 proteins.
However, the upper band appears to contain predominantly the N-terminal domain of full-length
DWnt5 based on peptide counts, whereas the lower band comprises primarily the ‘mature’ Wnt
homologous domain-containing protein that should result from the cleavage of N-terminal portion.
Why a protein containing primarily the N-terminal region would run at the higher molecular weight
is not clear.

Figure 3.3 Coomassie Blue-stained gel of purified DWnt5 protein (left) and mass spectroscopic
analyses of the two major DWnt5 bands on the gel (right). The mass spectrometry experiments
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were performed at the Proteomics Facility in the Wistar Institute. A in-house developed script
was used to analyze the raw data and to generate peptide plots.
Although our purification still has significant room to improve, the DWnt5 sample is sufficiently
pure for most biophysical assays of activity. In order to further purify the protein, an orthogonal
purification step will need to be added, perhaps employing a different tag, or a column with
different chemistry.

3.3

DWnt5 binds directly to Drl

In parallel to expressing and purifying DWnt5, we succeeded in expressing the isolated
extracellular regions of Drosophila Drl (sDrl), Drl-2 (sDrl-2) and Dnt (sDnt) by secretion from
insect cells (see Section 3.9.1). Using surface plasmon resonance (SPR), we were able to
demonstrate direct interactions between each of these proteins and wildtype purified DWnt5
(Figure 3.4, work done by Dr. Fumin Shi in the lab). Either sDrl or DWnt5 was covalently
immobilized on a Biacore CM5 chip, and the potential interacting molecule was flowed over the
chip while monitoring resonance signal. By performing SPR assays in two ways – with either
immobilized ligand or immobilized receptor fragment, we were able to eliminate the possibility of
that the apparent binding arises from contaminating proteins or artifactual interactions with the
Biacore chip, and can conclude confidently that DWnt5 binds directly to the extracellular region of
Drl family RTKs (with a sub-micromolar binding affinity).
In addition to assessing Drl family binding of wild-type DWnt5, I used similar binding
assays to analyze binding of the engineered DWnt5 proteins described in the previous section.
SPR data suggest that the engineered DWnt5 binds to Drl with an affinity comparable with that
measured for wild-type DWnt5 (Figure 3.4 B). Due to the higher yield and quality of the
engineered DWnt5 protein, unless otherwise explicitly stated, the engineered DWnt5 protein was
used in the rest of the experiments described in this chapter (the engineered construct without
thehexa-histidine tag).
It is worth noting that, the binding affinity is likely to be higher than the apparent Kd
reported for the SPR assays in Figure 3.4, since the DWnt5 protein sample is a mixture of the N74

terminal domain (which we do not expect to bind receptor) and the Wnt homologous domain (for
which binding signals are expected).

Figure 3.4 (A) SPR assays of DWnt5 binding to the extracellular regions of Derailed (sDrl),
Derailed-2 (sDrl-2) and Doughnut (sDnt) (work done by Dr. Fumin Shi in the lab). Left: DWnt5
was immobilized on a CM5 chip, and sDrl/Dnt proteins were flowed across the resulting surface
at different concentrations to measure the surface response unit (RU). Binding affinities were
estimated by fitting the data points to a simple single-site specific binding model. Right: The
complementary binding experiment in which sDrl or its homologues were immobilized and DWnt5
was flowed across the chip at different concentrations. (B) The engineered DWnt5 exhibits
similar Drl binding affinity compared to the wildtype protein.
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3.4

Structure and conformational dynamics of sDrl

Since we were able to purify both DWnt5 and sDrl, and to verify that they interact directly using
SPR studies, we used these Drosophila proteins as a model system to characterize Ryk/Wnt
interactions more generally. We first utilized X-ray crystallography to study the structure of the
receptor extracellular region, in parallel with hydrogen exchange studies to visualize the dynamics
of the sDrl WIF domain. Our crystallographic efforts led to a 2.2 Å resolution crystal structure of
sDrl-2 (work done by Fumin Shi in the Lemmon laboratory and illustrated in Figure 3.5). The
sDrl-2 WIF domain (cyan in Figure 3.5) consists of two α helices and nine β strands, and closely
resembles the structure of the WIF domain in hWIF-1 domain. In hWIF-1, a DPPC molecule was
found co-crystalized in the hydrophobic cavity between the two sheets and α helices (yellow
cartoon in Figure 3.5). The existence of this lipid molecule suggested that hWIF might interact
with lipidated Wnt molecules through this hydrophobic cavity (Malinauskas et al. 2011). By
contrast, there is neither a lipid molecule nor a central cavity in the sDrl-2 structure, arguing that
the basis for Wnt binding may be different in this case. Moreover, the hydrophobic residues
mediating the interactions with DPPC in hWIF are not conserved in the sDrl-2 structure. Thus,
although sDrl-2 exhibits a similar structure to the hWIF1 WIF domain, it seems likely to bind to
DWnt5 by a different mechanism.
It is worth noting that the two α helices in hWIF-1 crystal structure differ slightly in length
and orientation from their counterparts in the solution NMR structure of hWIF-1 (Figure 3.5, red
and yellow cartoons) (Liepinsh et al. 2006). In the hWIF-1 crystal structure, helix α1 and α2
appear shifted inwardly and outwardly, respectively, in order to accommodate the bound DPPC
molecule. In sDrl-2, although no DPPC was bound in the structure (and there is no cavity to
accommodate it), the positions of α1 and α2 are very similar to those in hWIF-1 crystal structure.
This may suggest that these two helices are mobile, and may play some role in Drl/DWnt5
interactions. Given the potential importance of these two helices, I next performed hydrogen
deuterium exchange (HX) coupled with mass spectrometry (HX-MS) experiments to characterize
the conformational dynamics of the sDrl WIF domain.
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Figure 3.5 Crystal structures of WIF domains. Left: crystal structure of the Derailed-2 WIF
domain; Middle: NMR structure of hWIF-1 WIF domain (PDB: 2D3J); Right: crystal structure of
hWIF-1 WIF domain (PDB: 2YGN).
In HX-MS studies, the backbone amide hydrogen exchange rate is characteristic of the local
environment of the amide group. Generally speaking, amide hydrogens in unstructured regions
exchange faster than those in structured region (in a hydrogen bond), and amides in structurally
rigid regions exchange slower than those in structurally dynamic regions (Skinner et al. 2012). By
discerning these differences, the hydrogen exchange rate can provides rich information for both
structure and conformational dynamics of proteins. I performed HX-MS studies on sDrl
N63Q/N143Q, a double mutant that lacks two N-glycosylation sites (and therefore has better
peptide coverage compared to wild-type sDrl) yet fully retains DWnt5 binding capacity. As shown
in Figure 3.6, sDrl-derived peptides exhibit a wide range of exchange rates. For instance, in the
peptide of residues 134-147 (upper red loop in Figure 3.6), more than half of the amide
hydrogens were completely exchanged within 10 seconds, suggesting that this region is likely to
be dynamic and largely unstructured. On the other hand, residues in the β-strands have low
exchange rates, indicating that they are relatively stable and rigid, as expected. Interestingly, the
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region spanning residues 27-66 (pink in Figure 3.6) displayed a fast exchange rate despite
including two α helices and two β strands. In particular, two peptides (residues 52-55 and 52-56,
shown in pink in Figure 3.6) spanning helix α2 in the model displayed an exchange rate that is
only slightly lower than that of unstructured peptides. These data suggest that this region,
especially around helix α2, is highly dynamic in solution and might constantly sample different
conformations, even though it appears to be fully folded in the crystal structure of sDrl-2 and its
derived homology model of sDrl.
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Figure 3.6 Conformational dynamics of the Drl WIF domain measured by hydrogen exchange
rates. For each peptide, the exchange time to exchange half of the protons on the peptide was
estimated and used to characterize the ‘speed’ of the exchange. Peptides were clustered based
on this characteristic time and colored on a sDrl WIF domain homology model based on the lab’s
structure of the sDrl2 WIF domain.

3.5

MD simulations of DWnt5 structure

It took 30 years to get the first molecular picture of Wnt molecule. In 2012, the Garcia lab
published the first crystal structure of Wnt. This structure of Xenopus Wnt8 in complex with (and
co-expressed with) mouse Frizzled8 CRD domain provided the first view of how Wnt family
proteins fold, and unveiled a novel mechanism of Wnt/CRD interactions. The XWnt8 protein is
composed of two domains, the N-terminal domain (NTD) and a C-terminal domain (CTD). NTD is
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largely composed of a helical bundle with a β sheet and a key serine residue (S187) modified with
a palmitoleic acid acyl chain. The CTD is composed of a long β strand and an unstructured loop
with disulfide linkages stabilizing the structure. The overall shape of XWnt8 resembles a hand –
a ‘thumb’ and an ‘index finger’ protruding from the ‘palm’ to pinch the two opposite sites of the
CRD domain that it binds (Janda et al. 2012).
Despite the significance of this crystal structure, much remains to be learned molecularly.
For instance, this crystal structure was obtained by co-expressing and co-purifying XWnt8 and
the mFz8 CRD domain, raising the question as to whether this structure truly represents a
biologically-relevant complex structure, or might be a kinetically-trapped intermediate. The ‘loose’
interface suggests this possibility. It is also worth noting that the association appears
substantially driven by hydrophobic interactions between the long acyl chain on the Wnt molecule
and the hydrophobic groove on the CRD. During the biogenesis of Wnts, they are typically first
acylated, and then either transported for further processing, or directly secreted. There are
known ‘chaperone’ type molecules that ‘shield’ the acyl chain before the Wnt finds its binding
partners, one example being the SWIM protein (Mulligan et al., 2012), a member of the lipocalin
family. However, in the co-expression of XWnt8 with mFz8, the mFz8 CRD may function as a
chaperone molecule to bury the acyl chain of XWnt8, and it is possible that the binding mode
seen crystallographically may not reflect the binding mode that occurs when the Wnt molecule
binds to a Fz CRD at the cell surface. It is equally possible that there is no such Wnt chaperone
protein. However, in this case, the XWnt8 structure in the complex shown in Figure 3.7 cannot
reflect the structure of this Wnt alone in solution. The long palmitoleic acid chain cannot directly
protrude into the solvent due to its hydrophobicity. Therefore, the Wnt must alter its conformation
(or oligomerization state) from that seen in the XWnt8/mFz8 structure to hide its acyl chain and
remain solubilized. In addition, DWnt5 may adopt a different conformation since the conserved
serine in DWnt5 is not modified (Fumin Shi, unpublished data). To test these hypotheses and to
shed more light on the possible structures of Wnt proteins, I conducted molecular dynamics (MD)
simulations to study the structure and conformational dynamics of Wnt molecule.
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I first built a homology model of DWnt5 based on the isolated structure of Xenopus Wnt8
in the crystal structure. The resulting homology model resembles XWnt8 except that it has no
acyl chain. Next, I performed 50 nanoseconds of MD simulations to allow the homology model to
‘relax’ in water solvent by sampling its conformational space. Analysis over the trajectory of the
molecule suggests that the starting conformation of DWnt5 is not likely to be the stable
conformation, since the structure of DWnt5 quickly diverged from the conformation at the
beginning of the simulations – and arrived at a completely different conformation after ~30 ns. In
the last 20 ns of the simulations, the overall conformation of DWnt5 did not change significantly,
as can be manifested by the local fluctuations of the RMSD value (Figure 3.7). Figure 3.7 plots
the RMSD (root-mean-square deviation) value of the main-chain carbon coordinates with respect
to the lowest-energy conformation. The plateau in the plot beginning at ~30 ns indicates the
convergence of the ‘free’ molecule (not bound to a Fz CRD domain) to a different and more likely
conformation of DWnt5.
Our MD simulations suggest that DWnt5 – without lipid modification – is likely to adopt a
different conformation than that seen in the XWnt8/mFz8 crystal structure. In the MD trajectory,
the ‘thumb’ and ‘index finger’ appear to attempt to ‘grab’ whatever lies between them. Without a
CRD in this location, however, the ‘thumb’ and ‘index finger’ ended up making direct contact.
These observations, summarized in Figure 3.7, lead to a hypothesis that Wnt molecules
constantly sample conformations by reorienting their ‘thumb’ and ‘index finger’. For Xenopus
Wnt8 (and most other Wnts), the thumb is equipped with a very ‘sticky’ chain to grab hydrophobic
molecules, whereas for DWnt5 a different mechanism might be used for the finger to cooperate in
‘grabbing’ the binding partner.
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Figure 3.7 (A) Crystal structure of Xenopus Wnt8 binding to mouse Fzd CRD domain from the
Garcia lab (Janda et al. 2012). (B) Molecular dynamics (MD) simulations of DWnt5 in solution.
Top: plot of the root-mean-square deviation of main-chain atoms in each snapshot with respect to
the lowest-energy conformation. Bottom: representative conformations of DWnt5 in the MD
simulations trajectory. In the first 30 nanoseconds, DWnt5 is actively sampling different
conformations by swinging the ‘thumb’ and ‘index finger’. In the last 20 nanoseconds, DWnt5
converged on a stable conformation in which the ‘thumb’ and ‘index finger’ contact each other
directly.

3.6

Ligand binding interface on Drl

One key question that we would like to address concerns how Drl recognizes DWnt5. Knowing
the structure of the WIF domain in Drl and having a homology model of the Wnt do not provide
much insight into the structural nature of the complex, and the interactions used. In order to
understand how the Drl WIF domain interacts with a non-lipidated DWnt5 molecule, we employed
both mutagenesis analysis and HX-MS approaches to map the DWnt5 binding interface on sDrl.
I performed HX-MS assays for both Drl alone and Drl/DWnt5 complex. The principle
underlying the HX-MS approach is that the binding interface of a molecule is exposed to solvent
when the components are studied alone, but is shielded by its binding partner in the complex.
Therefore, in HX-MS experiments, peptides showing a decreased exchange rate in the complex
tend to be located in the binding interface. As shown in Figure 3.8b, upon DWnt5 binding the
most significant changes of H/D exchange rates for Drl lay in the region of helix α1, strand β1 and
part of β2 (residues 2-42) together with helix α2 (residues 52-56). To a lesser extent, the loop
connecting strand β2 and helix α2, the loop between strand β3 and β4, as well as strand β3, β4
and β7 also displayed a decreased rate of exchange. On the other hand, amide hydrogens
residing in the rest of the WIF domain (strand β5, β8, and β9) and the C-terminal tail (residues
162-194) showed essentially no change in protection upon ligand binding. Therefore, our HX/MS
data suggest that the regions showing most significant change of hydrogen exchange rate upon
DWnt5 binding – helices α1, and α2, strand β1 and β2 – are likely to encompass the interface of
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Drl binding to Dwnt5. These regions coincide with those that appear to be highly dynamic in
Figure 3.6. Therefore, we hypothesize that the dynamic nature of the identified region (helices
α1, and α2, strand β1 and β2) may play a role in mediating DWnt5 binding.
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Figure 3.8 Identification of DWnt5 binding interface on Drl WIF domain. A: Representative Drl
peptides showing significant protection upon DWnt5 binding. B: cartoon representation of
conserved residues in a Drl model. Sidechains of the conserved residues are shown in sticks,
and colored according to their regions. C: Changes in hydrogen exchange rates of Drl peptides
upon DWnt5 binding were computed, grouped and colored on a Drl model. D: SPR-based
binding assays of point mutations of Drl, measured by flowing the mutants through DWnt5immobolized chip (Kd shown in the table).
In parallel to HX-MS analysis of Drl binding interface, we introduced point mutations to
Drl WIF domain and used SPR-based binding assays to test the effect of each mutation on
DWnt5 binding. We picked six residues (E40, L41, F56, V58, E126, and I154) located on an
evolutionarily conserved surface to mutate to either lysine or glutamate (Figure 3.8 B). SPR
results suggested that mutating E126 or I154 had little effect on DWnt5 binding – suggesting that
the corresponding region (in elements β8 and β9) is not involved in Wnt binding. Y52E, F56E
and V58E mutants all showed reduced DWnt binding (~ 50 fold), and an E40K mutant showed
~10-fold reduction of binding (Figure 3.8 D). These mutational studies are in excellent agreement
with the HX-MS results, further supporting the conclusion that the receptor binding interface is the
splayed corner/helical region and sandwich surface (colored region in Figure 3.8 C), which
encompasses helices α1 and α2 as well as strand β1 and part of β2.
In vivo assays done by our collaborators in Lee Fradkin’s lab also support our identified
Drl/DWnt5 binding interface. Drl directs axon pathfinding in fly embryo development. In an in
vivo study, wild type or F56E-mutated Drl was introduced into the chromosomal site of Drl to
generate transgenic flies. DWnt5-dependent commissural axon switching during embryonic
development was then assessed. Whereas wild type Drl was sufficient to drive the majority of
neurons to cross midline normally through the posterior commissure to switch to the adjacent
anterior commissure, overexpression of the F56E mutant (mutated in the binding interface) did
not support axon switching (unpublished data), suggesting that the mutation abolished Drl’s
signaling capacity – presumably due to a loss of DWnt5 binding.
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3.7

Efforts to identify binding interface on DWnt5

My MD simulations of DWnt5 suggest that the unbound, non-acylated DWnt5 molecule may
adopt a conformation that differs from that for XWnt8 seen in the XWnt8/mFz8 complex crystal
structure. This raises an important question: what is the binding site on DWnt5 that interacts with
the Drl WIF domain? Is it in a different location from the interface on XWnt8 that interacts with
the mFz8 CRD ? Indeed, given the lack of lipid modification, the binding interface on Wnt for Drl
WIF domain binding may be significantly different from that for CRD binding. In order to address
this question, I initiated efforts to perform HX-MS analysis to map the WIF domain-binding
interface on DWnt5.
Although such an approach successfully led us to the Drl/DWnt5 binding interface on Drl,
my pursuit of the interface on DWnt5 itself turned out to be difficult. The biggest challenge is a
technical one. In a typical HX-MS experiment setup, the protein sample needs to be denatured
and then cleaved by proteases (usually pepsin) to generate many overlapping peptides for LCMS/MS analysis. The cleavage procedures need to be conducted at low-temperature in a low-pH
solution for a very short period of time, in order to minimize back exchange of amide protons
which confounds the method – and the deuterium incorporated at amide groups starts to
exchange back with solvent protons immediately once the sample is removed from D2O solution.
At the same time, all of the disulfides need to be cleaved, since the mass spectrometer cannot
faithfully determine the primary sequence of disulfide-containing peptides. Unfortunately, the lowtemperature and low-pH conditions disfavor the disulfide reduction reactions required for this.
The problem is further aggravated when the protein sample has disulfide-rich region, because
complete reduction of multiple disulfides in one peptide is much less likely than reducing one
disulfide per peptide. Indeed, my data suffered greatly from this problem when attempting to
collect HX-MS data for DWnt5. Figure 3.9 illustrates my initial peptide coverage map of DWnt5. I
was able to identify ~ 100 peptides, over the region of the protein containing no disulfides. As
can be seen in Figure 3.9, the peptides corresponding to disulfide-rich regions were poorly
identified. Unfortunately, these regions are also the most interesting regions since they constitute
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the ‘thumb’ and ‘index finger’ that ‘pinch’ the frizzled CRD domain in the XWnt8/mFz9 complex
structure.
I aimed to improve peptide coverage using two different approaches. First, I screened
conditions for enhancing HX-MS compatible disulfide reduction. In a typical HX-MS experiment,
~10-50 mM TCEP (tris-2-(carboxyethyl)phosphine) was used as a reducing agent in the
quenching solution (used to stop the HX reaction – see Section 3.9.4), which is usually buffered
at pH 2.4. Increasing the concentration of TCEP in this solution could in principle speed up the
reduction reaction. However, TCEP is a strong acid (in the form of TCEP-HCl), and a high
concentration of TCEP significantly alters the acidity in the solution. After screening various
combinations of TCEP concentration, buffer concentration and optimal pH value, I arrived at a
condition containing 500 mM TCEP, pH 2.8 with 500 mM glycine/HCl as buffer agent. Under this
condition, I was able to maximize the number of reduced peptides while not having significant
back exchange effects. Secondly, I optimized data acquisition in order to collect MS spectra for
as many reduced peptides as possible. In the MS setup used for these studies (and most
Orbitrap mass spectrometers), the LC-MS/MS data collection uses a scheme called data
dependent acquisition (DDA). That is, at each slice of time, a fixed number of precursor ions are
selected based on their signal intensities – and are subjected to a second stage of tandem mass
spectrometry. Because of incomplete reduction, disulfide-containing peptides tend to have lower
abundances compared to those without disulfides, and thus tend to show lower m/z intensity in
the initial mass spectrum. As a result, even though they are partially reduced, their relatively low
abundance in the initial spectrum causes the disulfide-containing peptides not to be selected by
the DDA scheme. To tackle this issue, I changed the DDA rule so that all reduced peptides are
selected once detected – no matter how low abundant they are. In order to implement this DDA
rule, the elution time of these peptides must be known, so that DDA can select the relevant ions.
The complete list of all reduced peptides and their elution time is compiled by performing several
rounds of regular MS/MS experiments with a fully reduced protein sample. At the same time, I
compiled another list containing high-abundance contaminant ions. With these two lists, I could
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instruct the DDA scheme to ignore high-intensity contaminant ions and select only those (lowerlevel) reduced peptides that we are interested in.
Figure 3.9 summaries the new coverage map of DWnt5 after incorporating these two
approaches. The coverage was significantly improved, as expected – with ~180 peptides
representing the DWnt5 molecule (i.e. ~80 more peptides). More importantly, the disulfide-rich
region (‘thumb’ and ‘index finger’) are better covered. I next performed H/D exchange
experiments in an effort to identify the Drl-binding interface on DWnt5. Despite my efforts – and
partial success – in improving the coverage map, I found in the H/D exchange experiment itself
that many low-abundance peptides disappeared. This is likely due to the further spreading of the
isotopic distribution of those peptides upon HX that effectively reduces the intensity of the peaks
further, and makes them harder to detect. Among the peptides that I could detect, I was unable
to find any that showed a significantly altered H/D exchange rate upon Drl binding, suggesting
that these covered regions are not likely to be in the binding interface (Figure 3.10).

Figure 3.9 DWnt5 peptide coverage. Compared to the original DWnt5 peptide coverage map
(top, ~ 100 peptides), the new coverage (bottom, ~ 180 peptides) is significantly improved by
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using optimized reduction conditions and specific rules for data acquisition. The cysteines are
explicitly labeled along the residue number to indicate the disulfides.

Figure 3.10 Hydrogen exchange data of peptides colored in red have been fully collected, which
showed unaltered exchange rate upon binding of Drl WIF domain, suggesting these regions in
red are not likely to be the binding interface for Drl.

3.8

Conclusions

In this chapter, I aimed to study the molecular basis for Ryk/Wnt signaling, in particular trying to
understand how the Wnt molecule binds to Ryk family extracellular region. We used the
Drosophila Drl/DWnt5 system as a model to characterize the molecular mechanisms of Wnt5
binding to Ryk WIF domain. We were able to generate milligrams of purified DWnt5 protein, and
characterized the surface of the Drl WIF domain to which it binds. Using a combination of
hydrogen exchange experiments and MD simulations, we also characterized the structure and
conformational dynamics of Drl WIF domain and DWnt5 structure. Our efforts to identify the
binding interface on DWnt5 failed to locate the surface of the DWnt5 molecule that associates
with the Drl WIF domain, due to the limited peptide coverage of DWnt5. However, the limited HX
data we collected so far implied the regions that are unlikely to be the binding interface (the red
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regions in Figure 3.10). While the exact Drl binding interface (and mechanism) on DWnt5
remains to be revealed, our MD simulations suggest that DWnt5 might exhibit different
conformation and/or conformational dynamics compared to Xenopus Wnt8 in the crystal
structure, therefore there might exist a novel binding mechanism for Drl/DWnt5 binding.

3.9
3.9.1

Experimental procedures
Expression and purification of Drl, Drl2 and Dnt

A PCR product encoding the 6xHis tagged Drl extracellular region (sDrl: residues 1-242) was
subcloned into the pFastBac1 plasmid (Invitrogen). The extracellular regions of Drl-2 (sDrl-2: 1183) and Dnt (sDnt: 1-208) with a C-terminal 6xHis tag were also subcloned into pFastBac1 in
the same way (done by Dr. Fumin Shi in the lab). Recombinant baculoviruses were generated
using the Bac-to-Bac system (Invitrogen) as instructed by the manufacturers to infect Sf9 insect
cells. Cell medium was harvested three days after infection and subjected to diafiltration at 4˚C
against buffer (50 mM HEPES pH 7.5, 150 mM NaCl). Histidine-tagged protein was then
collected from the medium using a Ni-NTA affinity column (Qiagen). For sDrl purification, the NiNTA resin with bound protein was washed twice with low-imidazole buffer (20 mM HEPES pH
7.5, 150 mM NaCl and 15 mM imidazole) and sDrl protein was then eluted from the Ni-NTA resin
using buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl and 100 mM imidazole. sDrl
protein was further purified using a UnoQ anion exchange column (BioRad), loading the protein
on to the column in 20 mM HEPES pH 7.5 and 70 mM NaCl, and eluting with a gradient from 70
mM to 1 M NaCl in this buffer. A Superose 12 sizing column (GE Healthcare) was used for a final
purification step, run in 10mM HEPES pH 7.5 containing 150mM NaCl. The final protein yield
was ~ 1mg/liter of medium. Other sDrl variants and Drl homologs are purified with a similar
strategy. All purifications were performed at room temperature.
3.9.2

Expression and purification of DWnt5

DNA encoding full-length DWnt5 was sub-cloned in pUAST plasmid (gift from the Lee Fradkin
lab). For expression of engineered Dwnt5 proteins, similar pUAST constructs were generated
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using Quick Change (Stratagene) mutagenesis. Drosophila S2 cells were then stably transfected
with a mixture of three plasmids (i) pUAST-DWnt5, (ii) pAc-Gal4 and (iii) pCoHygro
(10µg:10µg:1µg) using the calcium phosphate method, and were selected in Schneider’s medium
(Sigma) supplemented with 10% fetal calf serum (Sigma, Cat# F0643) and 300 µg/ml hygromycin
(Cellgro) for 3 weeks. Schneider’s cell medium was then replaced with ESF921 serum-free
medium (Expression Systems) for subsequent cell culture. For DWnt5 expression, cells were
6

seeded at 2x10 cells/ml in spinner flasks. After 5 days of growth at 24˚C, spinning at 2,000 g,
medium (~3 liters) was harvested and flowed through a 4 ml Fractogel SO3 (EMD) cation
exchange resin at 4˚C. The column was then washed twice with 10 ml of wash buffer (20 mM
HEPES pH 7.5, 250 mM NaCl). DWnt5 was eluted from the SO3 column with 3x 4 ml elution
buffer (20 mM HEPES pH 7.5, 900 mM NaCl). The protein solution was then diluted with 3
volumes of 20 mM HEPES pH 7.5 buffer to lower the NaCl concentration to <250 mM. All
subsequent purification steps were performed at room temperature. The protein sample was next
loaded onto a self-packed 2 ml Fractogel SO3 column pre-equilibrated with 20 mM HEPES,
pH 7.5 containing 150 mM NaCl, developed with a gradient from 150 mM to 1 M NaCl in 20 mM
HEPES pH 7.5 (DWnt5 elution peak around 650 mM NaCl). Eluted fractions were then diluted
again with 3 volumes of 20 mM HEPES pH 7.5 buffer, loaded onto a ceramic hydroxyapatite, type
1 (CHT2-1) column (BioRad) equilibrated with 20 mM HEPES pH 7.5, 150 mM NaCl, 2.5 mM
NaH2PO4, 2.5 mM K2HPO4. A 0-100% gradient of Buffer B (250 mM NaH2PO4, 250 mM K2HPO4
and 150 mM NaCl, pH 7.5) was used to elute the protein. Finally, eluted fractions were pooled
together, concentrated, and loaded onto a Superose 6 column (GE Healthcare) with running
buffer containing 10 mM HEPES pH 7.5 and 150 mM NaCl. Judged by its ability to binding to Drl,
purified DWnt5 protein could be flash frozen in the presence of 10% glycerol with no significant
aggregation or loss of sDrl-binding activity upon thawing.

3.9.3

Molecular dynamics simulations of DWnt5

For MD simulations of DWnt5, a homology model of DWnt5 was generated based on the
Xenopus Wnt8 crystal structure (PDB: 40fa), using the software Modeller (Webb and Sali 2014).
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The disulfide linkages in DWnt5 were determined by comparing those with the disulfides in
XWnt8 crystal structure. The homology model of DWnt5 was then energy-minimized, first in
vacuum and then in a solvent box with constraints on the water molecules, and finally in a solvent
box without solvent constraints. The system was then slowly heated up from 0 K to 300 K over
the course of 3 nanoseconds, followed by constant temperature equilibrium, constant pressure
equilibrium run at 300 K and 101.325 kPa for 50 nanoseconds. Amber99SB force field was used
for the protein molecule (Cornell et al. 1995). Trajectory analysis was performed using the VMD
package (Humphrey, Dalke, and Schulten 1996) and in-house developed Tcl scripts.
3.9.4

Hydrogen exchange experiment of Drl/DWnt5

For HX-MS studies of sDrl, the H/D exchange (HX) reaction was initiated by mixing the sDrl
N63Q/N143Q double mutant protein stock (28.5 µM) into 96% D2O solution containing 150 mM
NaCl at a ratio of 1:4 (v:v). For the study of sDrl/DWnt5 complex, a protein mixture containing
28.5 µM sDrl and 29.5 µM DWnt5 was diluted into 96% D2O (150 mM NaCl). The final
concentrations of sDrl and DWnt5 in the exchange reaction were 5.7 µM and 5.9 µM,
respectively. In both studies, the pD of the HX reaction solution was estimated to be 7.2 (pHread +
2
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0.4). The HX reactions were carried out at 0°C. At each specific time point (10 s, 10 s, 10 s,
4

5

10 s and 10 s), an aliquot of 15 µl of the reaction mixture was quenched by adding 45 µl quench
solution (1.5 M GdmCl, 50 mM TCEP, 0.8% formic acid and 10% glycerol, pH 2.2). As controls,
non-deuterated (‘all-H’) and fully deuterated (‘all-D’) samples were prepared in the same way. All
samples were frozen in liquid nitrogen immediately after adding quench solution. For the studies
of binding interface on DWnt5, a quenching solution containing 1.5 GdmCl, 500 mM TCEP, 0.8%
formic acid, 500 mM glycine/HCl and 10% glycerol, at pH 2.8 was used to promote disulfide
reduction.
Prior to data collection, the frozen samples were quickly thawed on ice, and injected at a
flow rate of 100 µl/min into a cooled chamber maintained at 0°C. Inside the chamber, the protein
sample was digested by immobilized pepsin (Sigma) beads packed in column housings
(2 cm × 2 cm, IDEX). The digested peptides were flowed through a Piccolo microbore C18
column (trap column) to desalt the peptide fragments. An acetonitrile gradient (10-55%
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acetonitrile, 0.1% TFA) was then used to elute the peptides off the trap column and into an
analytical C18 column (5 cm × 0.3 mm, Higgins Analytical). The eluent was directly flowed into a
mass spectrometer (Thermo LTQ Orbitrap XL) for electrospray ionization. A tandem MS (CID
mode) run was carried out for the ‘all-H’ sample in order to identify the primary sequence of
digested peptides.
The SEQUEST algorithm (Bioworks, version 3.3.1) was used to identify peptides from
tandem MS data. The MATLAB-based software ExMS (Kan et al. 2011) was used to validate the
peptide assignment and subsequently to compute the centroid of isotopic distribution of each
deuterated peptide. An ‘All-D’ sample was included to calibrate back-exchange of the deuterated
samples. The detailed ExMS-based data collection and processing workflow were described by
Kan et al. (Kan et al. 2011). NumPy and Matplotlib were used to export ExMS results to the
Python environment for further data analysis and plotting. To assess the difference in HX rates
for sDrl –derived peptides in the absence and presence of DWnt5, the difference in number of
exchanged deuterons was calculated for each peptide at each time point. The maximum
difference among all of the time points was further divided by the number of amide hydrogen
atoms on the peptide. This computation results in a weighted relative difference of amide
hydrogen exchange rate of each sDrl peptide. This approach takes into consideration the wide
range of HX rates and the possibly multiple secondary structure components within one peptide,
and therefore represents the change of amide hydrogen protection upon DWnt5 binding. To
visualize the differences, each peptide was color-coded on sDrl homology model according to the
‘weighted relative difference’. An in-house PyMOL (Delano 2002) script was used to create the
heat maps of the model.
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Chapter 4 The role of the carboxy-terminal tail of the EGF
receptor in kinase activity regulation and linking to the
downstream signaling network
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4.1

Introduction

The carboxy-terminal region of the EGF receptor (EGFR), commonly referred to as the ‘C-tail’,
plays a crucial role in EGFR-mediated cell signaling. The C-tail contains all of the known
autophosphorylated tyrosines in EGFR except for one tyrosine in the kinase domain activation
loop (Y845). The phosphotyrosines (pYs) function as docking sites for downstream signaling
molecules (Gajiwala 2013). Early studies revealed that the recruitment of these downstream
signaling molecules is mediated by their SH2 (Src Homology 2) domains and PTB
(phosphotyrosine binding) domains, which both specifically recognize phosphotyrosines in
particular sequence contexts (Pawson, Gish, and Nash 2001; Schlessinger and Lemmon 2003).
Following the discovery of the SH2 domain, extensive studies were conducted in order to
characterize the binding properties of different SH2 domains in the human proteome. Many
different SH2 domains were identified and structurally characterized – from proteins with a variety
of functions – revealing the broad array of SH2 domain roles in the human proteome.
Phosphopeptides mimicking phosphotyrosine-containing sequences in receptors were used to
study the binding affinity and specificity of SH2 domains (Zhou 1993; Songyang and Cantley
2004). These efforts lead to the discovery of a proposed ‘code’ that governs SH2 domain binding
affinity and specificity, with the 3-4 residues immediately C-terminal to the phosphotyrosine
defining SH2 domain binding specificity.
Phosphopeptide binding to SH2 domains provides an explanation for how one receptor
can initiate multiple distinct signaling cascades. For example, in EGFR, multiple
phosphotyrosines are arrayed – with different sequence contexts – in such a way that they can
recruit different downstream binding molecules, possibly with several different SH2 domains
binding to each EGFR molecule. The Y992 (using mature protein numbering) site has a ‘code’
such that the PLCγ SH2 domains will bind when the tyrosine is phosphorylated, whereas the
signature sequences flanking Y1068 and Y1086 are associated with binding to the Grb2 SH2
domain. This view in which EGFR recruits multiple downstream molecules is now included in
textbooks. However, there are several unresolved questions that this textbook view does not
take into account or address. For example, current knowledge of the binding affinities and
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specificities of SH2 domain-mediated interactions is all derived from studies of short
phosphopeptides. It is unclear, though, whether phosphopeptides as short and unstructured
mimetics faithfully recapitulate phosphoproteins in their interactions with these modules.
Moreover, the phosphopeptides studied experimentally are short, and typically contain only one
phosphotyrosine – whereas phosphoproteins such as the EGFR C-tail contain multiple
phosphorylated tyrosines. It is unclear whether or not these multiple phosphotyrosines in EGFR
can all bind simultaneously to distinct SH2 domain-containing molecules and initiate different
signaling cascades. If so, it is also unknown whether binding of SH2 domains to a single C-tail
molecule is independent or cooperative, that is, whether binding of one SH2 domain will impact
the binding of a second (and subsequent) SH2 domain to another phosphotyrosine in the same
molecule.
The textbook view also considers the EGFR C-tail as a fully unstructured protein, and
focuses its function solely on SH2 domain recruitment. However, there is a body of evidence
suggesting that the EGFR C-tail is neither completely disordered nor restricted in its function to
SH2 domain binding. For instance, using FRET-based approaches it was shown that
phosphorylation induces conformational changes in the C-tail region, suggesting that the C-tail
may actually possess some structure (Lee and Koland 2005; Lee, Hazlett, and Koland 2006). In
addition, it was reported that sequential deletion of C-tail residues from EGFR results in a
hyperactive receptor in cell-based assays (Walton et al. 1990; Alvarez et al. 1995). This finding
suggests that the C-tail may have an auto-inhibitory function. Indeed, such a phenomenon in
which part of the intracellular region in a receptor autoinhibits its kinase domain is not uncommon
in other RTKs. The focus of the work described in this Chapter was to discern some details of the
structure of the EGFR C-tail – asking whether it is completely unstructured or bears some
conformational features and samples unique conformational ensembles that might contribute to
its autoinhibitory function. Another key goal was to understand how C-tail phosphorylation
impacts its conformation and influence on tyrosine kinase activity.
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4.2
4.2.1

The EGFR C-tail adopts a unique conformational ensemble
Circular dichroism spectra of EGFR C-tail protein

Although the EGFR C-tail is generally considered to be intrinsically disordered, the fact that its
progressive deletion increases the kinase activity of EGFR hints that the C-tail may have some
unique conformational features or elements that interact with the kinase domain to limit its activity
(through autoinhibitory interactions). In order to test this hypothesis, I first utilized circular
dichroism (CD) spectroscopy to study the solution conformation of an EGFR fragment that
contains the complete C-tail (EGFR 960-1186), expressed in E. coli (see Section 4.8.1). CD
spectra indeed suggested little in the way of α-helical or β-sheet features (Figure 4.1). I was
unable to determine whether there was a fraction of CD signal corresponding to any secondary
structure, because the random-coil CD signal dominates the spectrum to a degree that does not
allow faithful extraction of the underlying fractional secondary structure signals (if any exist).
Given that the majority of C-tail region lacks secondary structure in solution, I next asked
the question as to whether this region displays similar random coiled characteristics in a
molecularly ‘crowded’ environment more reflective of that found inside cells. It is now widely
recognized and appreciated that the environment inside cells is tremendously different from the
dilute solutions typically used for in vitro experiments. A typical intracellular environment contains
biomolecules at mass concentrations of up to 300-400 mg/ml (~40% by mass) – a full two orders
of magnitude higher than in dilute solutions typically used by biochemists. Proteins can exhibit
significantly altered conformations and structural stabilities inside cells compared to those in
dilute solution. Indeed, intrinsically disordered proteins can show different conformational
features in molecular crowding conditions (Sotomayor-Pérez et al. 2013; Flaugh and Lumb 2001;
Cino, Karttunen, and Choy 2012). I used a solution containing polyethylene glycol (PEG 20K,
25% m/v), an inert polymer, to mimic the molecular crowding conditions, and collected CD
spectra of EGFR C-tail in this solution. Interestingly, the molar ellipticity shown in the resulting
CD spectrum increased at 220 nm and decreased at 203 nm (Figure 1, cyan curve). This shift
indicates an small increased amount of α-helical elements.
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Figure 4.1 Circular dichroism spectra of EGFR C-tail protein in dilute solution (magenta) and
molecular crowding environment mimicked by 25 % PEG 20,000 (cyan). The difference spectrum
(red) suggests a slight shift of C-tail conformation under molecular crowding conditions,
associated with the acquisition of some helical features.
4.2.2

Small-angle X-ray scattering analysis of EGFR C-tail protein

We also used small-angle X-ray scattering (SAXS) to investigate the spatial extent and lowresolution structure of the EGFR C-tail. In SAXS analysis, the pairwise distance distribution (P(r))
curve can provide a low-resolution structural view of the molecule in solution, providing a map of
the lengths of all inter-electron vectors in the structure. The P(r) curve illustrated in Figure 4.2
suggest an extended structure, potentially as ‘beads on a strong’, with a maximum dimension
(Dmax) of 130 Å, compared with the expected value of approximately 40 Å (estimate) for a wellfolded globular ~26 kDa protein. It is worth noting that C-tail samples at different concentrations
showed slightly different P(r) curves. This may be due to a slightly altered conformational
ensemble that C-tail adopts at different concentrations (a linear Guinier region in all these curves
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eliminates the possibilities of protein aggregation at high concentrations). In addition, we
conducted shape reconstruction from these P(r) curves using the software DAMMIF (Franke and
Svergun 2009). The envelopes indicate that the EGFR C-tail adopts a rather elongated structure.
These data are also consistent with gel filtration chromatograms of the C-tail, which also imply a
large hydrodynamic radius.
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Figure 4.2 Top: pairwise-distribution curves (P(r)) of EGFR C-tail protein in solution. Black, red
and blue curves show the P(r) curves of protein at concentration of 2 mg/ml, 5 mg/ml and 10
mg/ml, respectively. The corresponding estimated Dmax values are 130 Å, 135 Å and 140 Å.
Bottom: representative reconstruction envelops of C-tail protein. These shapes illustrate
unstructured yet elongated conformations with ‘beads-on-a-string’ features.
Taken together, CD spectroscopy and SAXS analyses suggest that, although the C-tail
protein exhibits little secondary structure, it does explore a restricted conformational ensemble in
solution. In other words, not all possible conformations are equally sampled by the C-tail, and the
sampled distribution is subject to perturbation by protein concentration and the environment.

4.3

Identification of regions in the EGFR C-tail that are not completely
disordered

Although our CD and SAXS studies suggest a restricted conformational ensemble, these studies
provide no detailed structural information. For a higher resolution view of the C-tail structure, we
employed hydrogen deuterium exchange coupled with mass spectroscopy (HX-MS) to assess the
solution dynamics of the protein. As mentioned in the previous Chapter, HX-MS monitors the
exchange rate of amide hydrogens in the protein backbone with hydrogens (or deuterons) in the
solvent. The rates measured provide information on the local environment and dynamics of
amide protons. Those in stable hydrogen bonds, such as those in secondary structures, show
slow exchange rates, whereas amide hydrogens in disordered regions exchange much more
rapidly. I undertook HX-MS studies on EGFR C-tail protein as well as EGFR-ICR protein, which
contains the complete intracellular region (with kinase domain and C-tail region, but without the
intracellular juxtamembrane region).
I first performed hydrogen exchange experiments covering an exchange time course
5

ranging from 10 s to 1x10 s. This range covers exchange rates for a broad spectrum of
hydrogens, from unstructured amides to those present in stable secondary structure. These
experiments revealed that there are no amides in the C-tail region that show exchange rates
significantly lower than those of unstructured peptides. As shown in Figure 4.3 for EGFR-ICR, all
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amide protons in all peptides within the C-tail region were completely exchanged with deuterium
within seconds. This piece of data is consistent with our CD spectroscopy result – showing that
the C-tail does not have any obvious secondary structure when studied in dilute solution.

Figure 4.3 Hydrogen/deuterium exchange level of peptides in EGFR-ICR protein 10 second (top)
and 100 second (bottom) after the start of exchange reaction.
Even though our HX-MS analysis didn’t reveal any well-structured regions, several
peptides consistently stood out as being slightly protected (peptides that are boxed in the 10
second data in Figure 4.3). Although this decrease itself is too slight to be considered significant,
it prompted us to further the study. Specifically, in order to distinguish these peptides
unambiguously from the rest of the fully unstructured ones I utilized a higher time-resolution
approach established in Walter Englander’s laboratory here at University of Pennsylvania, namely
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stopped-flow HX-MS. In contrast to regular HX-MS, stopped-flow HX-MS enables analysis of
events with a time course down to milliseconds. Therefore, using this technique it is possible to
distinguish amides in completely disordered peptides from amides that are slightly protected –
such as those in loop regions or in unstable secondary structures. In my stopped-flow HX-MS
studies, two regions in the EGFR C-tail clearly stood out, while the peptides from the rest of the
protein showed virtually same exchange rates as theoretical rates calculated from unprotected
peptides. Figure 4.4 illustrates hydrogen exchange profiles of peptides corresponding to residues
979-992 and 1056-1068. Amides in these two regions exchange approximately 10 fold slower
compared to their theoretical exchange rate as disordered peptides.
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Figure 4.4 Representative peptides in stopped-flow HX-MS analysis of EGFR C-tail protein. Left
column: peptides exhibiting the same exchange rates as calculated rates for unprotected
peptides. Right column: peptides that show a 10-fold protection.
To the best of our knowledge, my stopped-flow data argue for the first time that certain
regions in the EGFR C-tail are not completely disordered. Instead, they may form a conformation
that involves short-lived hydrogen bonds. In other words, those hydrogen bonds significantly
reduce the conformational space that the C-tail samples. It is worth noting that the two slightly
protected regions both contain well known important tyrosines in EGFR (Y992 and Y1068), which
are binding sites for the PLCγ and Grb2 SH2 domains respectively. Therefore, it is possible that
phosphorylation or SH2 domain binding may affect (or be altered by) the conformations in these
regions.

4.4

Phosphorylation of EGFR C-tail promotes receptor dimerization

Our stopped-flow HX-MS analysis leads to the conclusion that the EGFR C-tail adopts a unique
conformational ensemble – not all parts of the protein are equally ‘unstructured’. I next asked
whether phosphorylation of the C-tail perturbs the conformational dynamics, hypothesizing that Ctail phosphorylation might serve as switch to regulate its influence on EGFR activity. Indeed, as a
precedent for such an effect, a recent study showed that multiple phosphorylation of the protein
4E-BP2 induced a disordered-to-helical folding transition, which in turn altered the affinity of its
binding to a substrate (Bah et al. 2014). To investigate this question, my goal was to determine
whether phosphorylation alters the structure of the C-tail, or its interactions with the kinase
domain. Another key goal was to investigate the interactions of SH2 domains with
phosphorylated C-tail rather than restricting these studies to phosphopeptides as has typically
been the case.
4.4.1

Preparation of phosphorylated C-tail protein

I first developed an approach to prepare the isolated phosphorylated EGFR C-tail. Using vesicles
containing lipids with Ni-NTA head groups, both E coli-derived purified C-tail protein and EGFR
kinase domain (both 6xHis-tagged) were co-enriched onto the vesicle, significantly increasing the
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local concentration of the substrate (C-tail) with respect to the kinase domain, and therefore
promoting the phosphorylation reaction. Native gel, Phos-tag gel (Kinoshita et al. 2006), and
mass spectrometry analyses all suggest that the resulting phosphorylation product was heavily
phosphorylated to near completion (Figure 4.5).

Figure 4.5 A: Native gel and Phostag gel assays monitoring phosphorylation of EGFR C-tail by
EGFR’s kinase domain. B: MALDI-TOF spectra of unphosphorylated and phosphorylated C-tail.
The mass difference between unphosphorylated and phosphorylated samples corresponds to
approximately to 8.5 phosphate groups per C-tail molecule on average.
4.4.2

Analytical ultracentrifugation sedimentation equilibrium experiment of
phosphorylated EGFR-ICR and isolated C-tail

Our SAXS analysis of phosphorylated C-tail showed no significant conformational change upon
phosphorylation when compared to the unphosphorylated protein (data not shown), suggesting
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that phosphorylation of the C-tail alone does not induce formation of stable secondary structures.
Nevertheless, we hypothesized that phosphorylation of the C-tail might affect its interaction with
the kinase domain in full-length receptor – either intramolecularly or intermolecularly. In other
words, we hypothesized that phosphorylation of the C-tail might regulate its auto-inhibitory
influence. To test this hypothesis, we generated EGFR-ICR protein (containing the kinase
domain and C-tail region) and phosphorylated it using a similar approach to that used for
preparing phosphorylated C-tail. Mass spectrometry suggests all the major sites in EGFR-ICR
are phosphorylated.
We first performed analytical ultracentrifugation sedimentation equilibrium (AUC-SE)
experiments to characterize phosphorylated EGFR-ICR. Surprisingly, we found that
phosphorylation of EGFR-ICR causes it to sediment as a significantly species, as manifested by
the increased slope in a log plot of AUC-SE data (Figure 4.6 Top). When these data are fit to a
simple monomer/dimer equilibrium, the fitting is consistent with a Kd for dimerization of ~15 µM
for the fully phosphorylated EGFR-ICR protein, whereas dimerization of unphosphorylated EGFRICR is undetectable (implying a Kd > 250 µM). Since we know both unphosphorylated and
phosphorylated EGFR kinase domains are monomeric in solution, and no dimerization can be
detected for EGFR C-tail whether phosphorylated or not (Figure 4.6 bottom), these data suggest
that phosphorylation of the EGFR C-tail promotes inter-molecular interactions between the kinase
domain and the (phosphorylated) C-tail region, which promotes dimerization of the alreadyactivated receptor. Intriguingly, this would serve as a positive feedback event (activation-induced
phosphorylation promoting further dimerization and activation), so should impart some switch-like
character to the EGFR in its response to ligand.
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Figure 4.6. Logarithm plots of AUC-SE data. Top: Log plot of unphosphorylated, phosphorylated
and kinase-dead EGFR-ICR proteins (done by Sung-Hee Choi in the lab). Phosphorylation of
EGFR-ICR results in a line with increased slope, suggesting a degree of oligomerization. Bottom:
Log plot of unphosphorylated and phosphorylated C-tail proteins. Both samples show lines of
same slope in the plot.

111

4.4.3

HX-MS analysis of phosphorylated EGFR-ICR protein

In order to understand how the phosphorylated C-tail might promote dimerization, I performed
HX-MS to map regions of EGFR-ICR that are responsible for this interaction. I performed three
HX-MS reactions in parallel:
(1) unphosphorylated (his-tagged) EGFR-ICR
(2) unphosphorylated (his-tagged) EGFR-ICR clustered on Ni-NTA vesicles and
(3) phosphorylated (his-tagged) EGFR-ICR protein enriched on Ni-NTA vesicles.
By comparing the HX-MS results from these three sample, the goal was to identify regions in
EGFR-ICR that are involved in dimerization when phosphorylated – but not affected dimerization
(on Ni-NTA vesicles) alone. As shown in Figure 4.7, my HX-MS data unveiled two regions (a.a.
688-699 and a.a. 764-774) that showed increased protection upon phosphorylation and
clustering. Figure 4.7 illustrates HX profiles of overlapping peptides in these two regions. The
hydrogen exchange rates for these peptides followed the order: “reaction 1 > reaction 2 >
reaction 3”. This suggests that EGFR-ICR dimerization/clustering leads to some protection, and
that phosphorylation further promotes the protection (or enhances dimerization). Judging by the
degrees of change in exchange rates, we infer that the interactions involving these two regions or
EGFR-ICR are not tight – anticipating that strong interactions would result in slower rates. In
addition, we did not find any phosphopeptides within the C-tail region that showed altered HX
rates upon phosphorylation or dimerization. This could have due origins: (1) the HX differences
in the C-tail region may simply not be large enough to be evident in regular HX-MS experiments,
and/or (2) the intermolecular interactions may be mediated by phosphate groups on the C-tail, so
no direct backbone hydrogen bond formation is involved (so no significant HX changes result).
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Figure 4.7 Hydrogen exchange profiles of peptides in EGFR-ICR phosphorylated and enriched
on vesicles. Peptides in two regions in EGFR-ICR (A-D: a.a. 688-699, E-H: a.a. 764-774)
showed an increased protection upon protein dimerization, and this was further enhanced upon
protein phosphorylation.
As mentioned above, the C-tail appears to play some auto-inhibitory function in the fulllength receptor. Our findings, on the other hand, suggest that phosphorylation of the C-tail could
enhance EGFR activity by promoting dimerization of the receptor. The C-tail thus plays two
seemingly opposite roles in regulating EGFR kinase activity. This controversy can be reconciled
by hypothesizing that EGFR requires an ultra-fast yet tightly controlled switch. In other words, the
auto-inhibitory role of the C-tail may prevent EGFR from being inadvertently activated by other
kinases or by another unliganded EGFR molecule. However, once the ligand-induced receptor
dimer is formed, a phosphorylated C-tail may not only release its auto-inhibitory check, but might
also further promote kinase activation once the C-tail is phosphorylated, by enhancing
dimerization of the receptor. In this guise, the phosphorylation-promoted enhancement would
only occur in the correct context, i.e. in a ligand-induced dimer. Effectively, phosphorylation of
the C-tail in this model would provide a positive feedback mechanism for EGFR activation,
rendering it more switch-like.

4.5

Binding of SH2 domains to EGFR C-tail protein

It is generally presumed in the field that the question of how and which SH2 domains bind to the
activated EGF receptor has been ‘solved’. Upon phosphorylation, the EGF receptor recruits
downstream signaling molecules to initiate various signaling cascades, such as the Ras/MAPK
and PI3K/Akt pathways. Even though this view is well established in textbooks, it is clear that a
more detailed mechanistic view is missing; the current textbook view does not account for the
unique conformational dynamics and effects of phosphorylation of the C-tail found in our studies.
Moreover, the stoichiometry of SH2 domain binding to the EGFR C-tail has not been established,
and it is not known whether SH2 domain-containing proteins bind independently to the
phosphotyrosines in the C-tail, or show some negative (or positive) cooperativity. Indeed, some
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studies have suggested that Cbl and Grb2 bind cooperatively to the EGFR C-tail (Sigismund et
al., 2013).
We reasoned that binding of an SH2 domain to the phosphorylated C-tail should
influence or perturb its sampling of the conformational ensemble, which in turn might favor or
disfavor the binding of other SH2 domains to additional sites in the C-tail. In addition, restrictions
in the conformational ensemble may result in SH2 domain binding to a given phosphotyrosine in
the C-tail being either stronger (if a favorable conformation is stabilized) or weaker (if not) than
binding to a short phosphopeptide. Thus, binding affinities of SH2 domains to full-length
phosphorylated C-tail or EGFR-ICR might be substantially different from those measured for
phosphopeptides. The hypothesis that recruitment of one SH2 domain to the C-tail affects
binding of another SH2 domain to a different pY in the same protein – by perturbing the
conformational ensemble – has never been tested. In fact, even the stoichiometry of SH2 domain
binding to the EGFR C-tail has never been assessed, because the phosphopeptides used in
previous studies have only contained one phosphotyrosine (or two at most) (Songyang and
Cantley 2004). In order to test these hypotheses, I aimed to study SH2 domain binding to
phosphorylated C-tail protein that spans the entire SH2 domain-binding region. I expressed a
handful of relevant SH2 domains in E. coli and purified them into homogeneity. I then studied
binding of these SH2 domains to phosphorylated C-tail protein.
4.5.1

SPR analysis of SH2 domain binding to phosphorylated EGFR C-tail

I used surface plasmon resonance (SPR) to analyze SH2 domain binding. SPR requires only
small amounts of protein sample. Moreover, it is an ideal technique for quantitative competition
assays. I immobilized phosphorylated C-tail on a CM5 chip as described in Section 4.7.6, and
singly tested binding of individual SH2 domains to the C-tail protein. We measured binding by the
SH2 domains from Grb2, PLCγ (N-terminal), PLCγ (C-terminal), and PI3K. Table 4.1 summarizes
the binding affinity derived from the SPR data.

Table 4.1 Summary of dissociation constant of SH2 domains binding to phosphorylated EGFR Ctail
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SH2 domain

Kd,app (µM)

Grb2

0.64 ± 0.18

PLCγ1-N

18.4 ± 1.2

PLCγ1-C

0.63 ± 0.12

PLCγ1-NC

0.28 ± 0.06

PIK3R-N

18.0 ± 1.8

PIK3R-C

15.0 ± 1.3

PLCγ1-C (10 µM Grb2)

88.4 ± 18.4

Grb2 (5 µM PLCγ1-C)

142 ± 30

The first result evident from these data is that the Kd values obtained for SH2 domain binding to
the EGFR C-tail are not dramatically smaller than the micromolar range values measured with
short phosphopeptides . Although the Grb2 SH2 domain showed a sub-micromolar Kd, this is
consistent with values obtained in peptide experiments (Marengere et al. 1994). The finding that
the PI3K SH2 domains exhibit relatively low binding affinities (18.0 and 15.0 µM for the N-terminal
and C-terminal SH2 domain, respectively) is also consistent with peptide studie (Zhou 1993). By
contrast, my SPR data for the PLCγ SH2 domains was quite surprising. The C-terminal SH2
domain from PLCγ1 binds much more tightly to phosphorylated EGFR C-tail than does the PLCγ
N-terminal SH2 domain (Kd for N-SH2: 18.4 µM, Kd for C-SH2: 0.63 µM). It is generally reported
that the N-terminal SH2 domain of PLCγ binds to receptors, while the C-terminal SH2 interacts
with a phosphotyrosine residue intra-molecularly (although the opposite result is also reported
sporadically in the literature) (Wahl et al. 1990; Kim et al. 1991; Gresset et al. 2010). My SPR
data, however, clearly argue that the full-length EGFR C-tail protein preferentially binds to the Cterminal SH2 domain of PLCγ1. I did run mass spectrometry of my samples to rule out the
possibility that the N-terminal and C-terminal SH2 domain samples were accidentally swapped
during the experiments.
Interesting, when I titrated the Grb2 and PLCγ1-C SH2 domains to a high concentration, I
could detect additional binding events, although with a much lower binding affinity. I was able to
fit the binding curves to a model that consists of multiple binding sites. For both the Grb2 and
PLCγ1-C SH2 domains, the additional binding shows a Kd value of approximately 200 µM.
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Estimation from the measured Bmax value suggests that four molecules of each SH2 domain bind
to the phosphorylated EGFR C-tail through this low affinity binding, whereas one molecule of SH2
domain binds with a sub-micromolar affinity. Although our SPR analysis cannot unequivocally
determine the binding stoichiometry, and the caveat that this binding might have a non-specific
component cannot be dismissed, these results do suggest that multiple SH2 domains can bind to
a single phosphorylated EGFR C-tail, and possibly with distinct affinities. This also provides an
explanation for the ‘rebinding’ of SH2 domains observed in single-molecule experiments of fulllength receptor (Oh et al. 2012).
In order to test whether binding of one SH2 domain to the EGFR C-tail affects binding of
a second, I performed a competition assay using Grb2 and PLCγ1-C SH2 domains, both of which
showed sub-micromolar Kds in my prior SPR experiments. I titrated one SH2 domain onto a
surface bearing the phosphorylated EGFR C-tail in the presence of a high concentration (510 µM) of the other. Since Grb2 and PLCγ1-C SH2 domains are though to bind to different
phosphotyrosine sites (pY1068 and pY992 respectively), if these two SH2 domains bind
independently to the C-tail, it is to be expected that the presence of an excess of another SH2
domain should not affect the binding curve – and that it will appear similar to that measured for
binding of a single SH2 domain. Quite surprisingly, my competition assay results suggest the
opposite. In the presence of 10 µM Grb2 SH2 domain, the PLCγ1 C-SH2 domain appears to bind
phosphorylated EGFR C-tail with a very low affinity, yielding a Kd value of 88.4 µM (Figure 4.8).
Similarly, the Kd measured for binding of the Grb2 SH2 domain is increased from 0.64 µM when
studied alone to a Kd of 142 µM when the experiment is performed in the presence of 5 µM
PLCγ1-C SH2 domain. These data clearly argue that the Grb2 and PLCγ1-C SH2 domains
compete for binding to the phosphorylated EGFR C-tail. Since their Kd values are similar for their
respective sites, it seems very unlikely that simple competition for the same set of sites would
cause the presence of 5-10 µM competitor to elevate Kds for the Grb2 and PLCγ1-C SH2
domains to the 100 µM range. Rather, given that the Grb2 and PLCγ1-C SH2 domains also have
distinct binding sites on the C-tail, it seems possible that binding of one SH2 domain to its specific
site on the C-tail alters the C-tail conformation (or conformational dynamics) in a way that
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disfavors binding of the other SH2 domain in a form of negative cooperativity – contrary to the
positive cooperativity suggested for Grb2 and Cbl (Sigismund et al., 2013).
Although this phenomenon requires more investigation, including studies of HX of the
phosphorylated C-tail (or EGFR-ICR) upon SH2 domain binding, the apparent competition
between the Grb2 and PLCγ1 SH2 domains suggests that the activated EGFR might be biased
towards particular pathways – such that a Grb2-bound receptor is diminished in its ability to
activated PLCγ signaling and vice versa. Indeed, competition between Grb2 and PLCγ signaling
has been reported in other contexts – notably in the case of FGFR2 signaling (Timsah et al.
Ladbury, 2014), although through competition for a different type of binding site in this case.

Figure 4.8 SPR competition binding assays of Grb2 and PLCg-1C SH2 domains. Left: Binding
curve of Grb2 SH2 domain binding to immobilized phosphorylated C-tail (Kd = 142 µM). Right:
Binding curve of PLCg-1C SH2 domain binding to phosphorylated C-tail (Kd = 88.4 µM).

4.5.2

SAXS analysis of SH2 domain binding

Although SPR data suggest the existence of both high-affinity and low-affinity binding sites for a
single SH2 domain on the EGFR C-tail, this approach does not allow us to observe these
interactions directly, provides no structural information, and may suffer from surface binding
artifacts. To study SH2 domain binding to the EGFR C-tail in solution, I further analyzed the
interactions using small angle X-ray scattering (SAXS). I chose Grb2 SH2 domain for the SAXS
studies because it is one of the widely studied SH2 domains and its ‘binding code’ is well
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understood. In SAXS experiments, the forward scattering intensity (I0) is a function of the
concentrations and masses of all the species in solution. By titrating one molecule into a solution
containing a constant concentration of its binding partner, it is possible to measure the weightaveraged molecular mass of all of the species in the solution (assuming a simple mixture), and
from that the binding affinity and stoichiometry can be extrapolated. Such an approach was
previously used successfully to discover the 2:2 stoichiometry of EGF binding to EGF receptor
(Lemmon et al. 1997).
I prepared mixtures of the Grb2 SH2 domain and phosphorylated EGFR C-tail at different
molar ratios of 1:0, 1:0.5, 1:1, 1:1.5 and 1:2 (C-tail:SH2), with a fixed concentration of
phosphorylated C tail (50 µM). I then measured the forward scattering (I0) of each sample by
extrapolating a Guinier plot back to zero angle. The resulting I0 values were normalized for mass
concentration of protein, and plotted with respect to the added molar ratio of Grb2 SH2 domain.
As shown in Figure 4.9, the normalized I0 plot peaked at a molar ratio of 1:1, suggesting that 1:1
is the binding stoichiometry in solution. I did not observe the additional weaker binding events in
these SAXS experiments – which were performed at a significantly lower concentration (50 µM)
than their estimated Kd (~200 µM).

Figure 4.9 SAXS I0 titration of Grb2 SH2 domain binding to phosphorylated EGFR C-tail protein.
The peak I0 centered at ratio 1 suggests a 1:1 binding stoichiometry.
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Both my SPR and SAXS analyses suggest that Grb2 has just one relatively high-affinity binding
site on the phosphorylated EGFR C-tail. Based on peptide experiments, however, it is generally
considered that Grb2 has two canonical binding sites in the EGFR C-tail: pY1068 and pY1086
(Zhou 1993). The fact that my studies suggest only a 1:1 stoichiometry may reflect a half-of-thesites negative cooperativity in which binding of the Grb2 SH2 domain to one site renders the
other site in the C-tail inaccessible for binding – or altered in conformation such that the affinity of
Grb2 SH2 domain binding is greatly reduced. Either simple steric hindrance (given the short
distance between the two sites) or a perturbed conformational ensemble could lead to the
observed 1:1 stoichiometry.

4.6

EGFR signaling network with multiple SH2 domains involved

The EGF receptor is a node for many intracellular signaling pathways and networks. Indeed, one
can construct a highly wired graph by incorporating protein species that have been reported to
interact directly and indirectly with EGFR (Oda et al. 2005). Such a graph involves components
involved in virtually all of the essential processes of living cells. Despite its central role, EGFR
has relatively few core functions to process its signal inputs (multiple ligands), and to produce
numerous distinct outputs (downstream events such as cell differentiation and proliferation).
Moreover, these activities partially overlap with other ErbB family receptors (Jones et al. 2006;
Schlessinger 2000). Thus, a key question arises as to how EGFR can regulate so many types of
cell events with a not-so-complicated ‘processing core’.
To tackle this question, it is now becoming clear that understanding EGF receptor
signaling – or signaling by any RTK – requires quantitative analysis at systems level (Lemmon
and Schlessinger 2010). Components involved in EGFR signaling are highly interconnected via
various positive and negative feedback mechanisms. Thus, understanding EGF receptor
signaling network is extremely challenging. Firstly, modeling a highly connected system is
fundamentally difficult. Mathematically speaking, it involves many NP-complete decision
problems, that is, they are mathematically proven to be extremely difficult to solve. Secondly,
even though a generation of computational biologists has started to develop approximate
approaches that can efficiently model signaling networks, such methods require a huge set of
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quantitative parameters, such as protein-protein binding constants, association/dissociation rate
constants, etc.. Many of these parameters are derived from simplified experiments, some are
based just on assumptions, and few have temporal or spatial information that is crucial for a
complete deterministic model. Thus, this methodology – using simplified data and assumptions
to model complicated systems – may be fundamentally flawed. I would argue that this is indeed
the case in EGF receptor signaling simulations. A typical simulation setup usually utilizes SH2
domain binding constants derived from peptide experiments. In addition, the binding
stoichiometry and binding cooperativity of multiple SH2 domains are usually not considered. I
hypothesize that these finer-grained details should play important roles in regulating the
downstream signaling networks, and thus are not negligible – so neglecting them is a major
problem.
In order to test this hypothesis, I performed ordinary differentiation equations (ODEs) based network simulations. Unlike other simulations(Kholodenko et al. 1999), I explicitly included
the possibility that the EGF receptor could simultaneously recruit multiple different SH2 domains
and that their binding could be cooperative. To implement this model, I used a rule-based
approach to generate all ODEs (Sekar and Faeder 2012). This approach defines rules that
describe possible reactions, rather than the reactions themselves. Doing so can avoid the
practical issue that the number of species and reactions grows exponentially with respect to the
number of modification sites. As illustrated in Figure 4.10, I considered three different SH2
domain-containing proteins, PLCγ Grb2 and Shc (which also contains a PTB domain). They bind
to EGFR Y992, Y1068 and Y1148 sites respectively. The rest of the parameters in our model,
such as ligand binding constant and dephosphorylation rate, are the same as literature values
(Kholodenko et al. 1999).
I first adjusted the parameters to match the Kholodenko model of EGFR signaling
(Kholodenko et al. 1999) to test the correctness of my methodology. Indeed my simulation
results resembled that of Kholodenko model, suggesting that the model could degrade to a
simplified ODE model when I turn off multiple domain binding. I next tested how multiple SH2
domain binding could affect the simulation results. To do so, I added rules to the model
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specifying the binding constant that describes binding of a second SH2 domain to a receptor
molecule with another SH2 domain already bound. I can adjust this binding constant to be
weaker or stronger than a typical SH2 domain/peptide binding, thus effectively introducing a
negative or positive binding cooperativity, respectively. As shown in Figure 4.10, introducing a
layer of multiple SH2 domain binding significantly affects signals. Although it still exhibits a
single-peaked transient, a weaker negative binding cooperativity (i.e. multiple SH2 domain
binding) in the simulation resulted in a much more sustained signal after the signal spike,
whereas a strong negative binding cooperativity (effectively mutually exclusive binding of SH2
domains) showed a much lowered sustained signal level. In addition, the intensity of the spike in
the simulation of multiple SH2 domain binding increases almost 50% compared to the intensity of
a model with strong negative binding cooperativity.
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Figure 4.10 Top: An illustration of the model used in ODE simulations. Rules that govern all
allowed interactions are indicated by blue lines. Bottom: Phosphorylation levels with respect to
time, as simulated by the model configured for three different scenarios.
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Although the EGF receptor uses a relatively simple mechanism, namely recruiting SH2
domains, to propagate downstream signals, my simulation data suggest that even this simple
mechanism involves complexity when I take into account binding stoichiometry and cooperativity.
To the best of our knowledge, these data for the first time point out that EGF receptor
phosphorylation levels could differ significantly (the Y axis values of the plots in Figure 4.10,
bottom) when the number of recruited SH2 domains is different, and when the recruited SH2
domains have cross-talks. It is especially worth noting that differences of the sort observed in
these simulations, i.e. in the ratio of transient signal to sustained signal, has been suggested to
be responsible for key decision-making processes in cells (e.g. differentiation versus
proliferation). Although my simulations are still greatly simplified, my efforts to explicitly include
SH2 domain binding stoichiometry and cooperativity do demonstrate that peptide-based data and
the simple assumptions typically applied are not sufficient for a quantitative understanding of
EGFR signaling networks.

4.7

Conclusions and future work

In this chapter, I investigated the roles of the EGFR C-tail, a region that is typically linked to
recruitment of downstream signaling molecules. The literature, together with my own studies,
argue that the C-tail, as a 230-residue protein, exhibits many additional properties that simple
peptide-based studies cannot recapitulate. For instance, using CD, SAXS and HX-MS
approaches I showed that the C-tail adopts a restricted conformational ensemble in which certain
conformations are likely to be favored. I further identified several segments in the C-tail that are
not completely unstructured. These regions may play a role in autoinhibition of EGFR by the Ctail. In addition, we discovered that phosphorylation of the C-tail promotes dimerization of EGFRICR. Using HX-MS, I discovered two regions in the kinase domain that are likely to be involved in
intermolecular kinase/C-tail interactions. My data, taken together, provide new insight into the
biophysical basis of the C-tail’s regulatory roles in the EGF receptor.
I also investigated SH2 domain binding to the phosphorylated EGFR C-tail. My aim was
to determine whether the C-tail can recruit multiple SH2 domains, and if so, whether this binding
is independent or cooperative. My SPR-based SH2 domain binding assays and SAXS-based
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stoichiometry determination both suggested that the Grb2 and PLCγ1-C SH2 domains each have
one submicromolar high-affinity binding site on the EGFR C-tail – and provided preliminary data
that these binding events are negatively cooperative. Using rule-based ODE simulations, I further
demonstrated that these findings are not only currently missing in the field, but more importantly,
can potentially regulate the signaling outcomes. As shown in my ODE simulations, SH2 domain
binding stoichiometry and cooperativity can directly affect the balance between transient and
sustained signaling – a key factor that decides cell fate.
While our work on the EGFR C-tail unveiled many interesting aspects that were previously
unknown, parallel studies showing similar results also emerged. For instance, Fortian et al used
a quantum dot-based approach to characterize the stoichiometry of EGFR signaling assemblies
in live cells (Fortian and Sorkin 2014). Sigismund et al showed that Grb2 and c-Cbl (which
contains a pseudo-SH2 domain) positively cooperate to initiate receptor degradation via ubiquitinproteosome pathway (Sigismund et al. 2013). These data, although still scant in the field, all
point to the suggestion that the C-tail of EGFR is much more complicated than a simple extended
polypeptide chain as it is typically drawn. More systematic analyses of all SH2 domains and
phosphoproteins are needed in order to fully understand the EGF receptor C-tail, its properties,
and its role in the EGFR signaling network.

4.8
4.8.1

Methods
Expression and purification of EGFR C-tail, TKD and ICR proteins

The EGFR C-tail protein (EGFR 960-1186 using numbering for mature protein) was expressed
with an N-terminal histidine tag from a pET28 construct in E. coli. Protein was extracted from
crude cell lysate using a Ni-NTA affinity column, and then further purified using a Uno-Q (BioRad) anion exchange column (using a gradient salt concentration from 70 mM to 1M in Tris
buffer, pH 8.0 ) and a Superose 6 (GE Healthcare) gel filtration column in a buffer containing 150
mM NaCl, 3 mM βME and 20 mM Tris-HCl, pH 8.0. N-terminally histidine-tagged EGFR TKD
(a.a. 672 – 998) and ICR (a.a. 672-1186) proteins were expressed from baculovirus-infected Sf9
cells. Baculoviruses were generated using a ‘Bac-to-Bac’ system and all the recommended
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conditions were followed. The infected Sf9 cells were harvested 3 days after infection. The cell
pellet was first washed in cold PBS solution (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and
1.8 mM KH2PO4) and were then lysed by sonication in 50 mM HEPES, pH 7.8, 150 mM NaCl, 5
mM β-mercaptoethanol and 1x protease inhibitor cocktail (Roche). After removing the cell debris
by centrifugation at 40,000 g for 45 minutes, the supernatant was incubated with Ni-NTA agarose
beads (Qiagen) for 1 hour at 4 °C. The mixture was then loaded onto a column. The beads were
washed by a gradient of imidazole. Eluted protein was further purified first by ion exchange
chromatography (TAME column) and then using a Superose 6 gel-filtration column. In all
chromatography processes, buffers containing 20 mM HEPES pH 7.6 ~ 7.8, 250 mM NaCl and 1
mM TCEP was used. TCEP and 250 mM NaCl were essential for EGFR-ICR proteins.
4.8.2

Circular dichroism spectroscopy of EGFR C-tail

Purified C-tail protein was concentrated to 160 µM (O.D. ~4.0). A cuvette with 0.1 cm path was
used to hold the sample. Buffer solution containing 10 mM potassium phosphate and 100 mM
potassium fluoride was used to minimize the background absorbance in the low wavelength
region. A buffer containing 20% PEG 20k was prepared the day before the experiment to allow
for the dissolve of PEG. Circular dichroism spectroscopy was performed on an AVIV model 202
CD spectrometer. Collected data were smoothed and plotted using an in-house developed script.
4.8.3

Preparation and characterization of phosphorylated C-tail

EGFR C-tail protein was phosphorylated using the purified EGFR kinase domain in the presence
of vesicles containing 10% Ni-NTA-DOGS in a DOPC background (Zhang et al. 2006). A typical
reaction solution contained vesicles up to 1 mM (100 µM Ni-NTA-DOGS, 50 µM
available/exposed Ni-NTA head groups) and a mixture of C-tail and kinase domain ( 3:1 molar
ratio). ATP and Mg

2+

were both added to the solution to a final concentration of 8 mM to allow

phosphorylation. The reaction was allowed to proceed for 5 hours at room temperature and was
subsequently quenched by 50 mM EDTA solution. The quenched mixture was then loaded onto
a Superose 6 gel-filtration column (GE Healthcare) in order to separate C-tail and kinase domain.
C-tail eluted first from the gel filtration column due to its large hydrodynamic radius.
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The phosphorylation status of the EGFR C-tail was characterized by Western blot assays
using pY20 antibody and EGFR pY1086 specific antibodies. Native gels using a Tris-HCl buffer
system and Phostag-Zn

2+

based gels (Kinoshita et al. 2006)were also employed to monitor the

completeness of phosphorylation reaction. MALDI-TOF mass spectrometry was additionally used
to measure the intact mass of phosphorylated C-tail by mixing the protein with sinapinic acid (SA)
at 1:1 ratio in 50% acetonitrile solution (0.1% TFA).
4.8.4

Hydrogen deuterium exchange coupled with mass spectrometry studies

For the HX-MS studies of the EGFR C-tail, kinase domain, and EGFR-ICR proteins, the hydrogen
exchange reaction was initiated by mixing the protein into 96% D2O solution containing 150 mM
NaCl. The protein sample and the D2O solution were mixed at a 1:4 (v:v) ratio. The final
concentration of the proteins was around 3 µM. In all HX reactions, the pD of the solution was
estimated to be 7.2 (pHread + 0.4). The HX reaction was carried out at 0 °C. At each specific time
2

3

4

5

point (10 s, 10 s, 10 s, 10 s and 10 s), an aliquot of 24 µl reaction mixture was quenched by
adding 36 µl quench buffer (1.5 M GdmCl, 50 mM TCEP, 0.8 % formic acid and 10% glycerol).
Non-deuterated (‘all-H’) and fully deuterated (‘all-D’) samples were prepared in the same way. All
samples were frozen in liquid nitrogen immediately after adding quench buffer and stored at 80°C. Prior to data collection, frozen samples were quickly thawed on ice and injected at a flow
rate of 100 ml/min into a cooled chamber maintained at 0 °C. Inside the chamber, the protein
sample was digested by immobilized pepsin (Sigma) beads packed in a column housing (2 cm x
2 cm, IDEX). The digested peptides were flowed through a Piccolo (Nest) C18 column (trap
column) to desalt the peptide fragments. An acetonitrile gradient (10-55%, 0.1% TFA) was then
used to elute the peptides off the trap column and into an analytical C18 column (5 cm x 0.3 mm,
Higgins Analytical). The effluent was directly flowed to an ESI-MS Orbitrap mass spectrometer
(Thermo LTQ Orbitrap XL).
The SEQUEST algorithm (Bioworks, version 3.3.1) was used to identify peptides from
tandem MS data. MATLAB-based software ExMS was used to validate the peptide assignment
and subsequently to compute the centroid of isotopic distribution of each deuterated peptide. The
‘All-D’ sample was included to calibrate back-exchange of the deuterated samples. The detailed
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ExMS-based data collection and processing workflow were described in (Kan, 2011). NumPy
and Matplotlib (Hunter, 2007) were used to export ExMS result to the Python environment for
further data analysis and plotting.
For HX studies of EGFR-ICR on vesicles, EGFR-ICR protein was first clustered on a
vesicle to allow for phosphorylation reaction. A typical phosphorylation reaction occurred in a
solution containing 1 mM lipid as vesicles (10% Ni-NTA-DOGS/DOPC), 20 mM HEPES pH 7.5,
150 mM NaCl, 8 mM ATP, 8 mM Mg

2+

and 50 µM EGFR-ICR protein. Upon completion of the

reaction, EDTA (final conc. 50 mM) was added to the solution to quench the reaction prior to the
onset of hydrogen exchange reaction.
4.8.5

AUC studies of phosphorylated EGFR-ICR and C-tail proteins

Sedimentation equilibrium experiments were performed using EGFR C-tail proteins. Freshly
prepared proteins (see above sections for expression and purification) from size-exclusion
chromatography were immediately pooled and concentrated. For phosphorylated protein, an
extra SEC column was used following completion of phosphorylation reaction. Proteins were
concentrated to 16 µM (O.D. 0.3) and 32 µM (O.D. 0.6) and loaded in 6-sector center piece AUC
assemblies. Experiments were performed in a Beckman XL-A ultracentrifuge equipment at 4 °C
using 15,000,18,000 and 21,000 rpm speeds. Data were collected at 280 nm absorbance with a
0.001 cm scan step. Scans were continued until the reach of equilibrium monitored by SedFit
software.
4.8.6

SPR binding assays of SH2 domains

SPR experiments were performed on a BiaCore 3000 instrument (GE). Phosphorylated C-tail
protein was immoblilized onto CM5 sensor chip using amine coupling chemistry. Briefly, the
phosphorylated C-tail protein was diluted in pH 3.5 buffer (20 mM Glycine-HCl) to a final
concentration of 1 µM. The final pH of the sample was adjusted to between 3.5 and 4.0. The
resulting solution was allowed to flow across an EDC-NHS activated CM5 chip at 5 µl/min for a
total volume of 100 µl as recommended by the manufacturer. The chip surface was then
quenched with 1M ethanolamine. Typically, about 8000 RU of C-tail was immobilized onto the
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sensorchip surface. SH2 domain proteins were sequentially injected until steady state binding
was achieved, and were then allowed to dissociate from chip surface after each injection in HBSEP running buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3mM EDTA, 0.005% v/v Surfactant
P20). RU values recorded from steady state binding were then used to fit binding curves using a
simple specific binding model in Prism software. More advanced multiple SH2 domain binding
models were fitted in iPython notebook using an in-house developed curve-fitting routine.
4.8.7

SAXS I0 analysis of Grb2 binding to phosphorylated C-tail

Fresh proteins from SEC columns were immediately pooled and concentrated. For C-tail
characterization, C-tail protein (1 mg/ml) in 150 mM NaCl, 20 mM HEPES pH 7.5 was used. For
SH2 domain binding analysis, Grb2 SH2 domain and phosphorylated C-tail proteins in 150 mM
NaCl, 20 mM HEPES pH 7.5 and 0.1 mM TCEP were mixed prior to data collection. All SAXS
data were collected on a Rigaku PSAXS S-Max3000 small-angle X-ray scattering system
equipped with a Osmic mirror optics, an evacuated sample chamber kept at 4 °C, and a gas-filled
multi-wire detector. A Rigaku MicroMax-007 HF microfocus rotating anode generator was used
as X-ray source. The raw data were first averaged and reduced using SAXSGUI software (ver.
2.5.7). The resulting data were analyzed by using ATSAS Primus software. P(r) curves were
calculated in Gnom (ver. 4.7). Shape reconstructions were conducted using the software Dammif
and Damaver (Franke and Svergun 2009).
4.8.8

ODE simulations of EGFR signaling network

ODE simulations were performed using an implementation of rule-based network simulation
software BioNetGen (ver. 2.2.0-stable) installed on a linux workstation. Perl 5.10 and Java
Runtime Environment 1.6 were configured to support the simulations. The BNGL language was
used to set up the models and interactions in the network. Parameters were used according to
Kholodenko model (Kholodenko et al. 1999). As conventions, all mole units were converted to
molecule unit if applicable. The details of the model configuration used in the study can be found
in our public web archive: https://www.dropbox.com/sh/00cqegpwnpxpk9h/AADXAyuKAsl3PX1jNtBQHjOa?dl=0
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Chapter 5 Developing computational tools for biophysical
studies of receptor tyrosine kinases
(This chapter desribes collaborative work done with Dr. Camilla Oxley in the Lemmon laboratory)
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5.1

Introduction

The field of biophysical research heavily relies on state-of-the-art technology. In parallel, data
processing and analysis programs are also in great demand. Unfortunately, many of these
programs lag behind the experimental technology. Academic software tends to be developed in a
‘quick-and-dirty’ way, as manifest by the use of outdated programming techniques and nonprofessional software design. The lack of sophisticated software tools creates a burden for
biologists in processing and analyzing data with ever-increasing scale and complexity. Recently,
SBGrid, a software consortium for structural biology, aimed to solve these problems by providing
a collection of commonly-used structure biology programs with a simple installation procedure
(Morin et al. 2013). Unfortunately, the SBGrid model itself also suffers from typical academic
software problems too. In order to make compilation and installation on multiple platforms
straightforward, it has to deliver the most generic versions of all software – for most Linux/Unix
platforms, it provides programs pre-compiled for the i386 platform, hence failing to take
advantage of the performance of today’s powerful hardware (especially the 64 bit platform and
multiprocessing capability). The generic versions of programs come with limited room for
customization as well. Moreover, the ‘SBGrid approach’ doesn’t change the inherent drawbacks
of each program.
In this Chapter, I document several pieces of computer programs that I developed
alongside my wet lab research work in order to facilitate data processing and analysis for smallangle X-ray scattering (SAXS). The programs are written with the principles of software
engineering in mind, and use modern technologies that are typically found in numerical
computations in other scientific and engineering disciplines. All the programs run on multiple
platforms, including Windows, Linux/Unix and Macintosh. Instead of ‘re-inventing the wheel’, my
programs are designed on top of commonly used SAXS program suites in the field, treating the
existing software as the core calculation engine and adding new features to it. In addition, I
briefly describe the collaborative work on studying the molecular basis for Drosophila
EGFR/Kekkon-1 interactions, using SAXS-based approaches and programs designed for these
studies.
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5.2
5.2.1

A framework for SAXS data processing and analysis
Principle of small-angle X-ray scattering

SAXS is a powerful technique for studying structures and dynamics of biomolecules. It
complements X-ray crystallography and nuclear magnetic resonance (NMR) approaches in that it
can directly measure samples in solution, and does not need isotopic labeling. Combined with
other approaches, SAXS can be used to discern the oligomeric state biomolecules and binding
affinity of partners in complexes, to calculate low-resolution shape and conformational dynamics
of proteins, to determine spatial distributions of domains connected by flexible linkers and to
facilitate protein docking and virtual drug screening, etc. (Jacques and Trewhella 2010). SAXS is
based on scattering of X-rays from a single molecule – waves scattered from different parts of a
molecule result in phase shift and an intensity of scattering pattern. In dilute solution, the SAXS
diffraction pattern is a rotationally-averaged pattern of all molecules (interference from widelyseparated solutes only occurs at very small angles and only becomes significant in concentrated
solution). Several factors contribute to SAXS signals, including the protein concentration, the
volume of the individual protein, the contrast between the biomolecule and the solvent, and the
scattering from a single rotationally-averaged protein. The following formula describes the
relationships between these factors and the intensity of the scattered radiation:
!

!
𝐼 𝑞 ∝    ! 𝑉!"#$%&'
(𝜌! − 𝜌! )! 𝐹(𝑞)𝑆(𝑞)

(1)

where 𝑞 = 4𝜋 sin 𝜃 /𝜆 (sometimes s is used denote q), called momentum transfer, is a function
of the scattering angle;

!
!

denotes the number of biomolecules per unit volume; 𝑉!"#$%&'( is the

volume of individual protein; 𝜌! and 𝜌! are the ‘electron density’ of the biomolecule and the
solvent. 𝐹(𝑞) is the Form factor describing the rotationally-averaged scattering of a single
protein. 𝑆(𝑞) is the structure factor (not to be confused with the ‘structure factor’ in
crystallography) that describes inter-particle behavior and is approximately one for dilute solution.
It is worth noting that the scattering intensity is proportional to the square of the volume of the
6

molecule, that is R in terms of the radius (R) of the molecule. As a result, large molecules
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scatters much more strongly than small particles. In addition, the difference of the density
between particle and solvent (the (𝜌! − 𝜌! ) term, sometimes called contrast) directly affects the
intensity.
One important parameter of SAXS is I(0), the forward scattering intensity. In order to
understand the physical meanings of I(0), it is worthwhile to show the relationship between the
intensity and the scattering angle. Assuming a particle is centrally-symmetric, then the intensity
I(q) can be expressed as a one-dimensional integral:

𝐼 𝑞 =   

𝜌(𝑟)𝑒 !!!∙!!

!

= 4𝜋 𝜌(𝑟)

!
!"#  (!") !
𝑟
𝑑𝑟
!"

(2)

For a sphere with uniform density, we have

𝜌 𝑟 =   

1  ,            𝑟   ≤ 𝑅
0  ,            𝑟   > 𝑅

(3)

Solving the integral (2) using (3), we have

𝐼 𝑞 = 4𝜋

!"# !" !!"#$%(!") !
(!")!

        

(4)

Plugging q= 0 into equation (4), we have

𝐼 0 =

!

!

𝜋𝑅!   
!

(5)

In above derivation, we define the density to be one electron per unit volume in the
molecule. Therefore, (5) indicates that the square root of I(0) equals the volume of (and the
number of electrons in) a particle. Therefore, the absolute value of I(0) is also a direct
measurement of the mass (squared) of the particle.
Unfortunately, I(0) cannot be directly measured. There are two different approaches to
obtain the I(0) value indirectly. The first approach is through the Guinier plot. If we expand
equation (4) at q=0 using Taylor’s expansion, we get an approximate equation:
! ! !

𝐼 𝑞 ≈ 𝐼 0 𝑒 !!!! !

(6)
2

where Rg is the radius of gyration. If we plot the logarithm of I(q) as a function of q , the
slope is −𝑅!! /3, and the intercept is I(0). Therefore, if we plot the Guinier plot of SAXS data and
extrapolate Guinier region to get the intercept, we can obtain I(0).
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The second way to get I(0) comes from the indirect Fourier transform (IFT) of the SAXS
experimental data. To see that, we have

𝐼 𝑞 =   4𝜋

!!"#
𝑝
!

𝑟

!"# !!"#
!!"#

d𝑟

(7)

d𝑞

(8)

It follows by Fourier transform that:
!!

𝑝 𝑟 =    !!!

! !
𝑞
!

𝐼(𝑞)

!"#  (!")
!"

Therefore, I(0) can be obtained by:

𝐼 0 =   4𝜋

!!"#
𝑝(𝑟)d𝑟
!

(9)

P(r) is called the pair-wise or radial distance distribution, the SAXS analogue of the
Patterson function in crystallography. Using P(r), IFT can yield both Rg and I(0).
Compared to the Guinier plot approach, the second approach (using real-space values)
has the advantage that it is less sensitive to inter-particle interactions and protein aggregation.
5.2.2

Current SAXS data processing and analysis programs

A typical SAXS experiment setup first requires conducting multiple data collections for both the
samples and the matching buffer. The intensity of excess scattering from the protein molecules is
then obtained by subtracting the buffer signal from the sample solution signal (assuming the Xray source is stable). For Guinier plot analysis, a data transformation from I(q) vs. q to log(I(q))
2

vs. q results in the Guinier plot. From that, the Rg and I(0) values can be obtained. Perhaps the
most popular program used for this step is PRIMUS from the ATSAS suite (Petoukhov et al.
2012). Another piece of software gaining popularity is RAW, developed at MacCHESS (Volkov et
al. 2003; Skou, Gillilan, and Ando 2014). However, any spreadsheet-like software suffices to
manipulate data transformation for Guinier plot.
In order to obtain Rg and I(0) values from the entire data set, one needs to perform IFT
on the experimental data. Perhaps the single most popular program for this purpose is GNOM
from the ATSAS package (Petoukhov et al. 2012). GNOM can be run in a terminal window using
either interactive mode or batch mode. In interactive mode, each parameter needed for the
calculation will be prompted, such as the unit of q, the guessed value of Dmax, etc.. In batch
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mode, these parameters are compiled in an input file. The output of GNOM files is usually a
single text file that contains the P(r) curve data, the statistics of the IFT calculations and other
detailed information. P(r) needs to be zero at the two ends of the plot (and positive everywhere
else). Since the IFT results do not necessarily have these properties, one usually needs to
specify a guessed value of Dmax and let GNOM force the P(r) values to reach zero at the two ends
of the P(r) curve. Therefore, a typical analysis of one set of experimental data using GNOM
requires multiple trials and error to find the correct Dmax value. Unfortunately, this process is not
only tedious but also subjective – since judgment of the best Dmax value is largely based on the
IFT statistics and the shape of the P(r) curve. A systematic scan of possible Dmax values – with
objective comparison of the resulting statistics in each case – is important in obtaining the correct
Rg, Dmax, and I(0) values as well as the P(r) curve from SAXS data.
Another common type of data processing for SAXS is three-dimensional shape
reconstruction. The resulting low-resolution shape (‘envelope’) can be used to visualize the lowresolution structure of the molecule and to facilitate partial model docking into a ‘most probable’
envelope. A typical approach is to use beads or ‘dummy residues’ to mimic the shape of the
particle (Volkov and Svergun 2003). The theoretical scattering can be calculated from the particle
composed of dummy residues. Minimizing the difference between the observed scattering and
the calculated scattering with respect to the positioning of the dummy residues leads to a lowresolution envelope that shows the same scattering profile as the experimental data.
Mathematically, this optimization is not guaranteed to converge on one solution (unless the
hypersurface is a convex function). Therefore, multiple runs of shape reconstruction from a
single set of experimental data typically leads to different envelopes. The practice is to run shape
reconstructions multiple times for a single piece of data, and then to average the results to get a
‘most likely’ shape. Along the averaging process, the deviations among the calculated shapes
are also calculated and described by average normalized spatial discrepancy (NSD) value. The
nature of this shape reconstruction approach implies that the calculation also requires multiple
iterations of trial and error. In addition, each iteration is computationally expensive. For those
popular programs used for shape reconstruction, such as DAMMIN and DAMMIF (Franke and
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Svergun 2009), each run can only process one set of parameters. Also, although today’s
computers are all equipped with multi-core processors, those programs can only run in serial
mode – using one core at a time.
In order to address the drawbacks in the programs mentioned above, I implemented a
suite of programs that facilitate SAXS data processing, analysis and visualization. These
programs are multi-platform compatible. Most importantly, they exploit all possible automation
processes and fully utilize the computing resources (potentially all cores on a computer).
5.2.3

Developing a new layer of programs to facilitate SAXS data processing and
analysis

The EZsaxs suite I developed contains three major components, each of which can be used
separately for a specific purpose, or can be combined to form a data processing pipeline (Figure
5.1). The first component, EZsaxs (same as the suite name), is used to perform indirect Fourier
transform (IFT) of experimental scattering data. The second component, EZanalysis, is used to
analyze and visualize the output results from EZsaxs. The third component, EZshape, is used for
three-dimensional data reconstructions. In addition, there are a few scripts developed to ease the
data truncation process, and an I(0) titration simulator that is equipped with numerical
computation capabilities in order to simulate I(0) titration experiment involving multiple species
and equilibria.

Figure 5.1 The overall architecture of the EZsaxs suite, which is composed of three separate
programs EZsaxs, EZanalysis and EZshape, auxiliary scripts, and an I0 titration simulator. These
programs can be used separately for a specific purpose, or can be combined to use as a data
processing and analysis pipeline.
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While the core of EZsaxs is same as GNOM, it builds many features on top of GNOM in
order to facilitate data processing automation. The key principles behind EZsaxs are to automate
the ‘trial and error’ process, and to organize the results for easy analysis later (manually or in
EZanalysis). The majority of EZsaxs is written in the Python programming language. Similar
approaches have been used to expand the function of GNOM. In particular, the design of EZsaxs
is in part inspired by the program developed in Tainer lab (Hura et al. 2009), although EZsaxs
contains more features. The current interface of EZsaxs (and EZanalysis and EZshape) is
command-line (or terminals), however, implementing a graphic user interface (GUI) is
straightforward, as all the underlying functions are already implemented in various modules.
The best way to illustrate the power of EZsaxs is through an example. Suppose one has
a folder of data files from SAXS experiments. These data are all buffer-subtracted, and properly
truncated (for which EZsaxs suite has scripts to automate too). The next step would be to use
GNOM to try all reasonable Dmax values and other parameters to generate a series of GNOM
result files. Suppose that one would like to try all possible Dmax values from 90 Å to 150 Å, with a
5 Å step size. One also would like test whether or not to force the end of P(r) curve to zero (not
zeroing the end of the P(r) curve helps to identify the best Dmax value). Assuming there are 10
different data files in the folder, that is ((150-90) / 5 + 1 ) x 2 x 10 = 260 GNOM runs. Between
each run, one needs to adjust the parameter accordingly for the next run. Using EZsaxs, one
only needs to type one command in the terminal, and all the 260 runs will be done within
seconds. The command is as follows:
$EZsaxs –B .dat –di 90 –do 150 –ds 5 –zi yes –ze no
In this command, ‘-B’ specifies the file extension for all the data files (10 files in the above
example), ‘-di’ specifies the start value of Dmax, ‘-do’ specifies the last guess of Dmax value, ‘-ds’
specifies the step of Dmax increase. In addition, ‘-zi’ and ‘-ze’ specify whether to try to ‘non-zero’
the beginning and the end of P(r) curve.
Even better, in this example, the resulting 260 output files are automatically organized
into different sub-folders with files properly named.
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In a typical data processing flow, the next thing to do is to open all of the 260 files and to
examine the IFT statistics (such as total estimate, chi-square value, etc..) and P(r) curves. This is
not only time-consuming but also error-prone. With EZanalysis, nothing in particular needs to be
done after EZsaxs and it is ready to analyze and visualize the IFT results of all 260 files.
EZanalysis will automatically go into each result file and extract useful information, such
as IFT statistics, P(r) curve data, back-calculated experimental data based on the P(r) curve, the
Kratky plot and so on. In addition, EZanalysis automatically groups this information according to
parameters used in EZsaxs. For instance, the total estimate of each IFT run will be grouped in a
file along with the Dmax value used for that run. It will also overlay P(r) curves based on whether it
is ‘zeroed’ or not. Figure 5.2 illustrates some of the plots generated by EZanalysis. Again, to
obtain all of this information, only one command is required and hundreds of resulting files will be
analyzed, grouped and plotted.
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Figure 5.2 Sample plots generated by EZanalysis. A: the experimental (green) and backcalculated (blue line) scattering data (top) and Kratky plot (bottom) for different Dmax values. B:
Plots of total estimate (TE) and Chi2 values with respect to Dmax values. C: Sample plot of
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superimposed P(r) curves with ‘non-zeroed’ intensity at Dmax. The correct Dmax produces a P(r)
curve which does not significantly ‘bounce back’ at the Dmax value. In these curve series, the blue
line represents the best Dmax value (130 Å in this example).
The EZanalysis program helps identify the Dmax value that best fits the experimental data.
After EZanalysis processing, one usually has a few P(r) curves in hand with which shape
reconstruction is desired. The EZshape program in EZsaxs suite facilitates this process.
Internally, EZshape can use various engines including DAMMIN, DAMMIF and GASBOR. A
typical shape reconstruction needs at least ten runs in order to get convincing results. In one
command, EZshape can automatically detect the number of processors available in the system
and distribute the calculation task among those cores. In addition, one can specify multiple
parameters for shape reconstruction through EZshape, such as which engine to use, the
resolution of the calculation (number of dummy atoms), and whether to include symmetry
constraints. Just like EZsaxs, EZshape can be run in batch mode – multiple files in a folder can
be processed simultaneously. After all the calculations are completed, EZshape will cluster the
results, copy them into a sub-folder and then run DAMAVER internally to compute the averaged
shape and NSD value, along with the back-calculated scattering curve based on that shape.
In all the modules of EZsaxs package, data files do not need to be modified. Rather, at
each new step, the data files are copied to a subfolder and renamed properly. In addition, the
input files are always automatically backed up ‘behind the scenes’ before the start of any
computations. This ensures that no file corruption can happen at any point during the EZsaxs
computations.

5.3

An Example: Using SAXS approaches to study Drosophila EGFR/Kekkon-1
interactions

5.3.1

Drosophila EGFR is negatively regulated by Kekkon-1

In Drosophila, EGFR is accompanied by Argos and Kekkon-1 that antagonize EGFR signaling as
feedback inhibition mechanisms (Derheimer et al. 2004; Alvarado, Rice, and Duffy 2004; Klein et
al. 2004). Argos is a secreted protein that sequesters the Drosophila EGFR (dEGFR) ligand
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Spitz, functioning as a ligand sink (Klein et al. 2004). Kekkon-1 (Kek1), a transmembrane
glycoprotein in Drosophila, was found to modulate dEGFR signaling through an inhibitory
feedback loop (Ghiglione et al. 1999). Genetic studies suggest that the extracellular region of
Kek1 is required for its dEGFR inhibitory effect, but it is unclear whether there is direct interaction
between dEGFR and Kek1 (Figure 5.3). Understanding this interaction molecularly should reveal
a new class of regulatory mechanisms for EGFR signaling, and has the potential to provide
important new insight into the development of EGFR inhibitors in humans – where they could
have value in cancer treatment.

I
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+
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V

Figure 5.3 Kekkon-1 is a transmembrane protein in Drosophila that negatively regulates
Drosophila EGFR signaling. Model of the intact dEGFR extracellular region (left) based on a
crystal structure of dEGFRΔV and a crystal structure of the extracellular portion of Kekkon-1
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(right) are shown in cartoon representation (Oxley et al. in preparation). The molecular basis for
dEGFR/Kek1 interactions has yet to be understood.
5.3.2

Kekkon-1 directly binds to dEGFR

Genetic analyses indicated that the influence of Kek1 on dEGFR signaling can be abolished by
extracellular mutations (Alvarado et al., 2004a,b), suggesting that the extracellular regions of the
two molecules may interact. Subsequent work in the Lemmon laboratory by Camilla Oxley and
Diego Alvarado has shown that the isolated extracellular region of Kek1 (sKek1) interacts directly
with the extracellular region of dEGFR (s-dEGFR), as assessed using sedimentation equilibrium
analytical ultracentrifugation (SE-AUC) and other approaches (unpublished data). In
sedimentation velocity analytical ultracentrifugation (SV-AUC) studies, the dEGFR/Kek1 binding
stoichiometry was determined to be 1:1 (unpublished data). Kek1 could inhibit dEGFR by two
possible types of mechanisms: (i) Kek1 could compete with ligand for binding to dEGFR ligand thus blocking the ability of dEGFR to signal; (ii) Kek1 could bind to a different site on dEGFR and
block ligand-induced receptor dimerization, while still allowing ligand to bind. One such place
would be dimerization arm of the receptor, which mediates the receptor-receptor interactions in
the active dimer complex. Binding assays showed that Kek1 cannot bind to a ligand-induced
receptor dimer, but can bind to a dimerization-deficient receptor mutant with an altered sequence
in its dimerization arm – and addition of excess Spitz does not influence this binding. Moreover,
Spitz can bind equally well to the dEGFR extracellular region itself and to a preassembled sdEGFR/sKek1 complex. These data suggest that indeed Kek1 binds to the dimerization arm
region of dEGFR and does not compete ligand binding.
In order to shed more light on the molecular basis for Kek1 binding to dEGFR, we
performed SAXS-based binding analysis to further confirm the binding affinity and stoichiometry,
and to characterize the binding mode by constructing low-resolution envelopes to describe the sdEGFR/sKek1 complex structure.
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5.3.3

Kekkon-1 and dEGFR forms a ‘side-by-side’ complex through bivalent interactions

Previous AUC analysis of sKek1 binding to different truncation mutants of dEGFR suggested that
sKek1 binds to both domain II and V of s-dEGFR. However, these AUC experiments were
performed at relatively low concentrations. At high concentrations of sKek1, it is possible that two
sKek1 molecules can bind to one s-dEGFR at domain II and V. In order to study the binding of
sKek1 to s-dEGFR in solution at high concentrations, and to test whether the Kek1/dEGFR
interaction is bivalent, we performed I(0)-based titration experiment to characterize the binding
affinity and stoichiometry. A similar approach has been used to determine the binding
stoichiometry of EGF to sEGFR in forming a 2:2 dimer (Lemmon et al. 1997). In the case of sdEGFR/sKek1, however, the data interpretation is more complex. Whereas the molecular weight
of the EGF ligand (~6 kDa) could essentially be neglected in studies of its binding to the
~100 kDa sEGFR molecule, we cannot neglect the molecular weight of sKek1 (45 KDa)
compared to s-dEGFR (115 KDa). In addition, the dimerization arm mutant of dEGFR used in our
SAXS binding analysis doesn’t completely abolish s-dEGFR dimerization. At high concentration,
there is still significant dimer formed by the mutated s-dEGFR variant. Since large molecules
scatter much more strongly than small molecules in SAXS, we cannot simply neglect the
dimerization of the receptor in our SAXS analysis.
We collected SAXS data for mixtures of sKek1 and dimerization arm-mutated s-dEGFR
at molar ratios of 1:0, 1:2, 1:1, 1.5:1, 2:1 and 3:1, with a constant concentration of s-dEGFR in all
these samples. Using the EZsaxs suite, we analyzed these data and extracted the I(0) values for
each sample. Next, we aimed to ‘fit’ the data guided by the binding model. To do so, we
developed an I(0) simulator that can incorporate complex binding models with arbitrary numbers
of species and binding equilibria. For this specific data set, we developed the following model:

𝑅!   ⟺   𝑅   +   𝑅,                                            K d =K 1

(1)

𝑅𝐿 ⟺   𝑅   +   𝐿,                                            K d =K 2

(2)

𝑅𝐿𝐿   ⟺   𝑅𝐿   +   𝐿,                                        K d =K 3

(3)
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R is s-dEGFR, and L is sKek1. Reaction (1) denotes s-dEGFR dimerization, with a dissociation
constant K1. Reaction (2) and (3) represent 1:1 binding (K2) and 1:2 binding (K3 for the second
ligand) of s-dEGFR (receptor) and sKek1 (ligand), respectively.
Next, we write the concentrations of all species, except the free receptor and ligand, in
terms of the free concentrations of receptor and ligand and dissociation constants. Specifically,

𝑅!    =   

! ⋅[!]

𝑅𝐿    =   
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It follows from equations (10) – (12) that:
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(13)
(14)
(15)
(16)

Note that Rtot and Ltot are the total concentrations of receptor and ligand (in all relevant
species). These are two known values. Therefore, from (14) and (16), we can solve [R] and [L]
in the form of K1, K2, K3, Rtot and Ltot (considering these values to be constants for each
experiment).
Having solved [R] and [L], we can then solve the concentrations of all the species ([R2],
[RL] and [RLL] in this model). Now that the concentrations of all the species are known, we can
then compute I(0) and normalized I(0), using the following relationships:

𝐼! ∝   

! 𝑐!

𝐼!,!"#$ ∝    !

⋅ 𝑀!!
!
! !! ⋅!!

!"! ⋅!! !!!"! ⋅!!

(17)
(18)

In (17) and (18), ci and Mi are the molar concentration and molecular weight of species i,
respectively. Note the denominator in (18) is the total mass of species in the solution, which is a
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constant value for a given sample. We normalized the I(0) value calculated in (17) by the total
mass of all the species in the solution to get the normalized I(0) value. Importantly, the right hand
side of equation (18) is the weight-averaged molecular mass of the system in disguise.
The above derivations showed that, given a model and the dissociation constants, one
can calculate the theoretical I(0) titration curve. In other words, minimizing the difference of
theoretical and observed I(0) values with respect to the dissociation constants will provide the
best-fitting values for those constants.
We implemented this ‘fitting’ routine in our I(0) simulator. By fitting the experimental data
(Figure 5.4), we obtained the following best fit dissociation Kd’s: K1 = 1.5 mM, K2 = 3 µM,
K3 = 5 M. These values suggest that s-dEGFR homodimerization is significantly reduced to
millimolar Kd by using the dimerization arm mutant, that 1:1 (s-dEGFR:sKek1) binding has a Kd of
about 3 µM, and that the second binding event is very weak (with a Kd in the molar range). These
data were consistent with previous AUC-based binding analyses. In addition, our dissection of
the I(0) data indicated that scattering by the 1:1 s-dEGFR:sKek1 complex constitutes ~86% of the
total scattering signal, arguing that we can use the SAXS data to run shape reconstruction to
approximate the low-resolution shape of this complex (the shapes of other species in the solution
should be negligible).
Using EZsaxs and EZshape, we calculated the P(r) curves and the low-resolution
envelopes for the receptor alone and the complex. Table 5.1 illustrates the geometry parameters
derived from these analyses. Interestingly, the Dmax values of the receptor and the complex are
the same, indicating that binding of Kek1 to dEGFR does not affect the long axis of the receptor.
In other words, Kek1 binds to the ‘side’ of the receptor – with the long axes of the two molecules
close to parallel in the complex. In order to visualize the possible interaction modes of sdEGFR/sKek1, we fit models of s-dEGFR and sKek1 into the envelope by using the SITUS
software (Wriggers 2010). As shown in Figure 5.4D, the sKek1 molecule indeed contacts both
domain II and domain V of s-dEGFR. The overall low-resolution molecular shape appears to be
‘bulky’ compared to the docked complex model. This is likely due to the glycosylation of both
molecules, since glycans also scatter X-ray and are known to add ‘bulk volume’ to shape
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reconstructions (Guttman et al. 2013). The local conformational fluctuations may also contribute
to the bulkiness of the envelope. Despite these complexities in the analysis, it is evident that the
two molecules align along their long axes to form the complex.

Figure 5.4 SAXS analyses of sKek1 binding to the s-dEGFR dimerization arm mutant. A: I0
values were measured for samples of s-dEGFR alone and with increasing concentrations of
sKek1. The concentration of s-dEGFR was 50 µM for all samples. The titration peaked at a 1:1
ratio, suggesting the binding stoichiometry is 1:1. The simulated red line is our best fitting for the
data (Kd = 3 µM for formation of the 1:1 complex). The simulated grey line represents
hypothetical I0 titration data expected for a 2:1 stoichiometry of sKek1/s-dEGFR binding.
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B: P(r) curves for s-dEGFR alone and the s-dEGFR/sKek1 complex at 50 µM. The Dmax values
for both particles are 160 Å. C,D: Low-resolution molecular envelopes of s-dEGFR (C) and the
1:1 complex (D). The model of intact s-dEGFR and the crystal structure of sKek1 were docked
into the envelope to help visualize the likely binding mode.

Table 5.1 Summary of Dmax, Rg and total estimate values for s-dEGFR and the s-dEGFR/sKek1
complex
s-dEGFR

5.4

dim-arm2

s-dEGFR

dim-arm2

Dmax (Å)

160 ± 5

160 ± 5

Guinier Rg (Å)

52 ± 0.83

56.2 ± 0.93

GNOM Rg (Å)

53.4 ± 0.75

56.4 ± 1.1

TE

0.93 ± 0.008

0.88 ± 0.05

/Kek1 complex

Conclusions

In this chapter, I described the EZsaxs suite, a collection of programs developed for SAXS data
processing and analysis. EZsaxs is designed with the need of the real-world problems in mind. It
contains easy-to-use interfaces to customize data processing, provides routines to plot and
visualize results, and automates many of the tedious data manipulations. We demonstrated the
application of SAXS-based approaches to the study of molecular basis for s-dEGFR/sKek1
interactions. SAXS data analysis was heavily relied on in order to characterize the sdEGFR/sKek1 binding stoichiometry and affinity, and to unveil the low-resolution structure of the
s-dEGFR/Kek1 complex. These studies led us to the findings that sKek1 binds to s-dEGFR with
a 1:1 stoichiometry and a Kd value of approximately 3 µM. SAXS envelopes suggest a ‘side-byside’ s-dEGFR/sKek1 binding mode where Kek1 simultaneously contacts both domain II and
domain V in s-dEGFR and blocks receptor dimerization. These findings revealed a new inhibitory
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mode of EGFR regulation, and provided a new avenue towards targeting and inhibiting EGFRmediated signaling.
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Chapter 6 Conclusions and future directions
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6.1

Conclusions

The receptor tyrosine kinases (RTKs) have been extensively investigated over the last three
decades. These efforts led to the discovery of the general regulatory and signaling mechanisms
of many RTKs. However we argued that there exists significant diversity among RTKs – different
RTKs utilize subtly (but importantly) distinct mechanisms for receptor activation and downstream
signaling. As discussed in Chapter 1, understanding this diversity is crucial for fully
understanding the molecular basis for activation and regulation of RTKs, and the RTK-mediated
cell signaling network – and for devising new ways to intervene when these processes go awry in
disease.
In Chapter 2, I investigated into the anaplastic lymphoma kinase (ALK) sub-family of
RTKs, aiming to understand how these receptors are activated. Despite the grouping or ALK into
the insulin receptor (IR) super-family, I showed that the activation mechanism of ALK differs
significantly from that of IRs. Using biophysical approaches, we proposed a model delineating
how heparin, a recently-reported ligand, activates the receptor. We also discussed the potential
activation mechanisms for both mammalian and Drosophila ALK by integrating all that we have
learnt so far. Finally, we suggest a model where multiple ligands and co-ligands may co-regulate
ALK.
In Chapter 3, we focused on those RTKs that are also Wnt receptors. In particular, we
studied the Drosophila ortholog of human Wnt5 protein, DWnt5, and its receptor Derailed (Drl).
We managed to express milligrams of bioactive DWnt5, thus effectively overcoming a barrier that
has hindered biochemical and biophysical studies of Wnt for decades. Next, we employed
hydrogen deuterium exchange approaches and mutagenesis analysis to identify the binding
interface on Drl. These studies revealed a new binding mode of WIF domain binding to (nonlipidated) Wnt protein. We also used molecular dynamics (MD) simulations to study the structure
and conformational dynamics of DWnt5, and uncovered unique conformational dynamics that
DWnt5 exhibits.
In Chapter 4, we shift our attention to the intracellular region of RTKs. Among the
‘RTKome’, many receptors have in their carboxy-terminus a disordered region (‘C-tail’) that
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harbors the phosphorylation sites that link to downstream signaling molecules responsible for
network activation. We investigated the C-tail of EGF receptor, showing that C-tail is not
completely disordered. Rather, it adopts a relatively restricted conformational ensemble. In
addition, we showed that phosphorylation of the EGFR C-tail promotes receptor dimerization. We
identified regions in the kinase domain that are likely to contact C-tail region upon
phosphorylation, thus suggesting a possible structural explanation for phosphorylation-promoted
receptor dimerization. In addition, we studied the binding of downstream SH2 domains to
phosphorylated C-tail. We discovered that the affinity of SH2 domain binding to C-tail differs
slightly from SH2 domain binding to short phosphopeptides. In addition, using surface plasmon
resonance approach, we identified the negative cooperativity of binding of Grb2 and PLCγ SH2
domains – that is, binding of one SH2 domain to one phosphotyrosine site negatively impacts the
binding of the second SH2 domain to a different pTyr site. Using ordinary differentiation equation
(ODE) – based simulations, we further showed that this binding effect could regulate the
dynamics of receptor signaling levels. While our studies so far are limited to only several SH2
domains, the principle we discovered is potentially applicable to other SH2 domains as well –
suggesting that C-tail not only recruits downstream signaling molecules but also regulates kinase
activity and downstream signaling.
In Chapter 5, we presented our work on developing novel tools to facilitate biophysical
studies of RTKs. In order to take advantage of small-angle X-ray scattering techniques to study
the ligand binding of receptors, and the low-resolution structure of receptors and receptor
complexes, we developed a series of programs that allow for sampling of large parameter space
in the process of data analysis. We described our work of Drosophila EGFR (dEGFR) and its
binding partner Kekkon1. Using SAXS and our programs, we identified the binding affinity and
stoichiometry of s-dEGFR/sKek1. In addition, based on the low-resolution structure of the sdEGFR/sKek1 complex derived from SAXS, we proposed a structural model where Kekkon1
contacts domain II and V in the extracellular region of dEGFR and thus blocks receptor
dimerization.
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6.2
6.2.1

Future directions
Extend current investigations to full-length receptors

Our work on EGFR reveals additional functions of the C-tail region – in addition to harboring the
phosphorylation sites to which signaling molecules bind, the C-tail also regulates receptor activity
and downstream signaling directly. Although these findings are important, to truly fit them into a
broad mechanistic view of EGF receptor (and other RTKs), one needs to extend these studies to
the intact receptor – full-length receptor comprising of all the components including the
ectodomain, transmembrane helix as well as the intact intracellular region (juxtamembrane region,
kinase domain and C-tail). Therefore, the next question, based on what we have determined so
far about EGF receptor and the C-tail in particular, would be to study the regulation of receptor
activity and of SH2 domain binding to the receptor’s C-tail in the context of full-length receptors
reconstituted in synthetic membrane systems such as liposome, detergent micelle, and
‘nanodiscs’ (Bayburt, Grinkova, and Sligar 2002). Similar approaches have been applied to other
membrane proteins and receptors, such as G-protein coupled receptors (Bayburt et al. 2007),
chemoreceptors (Boldog et al. 2006), and limited studies of EGFR in this context have been
reported (Mi et al. 2008). We aim to re-assess the conformational dynamics of the C-tail in the
context of the full-length receptor, to test whether the C-tail exhibits additional
structural/dynamical features in intact EGFR, and to determine the extent to which C-tail
phosphorylation regulates receptor dimerization and kinase activity (when additional components
are present). One approach to address this question is to employ hydrogen exchange mass
spectrometry as we did for the soluble C-tail protein, but using the intact membrane-reconstituted
receptor. A systematic analysis of hydrogen exchange profiles of the full-length receptor could
reveal additional interactions between the C-tail and other components of the receptor in this
context. In parallel, we can take advantage of HX and modern mass spectrometric approaches to
study any differences in the dynamics of EGFR C-tail phosphorylation in response to the different
EGFR ligands. The extracellular ligand-binding region of EGF receptor is well known for its ability
to bind various ligands to differentially invoke downstream signaling events. In this experimental
setup, we are in a position to really tackle the question as to how different ligand-binding signals
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are propagated through membrane to cause (potentially) different phosphorylation of the C-tail –
and how the negative cooperativity of ligand binding in the extracellular region might translate to
altered structure and dynamics in the intracellular region. These studies would significantly
extend our current understandings of EGF receptor, which is largely derived from studies of
individual components of the receptor separated from their native context.

6.2.2

Identify novel RTK binding partners

Our work discussed in previous chapters revealed several novel ligand-binding mechanisms of
RTKs, such as the binding mode of heparin/ALK and the Wnt5 binding interface on the Ryk WIF
domain. However, these findings cannot rule out other possible ligands and ligand-binding
mechanisms for these receptors. For instance, our biophysical studies on heparin/ALK binding
pointed out a possible heparin-induced receptor dimerization model. It is, however, possible that
there exist other ALK ligands that can bind to heparin/ALK complex (or compete with heparin).
Notably, how jelly belly (jeb) binds to Drosophila ALK still remains unclear, and we speculate that
jeb may need a co-ligand, such as heparin, to bind to fly ALK. The recent discovery of a secreted
protein as a novel LTK ligand (Zhang et al. 2014) also suggests that there might exist similar
molecules that target the corresponding region in the related ALK receptor. In addition, the
complement of domains in the extracellular region of ALK suggests its interactions with other
unknown proteins. Therefore, seeking novel ligands and co-receptors for ALK remains to be
important. Both hypothesis-driven and exploratory approaches can be applied for this purpose.
For example, based on our studies of heparin/ALK binding, we propose that heparin may induce
formation of a pre-dimer, but that other ligands may be required to fully activate the receptor.
Therefore, we can assess the binding of other proposed ALK ligands to heparin-induced ALK
dimer using biochemical and biophysical approaches, and test receptor activation by these
molecules in the presence of heparin using biochemical and cell-based assays. In addition, highthroughput screening of potential receptor-activating ligands in the extracellular proteome, the
approach that led to the discovery of the LTK ligands (Zhang et al. 2014), may also be used to
identify potential ALK ligands and co-ligands.
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Similar to ALK, there might exist additional molecules that interact with Ryk or Wnt/Ryk
complexes. In fact, our work suggests that the binding mode of Wnt/Ryk appears to be different
from that of Wnt/CRD, leading to the hypothesis that Wnt might be a multivalent ligand that can
bind to several different receptors simultaneously. To test this hypothesis, we aim to extend our
hydrogen exchange studies (which identifies the binding interface on Drl) to characterize the
binding interface of WIF domain and CRD on Wnt. If these two binding interfaces on Wnt are
distinct, then Wnt is likely to be a multi-valent ligand, and understanding the formation of heterocomplex would thus be crucial for unraveling Wnt signaling.
In addition to the studies of Wnt binding, we also aim to understand how Ryk, being a
‘dead-kinase’, transduces extracellular cues to downstream signaling events. This is an
important question, since most of the Wnt-binding RTKs turn out to be pseudokinases (the only
exception is MuSK, or Muscle-Specific Kinase) (Mendrola et al. 2013). For Ryk/Drl, two Srcfamily kinases Src64B and Src42A (Wouda et al. 2008) appear to be involved in DWnt5/Drl
signaling. While the detailed mechanism is still lacking, it is suggested that Drl, although kinasedead, can still allosterically activate other kinases. Similar mechanisms have been reported for
kinase domains outside the RTK group. For example, STRADα (Ste20-related adaptor α) is a
pseudokinase, but can bind to LKB1 kinase (and the MO25 adaptor) and allosterically activate it
(Zeqiraj et al. 2009). To test the hypothesis that Drl can function similarly, we aim to employ
proteomic approaches to identify possible binding partners of DWnt5/Drl complex in cells, and
then use biophysical and structural biology approaches to study how the pseudokinase domain of
Drl, upon DWnt5 binding, might activate its binding partner. These studies could reveal novel
mechanisms that complement the current view of RTK-mediated signaling.
6.2.3

Investigate RTKs at the systems level

Our work on various RTKs suggests that there are different levels of regulation across the RTK
family – from ligand binding to the activation of kinase domain, to the recruitment of downstream
signaling molecules. These diverse regulatory mechanisms add extra complexity to the
understanding of RTK signaling. To fully appreciate this complexity, we argue that one needs to
integrate the biochemical and structural studies using a ‘systems approach’. For example, our
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work on the EGFR C-tail suggests that there exists binding specificity and cooperativity in SH2
domain assembly. To understand how these effects contribute to cell decision-making, we need
to feed our binding data to a systems model. As discussed in Chapter 4, we have performed
ordinary differential equation (ODE) – based modeling to study the spiked and sustained receptor
signaling level controlled by SH2 domain binding. Despite having provided some insights into
EGFR-mediated signaling, such a model is severely limited in that it only considers the short-term
signal, and oversimplifies some important factors such as a variety of phosphatases and protein
degradation machineries in cells (in our model, there is only one dephosphorylation rate
parameter to account for ‘background phosphatase activity’). In order to further our
understanding of the role of the C-tail in signaling, we need to collect data for more molecular
events and then analyze them in a systems manner. For example, we may also investigate SH2
domains binding to the C-tail region in the full-length EGF receptor directly using in vivo singlemolecule approaches. Oh et al has studied the binding kinetics of SH2 domains to EGF receptor
by using total internal reflection (TIR) microscope (Oh et al. 2012). Using similar approaches, we
can verify our findings of SH2 domain binding to C-tail on the cell membrane (within TIR
illumination field). In addition, single-molecule studies in cells should allow us to study virtually all
combinations of SH2 domains, as long as they are differentially tagged. Using this approach, we
should be able to collect a huge number of parameters for systems-level analysis. Moreover,
cell-based assays could be used to introduce perturbations to interrogate the regulations of the
network. For example, we can measure phosphorylation and binding events with different levels
of certain phosphatases, therefore assessing the effect of phosphatases on signaling dynamics.
Or, we can over-express a specific signaling molecule or a subset of proteins belonging to one
pathway, effectively assessing the impact of one pathway to the entire network. Finally, we would
hope also to extend these studies to other ErbB family receptors and RTKs, to ultimately gain
insights into the cell signaling network mediated by RTKs.
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